{"d44f0b3c6bc04750679c3cc7be730c2ae4f15c45": [["Severe acute respiratory syndrome (SARS) is a new infection disease caused by a previously unknown representative of the coronavirus family [1] [2] [3] .", [["acute respiratory syndrome", "DISEASE", 7, 33], ["SARS", "DISEASE", 35, 39], ["infection disease", "DISEASE", 50, 67], ["coronavirus", "ORGANISM", 121, 132], ["[1] [2] [3]", "SIMPLE_CHEMICAL", 140, 151], ["Severe acute respiratory syndrome", "PROBLEM", 0, 33], ["a new infection disease", "PROBLEM", 44, 67], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome", "OBSERVATION", 13, 33], ["new", "OBSERVATION_MODIFIER", 46, 49], ["infection", "OBSERVATION", 50, 59]]], ["For the first time, this disease was described in late 2002 in the Guangdong province (southern China), and then it spread to many other regions of the world.", [["this disease", "PROBLEM", 20, 32], ["disease", "OBSERVATION", 25, 32]]], ["More than 8000 people have been infected with SARS.", [["SARS", "DISEASE", 46, 50], ["people", "ORGANISM", 15, 21], ["people", "SPECIES", 15, 21], ["SARS", "PROBLEM", 46, 50], ["infected", "OBSERVATION", 32, 40]]], ["The morbidity and mortality of SARS is rather high (mortality rate, up to 6-15%).", [["SARS", "DISEASE", 31, 35], ["The morbidity", "PROBLEM", 0, 13], ["SARS", "PROBLEM", 31, 35], ["mortality rate", "TEST", 52, 66], ["morbidity", "OBSERVATION", 4, 13]]], ["The etiological agent of the disease, SARS coronavirus (SARS-cv), was identified by WHO experts, who determined its genome sequence and primers for molecular biological diagnosis [1] .", [["SARS coronavirus", "DISEASE", 38, 54], ["SARS", "DISEASE", 56, 60], ["SARS coronavirus", "ORGANISM", 38, 54], ["SARS-cv", "ORGANISM", 56, 63], ["genome sequence", "DNA", 116, 131], ["SARS coronavirus", "SPECIES", 38, 54], ["SARS-cv", "SPECIES", 56, 63], ["the disease", "PROBLEM", 25, 36], ["SARS coronavirus", "PROBLEM", 38, 54], ["disease", "OBSERVATION", 29, 36]]]], "PMC7274337": [["Industrial production will be highly flexible in production volume and suppliers, and above all sustainable and efficient [10].", [["Industrial production", "PROBLEM", 0, 21]]], ["Smart factories using Industry 4.0 based on collaborative systems represent the future of industrial networks.IntroductionAccording to a PWC survey from 2013 [4], 50% of German enterprises plan their new industrial network and 20% are already involved in smart factories.", [["industrial networks", "MULTI-TISSUE_STRUCTURE", 90, 109], ["industrial network", "MULTI-TISSUE_STRUCTURE", 204, 222], ["collaborative systems", "TREATMENT", 44, 65]]], ["A survey by American Society for Quality (ASQ), from 2014 [1], states that 82% of organizations that implemented smart manufacturing experienced increased efficiency, 49% experienced fewer product defects and 45% experienced increased customer satisfaction [8].", [["increased efficiency", "PROBLEM", 145, 165], ["fewer product defects", "PROBLEM", 183, 204]]], ["Hence, companies can highly benefit from the implementation of Industry 4.0 concepts.IntroductionIndustry 4.0 represents a smart manufacturing network concept where machines and products interact with each other without human intervention.", [["human", "ORGANISM", 220, 225], ["human", "SPECIES", 220, 225], ["human", "SPECIES", 220, 225], ["IntroductionIndustry", "TREATMENT", 85, 105], ["a smart manufacturing network concept", "TREATMENT", 121, 158], ["human intervention", "TREATMENT", 220, 238]]], ["Supply chains in such networks have dynamic structures which evolve over time.", [["chains", "OBSERVATION_MODIFIER", 7, 13]]], ["In these settings, short-term supply chain scheduling is challenged by sources of uncertainty.", [["short-term supply chain scheduling", "TREATMENT", 19, 53]]], ["Manufacturing environments are dynamic by nature and there are several events which can occur and change the system status affecting the performance, known as real-time events.", [["several events", "PROBLEM", 63, 77]]], ["Exchanging data and information between different parties in real time is the key element of smart factories; such data could represent production status, energy consumption behaviour, material movements, customer orders and feedback, suppliers\u2019 data, etc. The next generation of smart factories, therefore, will have to be able to adapt, almost in real time, to the continuously changing market demands, technology options and regulations [2].Flexible Job Shop ProblemThe Flexible Job Shop Scheduling Problem (FJSSP) is a generalization of the classical Job Shop Scheduling Problem (JSSP).", [["production status", "PROBLEM", 136, 153]]], ["The JSSP follows the idea that a set of jobs", [["JSSP", "DNA", 4, 8]]]], "2f2339c3dc2dea779f9459f4ef758ed9c42be553": [["a b s t r a c tThe Brighton Collaboration Viral Vector Vaccines Safety Working Group (V3SWG) was formed to evaluate the safety of live, recombinant viral vaccines incorporating genes from heterologous viruses inserted into the backbone of another virus (so-called \"chimeric virus vaccines\").", [["chimeric virus", "ORGANISM", 265, 279], ["The Brighton Collaboration Viral Vector Vaccines", "TREATMENT", 15, 63], ["recombinant viral vaccines", "TREATMENT", 136, 162], ["heterologous viruses", "PROBLEM", 188, 208], ["chimeric virus vaccines", "TREATMENT", 265, 288]]], ["Many viral vector vaccines are in advanced clinical trials.", [["Many viral vector vaccines", "TREATMENT", 0, 26]]], ["The first such vaccine to be approved for marketing (to date in Australia, Thailand, Malaysia, and the Philippines) is a vaccine against the flavivirus, Japanese encephalitis (JE), which employs a licensed vaccine (yellow fever 17D) as a vector.", [["flavivirus", "DISEASE", 141, 151], ["Japanese encephalitis", "DISEASE", 153, 174], ["JE", "DISEASE", 176, 178], ["fever", "DISEASE", 222, 227], ["Japanese encephalitis", "ORGANISM", 153, 174], ["yellow fever 17D", "ORGANISM", 215, 231], ["Japanese encephalitis (JE)", "SPECIES", 153, 179], ["yellow fever 17D", "SPECIES", 215, 231], ["The first such vaccine", "TREATMENT", 0, 22], ["a vaccine", "TREATMENT", 119, 128], ["the flavivirus", "PROBLEM", 137, 151], ["Japanese encephalitis (JE)", "PROBLEM", 153, 179], ["a licensed vaccine", "TREATMENT", 195, 213], ["yellow fever", "PROBLEM", 215, 227], ["flavivirus", "OBSERVATION", 141, 151]]], ["In this vaccine, two envelope proteins (prM-E) of YF 17D virus were exchanged for the corresponding genes of JE virus, with additional attenuating mutations incorporated into the JE gene inserts.", [["prM-E", "GENE_OR_GENE_PRODUCT", 40, 45], ["YF 17D virus", "ORGANISM", 50, 62], ["JE virus", "ORGANISM", 109, 117], ["envelope proteins", "PROTEIN", 21, 38], ["prM", "PROTEIN", 40, 43], ["E", "PROTEIN", 44, 45], ["JE gene inserts", "DNA", 179, 194], ["YF 17D virus", "SPECIES", 50, 62], ["YF 17D virus", "SPECIES", 50, 62], ["JE virus", "SPECIES", 109, 117], ["this vaccine", "TREATMENT", 3, 15], ["two envelope proteins", "TEST", 17, 38], ["YF 17D virus", "PROBLEM", 50, 62], ["JE virus", "PROBLEM", 109, 117], ["additional attenuating mutations", "TREATMENT", 124, 156], ["the JE gene inserts", "TREATMENT", 175, 194], ["JE virus", "OBSERVATION", 109, 117], ["attenuating", "OBSERVATION_MODIFIER", 135, 146], ["mutations", "OBSERVATION", 147, 156]]], ["Similar vaccines have been constructed by inserting prM-E genes of dengue and West Nile into YF 17D virus and are in late stage clinical studies.", [["dengue", "DISEASE", 67, 73], ["prM-E", "GENE_OR_GENE_PRODUCT", 52, 57], ["West Nile", "ORGANISM", 78, 87], ["YF 17D virus", "ORGANISM", 93, 105], ["prM-E genes", "DNA", 52, 63], ["YF 17D virus", "SPECIES", 93, 105], ["dengue", "SPECIES", 67, 73], ["West Nile", "SPECIES", 78, 87], ["YF 17D virus", "SPECIES", 93, 105], ["Similar vaccines", "TREATMENT", 0, 16], ["dengue", "PROBLEM", 67, 73]]], ["The dengue vaccine is, however, more complex in that it requires a mixture of four live vectors each expressing one of the four dengue serotypes.", [["dengue", "DISEASE", 4, 10], ["dengue", "DISEASE", 128, 134], ["dengue", "SPECIES", 4, 10], ["The dengue vaccine", "TREATMENT", 0, 18], ["a mixture of four live vectors", "TREATMENT", 65, 95], ["the four dengue serotypes", "PROBLEM", 119, 144]]], ["This vaccine has been evaluated in multiple clinical trials.", [["This vaccine", "TREATMENT", 0, 12]]], ["No significant safety concerns have been found.", [["significant safety concerns", "PROBLEM", 3, 30], ["significant", "OBSERVATION_MODIFIER", 3, 14]]], ["The Phase 3 trials met their endpoints in terms of overall reduction of confirmed dengue fever, and, most importantly a significant reduction in severe dengue and hospitalization due to dengue.", [["dengue fever", "DISEASE", 82, 94], ["dengue", "DISEASE", 152, 158], ["dengue", "DISEASE", 186, 192], ["dengue", "SPECIES", 152, 158], ["The Phase 3 trials", "TREATMENT", 0, 18], ["dengue fever", "PROBLEM", 82, 94], ["severe dengue", "PROBLEM", 145, 158], ["dengue", "PROBLEM", 186, 192], ["dengue", "OBSERVATION_MODIFIER", 82, 88], ["fever", "OBSERVATION", 89, 94], ["significant", "OBSERVATION_MODIFIER", 120, 131], ["reduction", "OBSERVATION_MODIFIER", 132, 141], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["dengue", "OBSERVATION", 152, 158]]], ["However, based on results that have been published so far, efficacy in preventing serotype 2 infection is less than that for the other three serotypes.", [["infection", "DISEASE", 93, 102], ["serotype 2", "ORGANISM", 82, 92], ["serotype 2 infection", "PROBLEM", 82, 102], ["the other three serotypes", "PROBLEM", 125, 150], ["infection", "OBSERVATION", 93, 102]]], ["In the development of these chimeric vaccines, an important series of comparative studies of safety and efficacy were made using the parental YF 17D vaccine virus as a benchmark.", [["YF 17D vaccine virus", "ORGANISM", 142, 162], ["YF 17D vaccine virus", "SPECIES", 142, 162], ["YF 17D vaccine virus", "SPECIES", 142, 162], ["these chimeric vaccines", "TREATMENT", 22, 45], ["comparative studies", "TEST", 70, 89], ["the parental YF 17D vaccine virus", "TREATMENT", 129, 162]]], ["In this paper, we use a standardized template describing the key characteristics of the novel flavivirus vaccine vectors, in comparison to the parental YF 17D vaccine.", [["flavivirus", "ORGANISM", 94, 104], ["YF 17D", "ORGANISM", 152, 158], ["YF 17D", "SPECIES", 152, 158], ["a standardized template", "TREATMENT", 22, 45], ["the novel flavivirus vaccine vectors", "TREATMENT", 84, 120]]], ["The Brighton Collaboration V3SWG template may also be useful as a guide to the evaluation of other recombinant viral vector vaccines. \u00a9 2014 Published by Elsevier Ltd.Preamble1.1.", [["Preamble1.1", "GENE_OR_GENE_PRODUCT", 167, 178], ["Preamble1.1", "PROTEIN", 167, 178], ["the evaluation", "TEST", 75, 89], ["other recombinant viral vector vaccines", "TREATMENT", 93, 132]]], ["Need for working group and development of a standardized template for collection of key information for risk/benefit assessment of viral vector vaccinesPreambleRecombinant viral vectors provide an effective means for heterologous antigen expression in vivo and thus represent promising platforms for developing novel vaccines against human pathogens such as Ebola, human immunodeficiency virus (HIV), tuberculosis, and malaria) [1] [2] [3] [4] [5] [6] [7] [8] [9] .", [["Ebola, human immunodeficiency virus (HIV), tuberculosis", "DISEASE", 358, 413], ["malaria", "DISEASE", 419, 426], ["human", "ORGANISM", 334, 339], ["Ebola,", "ORGANISM", 358, 364], ["human immunodeficiency virus", "ORGANISM", 365, 393], ["HIV", "ORGANISM", 395, 398], ["[1] [2] [3] [4] [5] [6] [7] [8] [9]", "SIMPLE_CHEMICAL", 428, 463], ["human", "SPECIES", 334, 339], ["Ebola", "SPECIES", 358, 363], ["human immunodeficiency virus", "SPECIES", 365, 393], ["(HIV", "SPECIES", 394, 398], ["human", "SPECIES", 334, 339], ["human immunodeficiency virus", "SPECIES", 365, 393], ["HIV", "SPECIES", 395, 398], ["a standardized template", "TREATMENT", 42, 65], ["benefit assessment", "TEST", 109, 127], ["viral vector vaccines", "TREATMENT", 131, 152], ["PreambleRecombinant viral vectors", "TREATMENT", 152, 185], ["heterologous antigen expression", "TREATMENT", 217, 248], ["novel vaccines", "TREATMENT", 311, 325], ["human pathogens", "PROBLEM", 334, 349], ["Ebola", "PROBLEM", 358, 363], ["human immunodeficiency virus (HIV)", "PROBLEM", 365, 399], ["tuberculosis", "PROBLEM", 401, 413], ["malaria", "PROBLEM", 419, 426]]], ["Preclinical evaluation of such viral vector vaccines has indicated their potential for immunization and an increasing number of candidate vaccines are entering human clinical trials.", [["human", "ORGANISM", 160, 165], ["human", "SPECIES", 160, 165], ["human", "SPECIES", 160, 165], ["Preclinical evaluation", "TEST", 0, 22], ["such viral vector vaccines", "TREATMENT", 26, 52], ["immunization", "TREATMENT", 87, 99], ["vaccines", "TREATMENT", 138, 146]]], ["Improving our ability to anticipate potential safety issues and meaningfully assess or interpret safety data from trials of such new viral vector vaccines will increase the likelihood of public acceptance should they be licensed [10] [11] [12] [13] .PreambleThe Brighton Collaboration (www.brightoncollaboration.org) was formed in 2000 as an international voluntary collaboration to enhance the science of vaccine safety research [e.g., via development of standardized case definitions of adverse events following immunizations (AEFI)] [14] .", [["[10] [11] [12] [13]", "SIMPLE_CHEMICAL", 229, 248], ["potential safety issues", "PROBLEM", 36, 59], ["such new viral vector vaccines", "TREATMENT", 124, 154], ["adverse events", "PROBLEM", 489, 503], ["immunizations", "TREATMENT", 514, 527]]], ["In recognition of these needs in this domain, the Brighton Collaboration created the Viral Vector Vaccines Safety Working Group (V3SWG) in October 2008.", [["the Viral Vector Vaccines", "TREATMENT", 81, 106]]], ["Analogous to the value embodied in standardized case definitions for AEFI, the V3SWG believes a standardized template describing the key characteristics of a novel vaccine vector, when completed and maintained with the latest research, will facilitate scientific discourse among key stakeholders by increasing the transparency and comparability of information.", [["V3SWG", "DNA", 79, 84], ["AEFI", "PROBLEM", 69, 73], ["a standardized template", "TREATMENT", 94, 117], ["a novel vaccine vector", "TREATMENT", 156, 178]]], ["Fortunately, the International AIDS Vaccine Initiative (IAVI) had already developed an internal tool to assess the risk/benefit of different viral vectors under its sponsorship.", [["AIDS", "DISEASE", 31, 35], ["the International AIDS Vaccine", "TREATMENT", 13, 43], ["an internal tool", "PROBLEM", 84, 100], ["different viral vectors", "TREATMENT", 131, 154], ["viral vectors", "OBSERVATION", 141, 154]]], ["The IAVI graciously shared this tool with the V3SWG for adaptation and broader use as a standardized template for collection of key information for risk/benefit assessment on any viral vector vaccine.", [["V3SWG", "DNA", 46, 51], ["a standardized template", "TREATMENT", 86, 109], ["benefit assessment", "TEST", 153, 171], ["any viral vector vaccine", "TREATMENT", 175, 199]]], ["This tool was aimed at identifying potential major hurdles or concerns that would need to be addressed during the development of a vectored vaccine.", [["a vectored vaccine", "TREATMENT", 129, 147]]], ["The template collects information on the characteristics of the wild type virus from which the vector was derived as well as known effects of the proposed vaccine vector in animals and humans, manufacturing features, toxicology and potency, nonclinical studies, and human use, with an overall adverse effect and risk assessment.PreambleThe V3SWG hopes that eventually all developers/researchers of viral vector vaccines (especially those likely to be used in humans in the near future) will complete this template and submit it to the V3SWG and Brighton Collaboration for peer review and eventual publication in Vaccine.", [["wild type virus", "ORGANISM", 64, 79], ["humans", "ORGANISM", 185, 191], ["human", "ORGANISM", 266, 271], ["humans", "ORGANISM", 459, 465], ["humans", "SPECIES", 185, 191], ["human", "SPECIES", 266, 271], ["humans", "SPECIES", 459, 465], ["humans", "SPECIES", 185, 191], ["human", "SPECIES", 266, 271], ["humans", "SPECIES", 459, 465], ["the wild type virus", "PROBLEM", 60, 79], ["the proposed vaccine vector", "TREATMENT", 142, 169], ["nonclinical studies", "TEST", 241, 260], ["risk assessment", "TEST", 312, 327], ["viral vector vaccines", "TREATMENT", 398, 419], ["this template", "TREATMENT", 500, 513], ["eventual publication in Vaccine", "TREATMENT", 588, 619]]], ["Furthermore, recognizing the rapid pace of new scientific developments in this domain (relative to AEFI case definitions), we hope to maintain these completed templates \"wiki-\" style with the help of Brighton Collaboration and each vector vaccine \"community.\" 1.2.", [["rapid", "OBSERVATION_MODIFIER", 29, 34]]], ["Need for risk/benefit assessment of live virus vaccines based upon a yellow fever vaccine backbone Yellow fever (YF) is a mosquito-borne flavivirus disease that is has long endangered persons in sub-Saharan Africa and tropical areas in South America and is associated with a case fatality rate of 20-50% [15] .", [["yellow fever", "DISEASE", 69, 81], ["Yellow fever", "DISEASE", 99, 111], ["YF", "DISEASE", 113, 115], ["flavivirus disease", "DISEASE", 137, 155], ["live virus", "ORGANISM", 36, 46], ["yellow fever", "ORGANISM", 69, 81], ["Yellow fever", "ORGANISM", 99, 111], ["yellow fever vaccine", "SPECIES", 69, 89], ["Yellow fever", "SPECIES", 99, 111], ["persons", "SPECIES", 184, 191], ["Yellow fever (YF)", "SPECIES", 99, 116], ["benefit assessment", "TEST", 14, 32], ["live virus vaccines", "TREATMENT", 36, 55], ["a yellow fever vaccine backbone", "PROBLEM", 67, 98], ["Yellow fever", "PROBLEM", 99, 111], ["YF", "PROBLEM", 113, 115], ["a mosquito-borne flavivirus disease", "PROBLEM", 120, 155], ["fatality rate", "TEST", 280, 293], ["flavivirus disease", "OBSERVATION", 137, 155]]], ["Since no effective anti-yellow fever virus medications are available and current mosquito-control measures are inadequate, vaccination remains paramount to YF prevention and control.", [["fever", "DISEASE", 31, 36], ["anti-yellow fever virus", "ORGANISM", 19, 42], ["YF", "ORGANISM", 156, 158], ["anti-yellow fever virus", "SPECIES", 19, 42], ["YF", "SPECIES", 156, 158], ["effective anti-yellow fever virus medications", "TREATMENT", 9, 54], ["current mosquito-control measures", "TREATMENT", 73, 106], ["vaccination", "TREATMENT", 123, 134], ["no", "UNCERTAINTY", 6, 8], ["effective", "OBSERVATION_MODIFIER", 9, 18]]], ["Although appropriately controlled efficacy studies have never been carried out, the decline in YF cases following vaccination campaigns and the production in most studies of neutralizing antibodies in more than 95% of vaccinees are considered sufficient evidence that the 17D vaccine is effective.", [["YF", "DISEASE", 95, 97], ["YF", "ORGANISM", 95, 97], ["vaccinees", "ORGANISM", 218, 227], ["neutralizing antibodies", "PROTEIN", 174, 197], ["the decline", "PROBLEM", 80, 91], ["vaccination campaigns", "TREATMENT", 114, 135], ["neutralizing antibodies", "TEST", 174, 197], ["vaccinees", "PROBLEM", 218, 227], ["the 17D vaccine", "TREATMENT", 268, 283]]], ["Regulations call for the vaccine to be administered every ten years; however, a recent recommendation by WHO's Strategic Advisory Group is that the vaccine need only be given once [16] .PreambleThe live, attenuated YF 17D vaccine was previously deemed to be the world's safest and a model for the development of other live virus vaccines including polio, measles, mumps and varicella.", [["Preamble", "CHEMICAL", 186, 194], ["polio, measles, mumps and varicella", "DISEASE", 348, 383], ["YF 17D", "ORGANISM", 215, 221], ["polio", "ORGANISM", 348, 353], ["mumps", "ORGANISM", 364, 369], ["YF 17D", "SPECIES", 215, 221], ["the vaccine", "TREATMENT", 21, 32], ["the vaccine", "TREATMENT", 144, 155], ["other live virus vaccines", "TREATMENT", 312, 337], ["polio", "PROBLEM", 348, 353], ["measles", "PROBLEM", 355, 362], ["mumps", "PROBLEM", 364, 369], ["varicella", "PROBLEM", 374, 383], ["varicella", "OBSERVATION", 374, 383]]], ["Consequently, live vaccines against other flaviviruses, such as Japanese encephalitis virus, West Nile virus, and the four serotypes of dengue viruses, based on the YF 17D virus vaccine began to be developed.", [["flaviviruses", "DISEASE", 42, 54], ["Japanese encephalitis", "DISEASE", 64, 85], ["dengue viruses", "DISEASE", 136, 150], ["Japanese encephalitis virus", "ORGANISM", 64, 91], ["West Nile virus", "ORGANISM", 93, 108], ["dengue viruses", "ORGANISM", 136, 150], ["YF 17D virus", "ORGANISM", 165, 177], ["Japanese encephalitis virus", "SPECIES", 64, 91], ["West Nile virus", "SPECIES", 93, 108], ["YF 17D virus", "SPECIES", 165, 177], ["Japanese encephalitis virus", "SPECIES", 64, 91], ["West Nile virus", "SPECIES", 93, 108], ["dengue viruses", "SPECIES", 136, 150], ["YF 17D virus", "SPECIES", 165, 177], ["live vaccines", "TREATMENT", 14, 27], ["other flaviviruses", "PROBLEM", 36, 54], ["Japanese encephalitis virus", "PROBLEM", 64, 91], ["West Nile virus", "PROBLEM", 93, 108], ["dengue viruses", "PROBLEM", 136, 150], ["the YF 17D virus vaccine", "TREATMENT", 161, 185], ["dengue viruses", "OBSERVATION", 136, 150]]], ["In 2001, however, severe rare reactions that were frequently fatal became recognized [17] [18] [19] .", [["severe rare reactions", "PROBLEM", 18, 39], ["severe", "OBSERVATION_MODIFIER", 18, 24]]], ["These reactions involved multiple organ systems and were named yellow fever vaccine-associated viscerotropic disease (YEL-AVD).", [["organ", "ANATOMY", 34, 39], ["viscerotropic", "ANATOMY", 95, 108], ["yellow fever", "DISEASE", 63, 75], ["viscerotropic disease", "DISEASE", 95, 116], ["YEL-AVD", "DISEASE", 118, 125], ["organ", "ORGAN", 34, 39], ["yellow fever vaccine", "ORGANISM", 63, 83], ["yellow fever vaccine", "SPECIES", 63, 83], ["These reactions", "PROBLEM", 0, 15], ["multiple organ systems", "PROBLEM", 25, 47], ["yellow fever vaccine", "PROBLEM", 63, 83], ["viscerotropic disease", "PROBLEM", 95, 116], ["viscerotropic disease", "OBSERVATION", 95, 116]]], ["As a consequence, in addition to live virus vaccines, inactivated vaccines, including one for YF, are being developed.PreambleRisk groups for the development of YEL-AVD include elderly males as young as 56 years [20] , women in their prime child-bearing years [21] , and persons thymectomized as treatment for thymoma [22] .", [["thymoma", "ANATOMY", 310, 317], ["YEL-AVD", "DISEASE", 161, 168], ["thymoma", "DISEASE", 310, 317], ["YF", "ORGANISM", 94, 96], ["women", "ORGANISM", 219, 224], ["persons", "ORGANISM", 271, 278], ["women", "SPECIES", 219, 224], ["persons", "SPECIES", 271, 278], ["YF", "SPECIES", 94, 96], ["live virus vaccines", "TREATMENT", 33, 52], ["inactivated vaccines", "TREATMENT", 54, 74], ["YF", "PROBLEM", 94, 96], ["thymoma", "PROBLEM", 310, 317]]], ["Guidelines for the definition of viscerotropic disease and for the association of YF vaccine with viscerotropic disease have been developed by a Brighton Collaboration working group [23] .", [["viscerotropic disease", "DISEASE", 33, 54], ["YF", "DISEASE", 82, 84], ["viscerotropic disease", "DISEASE", 98, 119], ["YF", "ORGANISM", 82, 84], ["viscerotropic disease", "PROBLEM", 33, 54], ["YF vaccine", "TREATMENT", 82, 92], ["viscerotropic disease", "PROBLEM", 98, 119]]], ["In addition to YEL-AVD, other rare vaccine reactions include anaphylaxis and neurological disease called YF vaccine-associated neurological disease (YEL-AND).", [["neurological", "ANATOMY", 77, 89], ["neurological", "ANATOMY", 127, 139], ["anaphylaxis", "DISEASE", 61, 72], ["neurological disease", "DISEASE", 77, 97], ["neurological disease", "DISEASE", 127, 147], ["YEL", "DISEASE", 149, 152], ["YEL", "TREATMENT", 15, 18], ["AVD", "PROBLEM", 19, 22], ["other rare vaccine reactions", "TREATMENT", 24, 52], ["anaphylaxis", "PROBLEM", 61, 72], ["neurological disease", "PROBLEM", 77, 97], ["YF vaccine", "TREATMENT", 105, 115], ["neurological disease", "PROBLEM", 127, 147]]], ["These reactions are rarely fatal or result in long term sequelae.", [["These reactions", "PROBLEM", 0, 15], ["long term sequelae", "PROBLEM", 46, 64], ["long term", "OBSERVATION_MODIFIER", 46, 55]]], ["Recognition of YEL-AVD has had a number of consequences including changes in recommendations for the vaccination of prospective travelers to and inhabitants in jungle (sylvatic) or savanna (intermediate) regions where they have a risk of exposure to YF virus-infected mosquitoes.PreambleThe feared complication of YF is spread of the virus to urban areas where the principal mosquito vector is Aedes aegypti, a mosquito that has become difficult if not impossible to eradicate in areas of huge tropical and subtropical municipalities with their large urban slums.", [["YF virus-infected mosquitoes", "DISEASE", 250, 278], ["YF", "DISEASE", 314, 316], ["YEL", "GENE_OR_GENE_PRODUCT", 15, 18], ["YF virus", "ORGANISM", 250, 258], ["mosquitoes", "ORGANISM", 268, 278], ["YF", "ORGANISM", 314, 316], ["Aedes aegypti", "ORGANISM", 394, 407], ["Aedes aegypti", "SPECIES", 394, 407], ["YF virus", "SPECIES", 250, 258], ["Aedes aegypti", "SPECIES", 394, 407], ["AVD", "PROBLEM", 19, 22], ["the vaccination of prospective travelers", "TREATMENT", 97, 137], ["savanna (intermediate) regions", "PROBLEM", 181, 211], ["YF virus", "PROBLEM", 250, 258], ["infected mosquitoes", "PROBLEM", 259, 278], ["YF", "PROBLEM", 314, 316], ["the virus", "PROBLEM", 330, 339], ["YEL", "OBSERVATION", 15, 18], ["huge", "OBSERVATION_MODIFIER", 489, 493], ["tropical", "OBSERVATION_MODIFIER", 494, 502], ["large", "OBSERVATION_MODIFIER", 545, 550]]], ["Strategies for vaccination have also become complex as the number of cases of YEL-AVD in travelers have exceeded the number of cases of YF [15] .", [["AVD", "DISEASE", 82, 85], ["YF", "DISEASE", 136, 138], ["travelers", "ORGANISM", 89, 98], ["vaccination", "TREATMENT", 15, 26], ["AVD", "PROBLEM", 82, 85]]], ["In South America, during periods of low virus activity, the risk to travelers of serious adverse events from the vaccine, particularly males over the age of 60, may be similar to that of developing yellow fever.", [["yellow fever", "DISEASE", 198, 210], ["yellow fever", "ORGANISM", 198, 210], ["low virus activity", "PROBLEM", 36, 54], ["serious adverse events", "PROBLEM", 81, 103], ["yellow fever", "PROBLEM", 198, 210], ["low virus", "OBSERVATION_MODIFIER", 36, 45], ["yellow", "OBSERVATION_MODIFIER", 198, 204], ["fever", "OBSERVATION", 205, 210]]], ["In contrast, in Africa, the risk of acquiring yellow fever can be 600 times, and of death 700 times, the risk of vaccination.PreambleAn understanding of the makeup of the flavivirus genome is helpful in understanding the new vaccines being developed based upon the yellow fever vaccine virus as a vector.", [["yellow fever", "DISEASE", 46, 58], ["death", "DISEASE", 84, 89], ["fever", "DISEASE", 272, 277], ["yellow fever vaccine virus", "ORGANISM", 265, 291], ["flavivirus genome", "DNA", 171, 188], ["yellow fever vaccine virus", "SPECIES", 265, 291], ["yellow fever vaccine virus", "SPECIES", 265, 291], ["acquiring yellow fever", "PROBLEM", 36, 58], ["vaccination", "PROBLEM", 113, 124], ["the flavivirus genome", "PROBLEM", 167, 188], ["the new vaccines", "TREATMENT", 217, 233], ["the yellow fever vaccine virus", "PROBLEM", 261, 291]]], ["Flaviviruses are single stranded, positive sense RNA viruses.", [["Flaviviruses", "GENE_OR_GENE_PRODUCT", 0, 12], ["Flaviviruses", "PROBLEM", 0, 12], ["single stranded", "PROBLEM", 17, 32], ["positive sense RNA viruses", "PROBLEM", 34, 60], ["positive", "OBSERVATION_MODIFIER", 34, 42], ["sense RNA viruses", "OBSERVATION", 43, 60]]], ["Their genomes encode three structural genes (capsid [C], pre-membrane [prM], envelope [E] ) and at least seven non-structural genes (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and NS5) in that order [24] .", [["capsid [C]", "GENE_OR_GENE_PRODUCT", 45, 55], ["pre-membrane [prM", "GENE_OR_GENE_PRODUCT", 57, 74], ["NS1", "GENE_OR_GENE_PRODUCT", 133, 136], ["NS2a", "GENE_OR_GENE_PRODUCT", 138, 142], ["NS2b", "GENE_OR_GENE_PRODUCT", 144, 148], ["NS3", "GENE_OR_GENE_PRODUCT", 150, 153], ["NS4a", "GENE_OR_GENE_PRODUCT", 155, 159], ["NS4b", "GENE_OR_GENE_PRODUCT", 161, 165], ["structural genes", "DNA", 27, 43], ["capsid [C]", "PROTEIN", 45, 55], ["non-structural genes", "DNA", 111, 131], ["NS1", "DNA", 133, 136], ["NS2a", "DNA", 138, 142], ["NS2b", "DNA", 144, 148], ["NS3", "DNA", 150, 153], ["NS4a", "DNA", 155, 159], ["NS4b", "DNA", 161, 165], ["NS5", "DNA", 171, 174], ["pre-membrane", "TEST", 57, 69], ["NS1", "TEST", 133, 136], ["NS2a", "TEST", 138, 142], ["NS2b", "TEST", 144, 148], ["NS3", "TREATMENT", 150, 153], ["NS4a", "TEST", 155, 159], ["NS4b", "TEST", 161, 165], ["NS5", "TEST", 171, 174]]], ["The coding region is flanked by non-coding regions at the 5 \u2032 and 3 \u2032 ends of the genome.", [["genome", "CELLULAR_COMPONENT", 82, 88], ["non-coding regions", "DNA", 32, 50], ["5 \u2032 and 3 \u2032 ends", "DNA", 58, 74], ["genome", "OBSERVATION", 82, 88]]], ["The YF 17D vaccine was developed by serial passage of a Additional cases of YEL-AVD in prospective travelers and in inhabitants of South America were recognized.", [["YEL", "CHEMICAL", 76, 79], ["YF 17D", "ORGANISM", 4, 10], ["YF 17D", "SPECIES", 4, 10], ["The YF 17D vaccine", "TREATMENT", 0, 18]]], ["In S. America the incidence may be underestimated because much of the vaccine is administered to previously vaccinated individuals.PreambleIn Peru the incidence of fatal reactions in a previously unimmunized population approached 1 in 10,000.", [["S. America", "ORGANISM", 3, 13], ["the vaccine", "TREATMENT", 66, 77], ["fatal reactions", "PROBLEM", 164, 179], ["fatal", "OBSERVATION_MODIFIER", 164, 169], ["reactions", "OBSERVATION", 170, 179]]], ["In Africa surveillance for AEFI remains inadequate, although WHO has conducted follow-up for adverse events after mass YF vaccine campaigns, without definitive identification of YEL-AVD [17] [18] [19] [20] [27] [28] [29] [30] In immunocompromized Association of thymic disease with YEL-AVD.", [["thymic", "ANATOMY", 262, 268], ["AEFI", "DISEASE", 27, 31], ["thymic disease", "DISEASE", 262, 276], ["YEL-AVD [17] [18] [19] [20] [27] [28] [29] [30]", "CHEMICAL", 178, 225], ["YEL-AVD [17] [18] [19] [20] [27] [28] [29] [30", "SIMPLE_CHEMICAL", 178, 224], ["thymic", "ORGAN", 262, 268], ["adverse events", "PROBLEM", 93, 107], ["mass YF vaccine campaigns", "TREATMENT", 114, 139], ["YEL", "TEST", 178, 181], ["AVD", "TEST", 182, 185], ["thymic disease", "PROBLEM", 262, 276], ["AVD", "PROBLEM", 286, 289], ["thymic", "ANATOMY", 262, 268], ["disease", "OBSERVATION", 269, 276]]], ["Immune deficiency a contraindication to YF 17D.Systemic lupus erythematosus on corticosteroidsThymic disease is a contraindication to YF 17D.", [["Thymic", "ANATOMY", 94, 100], ["Immune deficiency", "DISEASE", 0, 17], ["Systemic lupus erythematosus", "DISEASE", 47, 75], ["corticosteroids", "CHEMICAL", 79, 94], ["Thymic disease", "DISEASE", 94, 108], ["corticosteroids", "CHEMICAL", 79, 94], ["YF 17D", "ORGANISM", 40, 46], ["Thymic", "ORGAN", 94, 100], ["YF 17D", "SPECIES", 40, 46], ["YF 17D", "SPECIES", 134, 140], ["Immune deficiency", "PROBLEM", 0, 17], ["Systemic lupus erythematosus", "PROBLEM", 47, 75], ["corticosteroids", "TREATMENT", 79, 94], ["Thymic disease", "PROBLEM", 94, 108], ["lupus erythematosus", "OBSERVATION", 56, 75], ["corticosteroids", "OBSERVATION", 79, 94], ["disease", "OBSERVATION", 101, 108]]], ["One report of YEL-AND (fatal) in a patient with HIV/AIDS 3 fatal cases.", [["HIV/AIDS", "DISEASE", 48, 56], ["patient", "ORGANISM", 35, 42], ["patient", "SPECIES", 35, 42], ["HIV", "SPECIES", 48, 51], ["HIV/AIDS 3 fatal cases", "PROBLEM", 48, 70]]], ["No safety issues after administration of YF17D in 102 HIV+ volunteers, although rate of serious adverse events of up to 3% cannot be excluded [22, 29, [31] [32] [33] In neonates, infants, children Age < 6 months associated with risk of YEL-AND, and is a contraindication.", [["YF17D", "CHEMICAL", 41, 46], ["volunteers", "ORGANISM", 59, 69], ["neonates", "ORGANISM", 169, 177], ["infants", "ORGANISM", 179, 186], ["children", "ORGANISM", 188, 196], ["HIV", "SPECIES", 54, 57], ["infants", "SPECIES", 179, 186], ["children", "SPECIES", 188, 196], ["HIV", "SPECIES", 54, 57], ["YF17D", "TREATMENT", 41, 46], ["serious adverse events", "PROBLEM", 88, 110]]], ["Children aged 6-9 months only vaccinated under special circumstances and on the basis of current official advice [15, 34] During pregnancy and in the unborn Pregnancy a hypothetical contraindication.", [["Children", "ORGANISM", 0, 8], ["Children", "SPECIES", 0, 8]]], ["However congenital infections very rare and no reports of adverse effects on fetus [39, 54] 4.11.", [["fetus", "ANATOMY", 77, 82], ["congenital infections", "DISEASE", 8, 29], ["fetus", "ORGANISM", 77, 82], ["congenital infections", "PROBLEM", 8, 29], ["adverse effects", "PROBLEM", 58, 73], ["congenital", "OBSERVATION_MODIFIER", 8, 18], ["infections", "OBSERVATION", 19, 29]]], ["What is known about the effect of pre-existing immunity on 'take', safety or efficacy in animal models?Systemic lupus erythematosus on corticosteroidsNo antivector immunity because prM-E (containing neutralizing epitopes) of YF replaced by corresponding genes of target vaccine virus.", [["Systemic lupus erythematosus", "DISEASE", 103, 131], ["corticosteroids", "CHEMICAL", 135, 150], ["corticosteroids", "CHEMICAL", 135, 150], ["prM-E", "GENE_OR_GENE_PRODUCT", 181, 186], ["YF", "ORGANISM", 225, 227], ["vaccine virus", "ORGANISM", 270, 283], ["prM", "PROTEIN", 181, 184], ["E", "PROTEIN", 185, 186], ["neutralizing epitopes", "PROTEIN", 199, 220], ["YF", "SPECIES", 225, 227], ["Systemic lupus erythematosus", "PROBLEM", 103, 131], ["corticosteroids", "TREATMENT", 135, 150], ["antivector immunity", "TREATMENT", 153, 172], ["neutralizing epitopes", "TREATMENT", 199, 220], ["YF", "PROBLEM", 225, 227], ["target vaccine virus", "PROBLEM", 263, 283], ["lupus erythematosus", "OBSERVATION", 112, 131], ["corticosteroids", "OBSERVATION", 135, 150]]], ["Prior YF immunity does not interfere.", [["YF", "ORGANISM", 6, 8], ["YF", "SPECIES", 6, 8]]], ["T cell responses to YF 17D non-structural proteins do not preclude effective immunization or re-use of vectorsSystemic lupus erythematosus on corticosteroidsPositive effect on chimeric dengue vaccine immunogenicity due to prior 17D immunity See above reviews [54, 77, 81, 83] Human?Systemic lupus erythematosus on corticosteroidsThe ChimeriVax-JE vaccine (Imojev\u00ae) was approved in Australia, Thailand and other Asian countries based on Phase 1-3 studies showing non-inferiority of neutralizing antibody responses to approved JE vaccine.", [["T cell", "ANATOMY", 0, 6], ["Systemic lupus erythematosus", "DISEASE", 110, 138], ["corticosteroids", "CHEMICAL", 142, 157], ["dengue", "DISEASE", 185, 191], ["Systemic lupus erythematosus", "DISEASE", 282, 310], ["corticosteroids", "CHEMICAL", 314, 329], ["ChimeriVax", "CHEMICAL", 333, 343], ["Imojev\u00ae", "CHEMICAL", 356, 363], ["corticosteroids", "CHEMICAL", 142, 157], ["corticosteroids", "CHEMICAL", 314, 329], ["T cell", "CELL", 0, 6], ["YF 17D", "ORGANISM", 20, 26], ["Human", "ORGANISM", 276, 281], ["ChimeriVax-JE", "ORGANISM", 333, 346], ["Imojev\u00ae", "SIMPLE_CHEMICAL", 356, 363], ["JE", "ORGANISM", 525, 527], ["YF 17D non-structural proteins", "PROTEIN", 20, 50], ["Human", "SPECIES", 276, 281], ["YF 17D", "SPECIES", 20, 26], ["dengue", "SPECIES", 185, 191], ["JE", "SPECIES", 525, 527], ["YF 17D non-structural proteins", "PROBLEM", 20, 50], ["effective immunization", "TREATMENT", 67, 89], ["Systemic lupus erythematosus", "PROBLEM", 110, 138], ["corticosteroids", "TREATMENT", 142, 157], ["Positive effect", "PROBLEM", 157, 172], ["chimeric dengue vaccine immunogenicity", "TREATMENT", 176, 214], ["Systemic lupus erythematosus", "PROBLEM", 282, 310], ["corticosteroids", "TREATMENT", 314, 329], ["The ChimeriVax-JE vaccine", "TREATMENT", 329, 354], ["neutralizing antibody responses", "PROBLEM", 481, 512], ["JE vaccine", "TREATMENT", 525, 535], ["lupus erythematosus", "OBSERVATION", 119, 138], ["effect", "OBSERVATION_MODIFIER", 166, 172], ["lupus erythematosus", "OBSERVATION", 291, 310], ["corticosteroids", "OBSERVATION", 314, 329]]], ["The ChimeriVax-WN vaccine has been shown to elicit protective levels of neutralizing antibodies as well as strong T cell responses in Phase 1-2 clinical trials.", [["T cell", "ANATOMY", 114, 120], ["ChimeriVax", "CHEMICAL", 4, 14], ["ChimeriVax-WN", "ORGANISM", 4, 17], ["T cell", "CELL", 114, 120], ["neutralizing antibodies", "PROTEIN", 72, 95], ["The ChimeriVax-WN vaccine", "TREATMENT", 0, 25], ["neutralizing antibodies", "TREATMENT", 72, 95]]], ["A placebo-controlled phase 2b study of tetravalent ChimeriVax-DEN in Thai children conducted in a single site demonstrated protection against types 1, 3 and 4 but, despite the production of neutralizing antibodies, there was no observed protection from disease with type 2 dengue, the most prevalent circulating serotype.", [["ChimeriVax-DEN", "CHEMICAL", 51, 65], ["type 2 dengue", "DISEASE", 266, 279], ["ChimeriVax-DEN", "ORGANISM", 51, 65], ["Thai", "ORGANISM", 69, 73], ["children", "ORGANISM", 74, 82], ["neutralizing antibodies", "PROTEIN", 190, 213], ["children", "SPECIES", 74, 82], ["type 2 dengue", "SPECIES", 266, 279], ["A placebo-controlled phase 2b study", "TEST", 0, 35], ["tetravalent ChimeriVax", "TREATMENT", 39, 61], ["neutralizing antibodies", "PROBLEM", 190, 213], ["disease", "PROBLEM", 253, 260], ["type 2 dengue", "PROBLEM", 266, 279], ["no observed", "UNCERTAINTY", 225, 236]]], ["A subsequent phase 3 study in Asian children conducted in 5 countries and 11 sites found 56% overall protection against dengue fever (which met the proscribed study end-point), however efficacy against dengue 2 was lower than for other serotype.", [["dengue fever", "DISEASE", 120, 132], ["dengue", "DISEASE", 202, 208], ["children", "ORGANISM", 36, 44], ["children", "SPECIES", 36, 44], ["dengue", "SPECIES", 120, 126], ["dengue", "SPECIES", 202, 208], ["A subsequent phase 3 study", "TEST", 0, 26], ["dengue fever", "PROBLEM", 120, 132], ["the proscribed study", "TEST", 144, 164], ["dengue 2", "PROBLEM", 202, 210], ["other serotype", "PROBLEM", 230, 244]]], ["35% protection against type 2 dengue was observed, compared to 50 to 78% protection against the other serotypes.", [["type 2 dengue", "DISEASE", 23, 36], ["type 2 dengue", "PROBLEM", 23, 36], ["the other serotypes", "PROBLEM", 92, 111], ["serotypes", "OBSERVATION", 102, 111]]], ["Vaccine efficacy of against dengue hemorrhagic fever (DHF) was 88.5% (per protocol) and 67.2% against hospitalization (intent to treat).", [["dengue hemorrhagic fever", "DISEASE", 28, 52], ["DHF", "DISEASE", 54, 57], ["dengue hemorrhagic fever", "SPECIES", 28, 52], ["dengue hemorrhagic fever (DHF)", "SPECIES", 28, 58], ["Vaccine efficacy", "TREATMENT", 0, 16], ["dengue hemorrhagic fever", "PROBLEM", 28, 52], ["DHF", "PROBLEM", 54, 57]]], ["A phase 3 study in Latin America further confirmed the results obtained in Asia, with a 61% overall protection against dengue fever, with an efficacy of 50% against serotype 1, 42% against serotype 2, 74% against serotype 3 and 77% against serotype 4.", [["dengue fever", "DISEASE", 119, 131], ["dengue", "SPECIES", 119, 125], ["serotype 1", "SPECIES", 165, 175], ["serotype 2", "SPECIES", 189, 199], ["A phase 3 study", "TEST", 0, 15], ["dengue fever", "PROBLEM", 119, 131], ["serotype", "TEST", 165, 173], ["serotype", "TEST", 189, 197], ["serotype", "PROBLEM", 213, 221]]], ["A significant protection was also observed against severe disease and hospitalization.", [["severe disease", "PROBLEM", 51, 65], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["protection", "OBSERVATION", 14, 24]]], ["Multiple previous Phase 2 studies also suggested a similar level of efficacySystemic lupus erythematosus on corticosteroidsThe Thai study of ChimeriVax-DEN with confirmation from an Asian and Latin American study, raises the possibility that protective efficacy is lower against type 2 dengue.", [["Systemic lupus erythematosus", "DISEASE", 76, 104], ["corticosteroids", "CHEMICAL", 108, 123], ["ChimeriVax-DEN", "CHEMICAL", 141, 155], ["type 2 dengue", "DISEASE", 279, 292], ["corticosteroids", "CHEMICAL", 108, 123], ["ChimeriVax-DEN", "CHEMICAL", 141, 155], ["ChimeriVax-DEN", "ORGANISM", 141, 155], ["type 2 dengue", "SPECIES", 279, 292], ["Phase 2 studies", "TEST", 18, 33], ["Systemic lupus erythematosus", "PROBLEM", 76, 104], ["corticosteroids", "TREATMENT", 108, 123], ["The Thai study", "TEST", 123, 137], ["Latin American study", "TEST", 192, 212], ["type 2 dengue", "PROBLEM", 279, 292], ["lupus erythematosus", "OBSERVATION", 85, 104], ["corticosteroids", "OBSERVATION", 108, 123], ["raises the possibility", "UNCERTAINTY", 214, 236]]], ["However, protection against hospitalization and severe dengue involved all 4 serotypes.", [["dengue", "DISEASE", 55, 61], ["dengue", "SPECIES", 55, 61], ["severe dengue involved all 4 serotypes", "PROBLEM", 48, 86], ["severe", "OBSERVATION_MODIFIER", 48, 54], ["dengue", "OBSERVATION", 55, 61]]], ["In the phase 3 studies there were no deaths caused by dengue in the control or vaccine groups.", [["deaths", "DISEASE", 37, 43], ["dengue", "DISEASE", 54, 60], ["dengue", "SPECIES", 54, 60], ["deaths", "PROBLEM", 37, 43], ["dengue", "PROBLEM", 54, 60], ["no", "UNCERTAINTY", 34, 36]]], ["Accordingly the efficacy of the vaccine in preventing mortality remains to be studied [38,39, [22] .", [["the vaccine", "TREATMENT", 28, 39]]], ["Another aspect of the chimeric flavivirus technology that is distinguished from other viral vectors, is that anti-vector immunity is not a significant problem for flavivirus vaccine development.", [["flavivirus", "DISEASE", 163, 173], ["flavivirus", "ORGANISM", 163, 173], ["flavivirus", "SPECIES", 163, 173], ["the chimeric flavivirus technology", "TREATMENT", 18, 52], ["flavivirus vaccine development", "TREATMENT", 163, 193]]], ["This feature is due to the fact that the prM-E region is solely responsible for generating epitopes recognized by neutralizing antibodies.", [["prM-E", "GENE_OR_GENE_PRODUCT", 41, 46], ["prM-E region", "PROTEIN", 41, 53], ["epitopes", "PROTEIN", 91, 99], ["neutralizing antibodies", "PROTEIN", 114, 137], ["the prM-E region", "PROBLEM", 37, 53], ["generating epitopes", "PROBLEM", 80, 99], ["neutralizing antibodies", "PROBLEM", 114, 137], ["neutralizing antibodies", "OBSERVATION", 114, 137]]], ["Thus, the chimeric vector contains the only neutralizing antigens of the intended target for immunization.", [["neutralizing antigens", "PROTEIN", 44, 65], ["the chimeric vector", "TREATMENT", 6, 25], ["immunization", "TREATMENT", 93, 105]]], ["Previous immunization with YF17D and T cell responses to the YF 17D backbone are insufficient to prevent effective immunization with a chimeric vector expressing a heterologous flavivirus prM-E transgene.Systemic lupus erythematosus on corticosteroidsThe efforts of the V3SWG were focused initially on the above flavivirus vaccines.", [["T cell", "ANATOMY", 37, 43], ["Systemic lupus erythematosus", "DISEASE", 204, 232], ["corticosteroids", "CHEMICAL", 236, 251], ["corticosteroids", "CHEMICAL", 236, 251], ["YF17D", "GENE_OR_GENE_PRODUCT", 27, 32], ["T cell", "CELL", 37, 43], ["YF 17D", "ORGANISM", 61, 67], ["prM-E", "GENE_OR_GENE_PRODUCT", 188, 193], ["V3SWG", "SIMPLE_CHEMICAL", 270, 275], ["heterologous flavivirus prM-E transgene", "DNA", 164, 203], ["V3SWG", "DNA", 270, 275], ["YF 17D", "SPECIES", 61, 67], ["Previous immunization", "TREATMENT", 0, 21], ["T cell responses", "TREATMENT", 37, 53], ["effective immunization", "TREATMENT", 105, 127], ["a chimeric vector", "TREATMENT", 133, 150], ["a heterologous flavivirus prM", "TREATMENT", 162, 191], ["Systemic lupus erythematosus", "PROBLEM", 204, 232], ["corticosteroids", "TREATMENT", 236, 251], ["the above flavivirus vaccines", "TREATMENT", 302, 331], ["lupus erythematosus", "OBSERVATION", 213, 232], ["corticosteroids", "OBSERVATION", 236, 251]]], ["Not addressed are additional possible vaccines in which nucleotide sequences encoding for epitopes of other microorganisms might be added into the complete YF virus vaccine yielding live virus vaccines with additional vaccination potential.", [["nucleotide", "CHEMICAL", 56, 66], ["nucleotide", "CHEMICAL", 56, 66], ["YF virus", "ORGANISM", 156, 164], ["live virus", "ORGANISM", 182, 192], ["epitopes", "PROTEIN", 90, 98], ["YF virus", "SPECIES", 156, 164], ["vaccines", "TREATMENT", 38, 46], ["nucleotide sequences", "TEST", 56, 76], ["epitopes of other microorganisms", "PROBLEM", 90, 122], ["the complete YF virus vaccine", "TREATMENT", 143, 172], ["live virus vaccines", "TREATMENT", 182, 201]]], ["Vaccines employing other methods of attenuating flaviviruses through mechanisms such as nucleotide deletions and which do not involve a viral vector are not considered in this project [25] .Systemic lupus erythematosus on corticosteroidsThe chimeric vaccines indicated for the prevention of dengue, Japanese encephalitis, and West Nile will be considered new entities from the regulatory perspective, and will need to be independently assessed for safety and efficacy.", [["flaviviruses", "DISEASE", 48, 60], ["nucleotide", "CHEMICAL", 88, 98], ["Systemic lupus erythematosus", "DISEASE", 190, 218], ["corticosteroids", "CHEMICAL", 222, 237], ["dengue", "DISEASE", 291, 297], ["Japanese encephalitis", "DISEASE", 299, 320], ["nucleotide", "CHEMICAL", 88, 98], ["corticosteroids", "CHEMICAL", 222, 237], ["dengue", "SPECIES", 291, 297], ["Vaccines", "TREATMENT", 0, 8], ["attenuating flaviviruses", "PROBLEM", 36, 60], ["nucleotide deletions", "PROBLEM", 88, 108], ["a viral vector", "PROBLEM", 134, 148], ["Systemic lupus erythematosus", "PROBLEM", 190, 218], ["corticosteroids", "TREATMENT", 222, 237], ["The chimeric vaccines", "TREATMENT", 237, 258], ["dengue", "PROBLEM", 291, 297], ["Japanese encephalitis", "PROBLEM", 299, 320], ["lupus erythematosus", "OBSERVATION", 199, 218], ["corticosteroids", "OBSERVATION", 222, 237]]], ["However, in the development of these new vaccines, the parental YF 17D vaccine virus has provided an important comparator and benchmark in all preclinical and many clinical trials.", [["YF 17D vaccine virus", "ORGANISM", 64, 84], ["YF 17D vaccine virus", "SPECIES", 64, 84], ["these new vaccines", "TREATMENT", 31, 49], ["the parental YF 17D vaccine virus", "TREATMENT", 51, 84], ["new", "OBSERVATION_MODIFIER", 37, 40], ["vaccines", "OBSERVATION", 41, 49]]], ["For example, the monkey neurovirulence test is an important measure of safety of YF 17D vaccines, and YF 17D was used as the reference strain in many studies, which showed that the chimeric vaccines were more attenuated than parental YF 17D.", [["monkey", "ORGANISM", 17, 23], ["YF 17D", "ORGANISM", 81, 87], ["YF 17D", "ORGANISM", 102, 108], ["YF 17D", "ORGANISM", 234, 240], ["YF 17D", "SPECIES", 81, 87], ["YF 17D", "SPECIES", 102, 108], ["YF 17D", "SPECIES", 234, 240], ["the monkey neurovirulence test", "TEST", 13, 43], ["YF 17D vaccines", "TREATMENT", 81, 96], ["many studies", "TEST", 145, 157], ["the chimeric vaccines", "TREATMENT", 177, 198]]], ["An important regulatory question thus arises as to whether the age range for vaccination, precautions and contraindications in labelling for use of YF 17D vaccines should apply to the new, chimeric vaccines.", [["YF 17D", "ORGANISM", 148, 154], ["YF", "SPECIES", 148, 150], ["vaccination", "TREATMENT", 77, 88], ["precautions", "TREATMENT", 90, 101], ["YF 17D vaccines", "TREATMENT", 148, 163], ["the new, chimeric vaccines", "TREATMENT", 180, 206]]], ["This question is particularly important since data on very rare adverse events will likely not be available at the time the new vaccines are approved.", [["very rare adverse events", "PROBLEM", 54, 78], ["the new vaccines", "TREATMENT", 120, 136]]], ["The template supplied in this paper contains information that can potentially be useful in considering how new chimeric vaccines should be described in reference to parental YF 17D vaccines.Systemic lupus erythematosus on corticosteroids1.3.", [["Systemic lupus erythematosus", "DISEASE", 190, 218], ["corticosteroids", "CHEMICAL", 222, 237], ["corticosteroids", "CHEMICAL", 222, 237], ["YF 17D", "ORGANISM", 174, 180], ["YF 17D", "SPECIES", 174, 180], ["new chimeric vaccines", "TREATMENT", 107, 128], ["parental YF 17D vaccines", "TREATMENT", 165, 189], ["Systemic lupus erythematosus", "PROBLEM", 190, 218], ["corticosteroids", "TREATMENT", 222, 237], ["lupus erythematosus", "OBSERVATION", 199, 218]]], ["Methods for developing, completing and reviewing the standardized templateSystemic lupus erythematosus on corticosteroidsFollowing the process described in the accompanying overview paper [26] as well as on the Brighton Collaboration website (http://cms.brightoncollaboration.org:8080/public/what-we-do/ setting-standards/case-definitions/process.html), the Brighton Collaboration V3SWG was formed in October 2008 and includes \u223c15 members with clinical, academic, public health, regulatory and industry backgrounds with appropriate expertise and interest.", [["lupus erythematosus", "DISEASE", 83, 102], ["corticosteroids", "CHEMICAL", 106, 121], ["corticosteroids", "CHEMICAL", 106, 121], ["the standardized templateSystemic lupus erythematosus", "PROBLEM", 49, 102], ["corticosteroids", "TREATMENT", 106, 121], ["lupus erythematosus", "OBSERVATION", 83, 102]]], ["The workgroup meets via emails and monthly conference calls coordinated by a secretariat [currently at CDC's Division of HIV/AIDS Prevention].Systemic lupus erythematosus on corticosteroidsThe V3SWG invited a flavivirus expert, Thomas P. Monath (TPM), who has been intimately associated with the development of flavivirus vaccines based on the YF virus vaccine backbone to complete the template in 2011.", [["HIV/AIDS", "DISEASE", 121, 129], ["Systemic lupus erythematosus", "DISEASE", 142, 170], ["corticosteroids", "CHEMICAL", 174, 189], ["TPM", "CHEMICAL", 246, 249], ["corticosteroids", "CHEMICAL", 174, 189], ["flavivirus", "ORGANISM", 311, 321], ["YF virus", "ORGANISM", 344, 352], ["YF virus vaccine", "SPECIES", 344, 360], ["YF virus", "SPECIES", 344, 352], ["HIV/AIDS Prevention", "TREATMENT", 121, 140], ["Systemic lupus erythematosus", "PROBLEM", 142, 170], ["corticosteroids", "TREATMENT", 174, 189], ["flavivirus vaccines", "TREATMENT", 311, 330], ["the YF virus vaccine backbone", "TREATMENT", 340, 369], ["lupus erythematosus", "OBSERVATION", 151, 170], ["corticosteroids", "OBSERVATION", 174, 189], ["flavivirus", "OBSERVATION", 311, 321]]], ["The first draft was then critiqued by a member of the working group knowledgeable about flaviviruses, Stephen J. Seligman (SJS), moderated by another member, James S. Robertson (JSR), discussed by the V3SWG as a whole, and then peer reviewed by reference groups (e.g., American Society of Virology, American Society of Tropical Medicine and Hygiene) and the Brighton Collaboration membership.", [["flaviviruses", "DISEASE", 88, 100], ["SJS", "DISEASE", 123, 126], ["Tropical Medicine", "TREATMENT", 319, 336]]], ["Sections 8 (overall risk assessment) and 9 (adverse effect assessment) of the template seeks to rate the risk of the viral vector in various situations as: none, minimal, low, moderate, high, or unknown.", [["Sections", "TEST", 0, 8], ["overall risk assessment", "TEST", 12, 35], ["adverse effect assessment", "TEST", 44, 69], ["the viral vector in various situations", "PROBLEM", 113, 151], ["minimal, low, moderate, high", "PROBLEM", 162, 190], ["viral vector", "OBSERVATION", 117, 129], ["minimal", "OBSERVATION_MODIFIER", 162, 169], ["low", "OBSERVATION_MODIFIER", 171, 174], ["moderate", "OBSERVATION_MODIFIER", 176, 184]]], ["An initial assessment was made by TPM and then reviewed by others, based largely on the anticipated frequency and severity of the vaccine adverse event versus the expected frequency and severity of the target vaccine preventable disease [15] .", [["An initial assessment", "TEST", 0, 21], ["the vaccine adverse event", "PROBLEM", 126, 151], ["the target vaccine preventable disease", "PROBLEM", 198, 236]]], ["Depending on the season, the risk of the yellow fever vaccine approaches the risk of YF in S. America.", [["yellow fever", "DISEASE", 41, 53], ["YF", "DISEASE", 85, 87], ["yellow fever", "ORGANISM", 41, 53], ["S. America", "ORGANISM", 91, 101], ["YF", "SPECIES", 85, 87], ["the yellow fever vaccine", "TREATMENT", 37, 61], ["YF", "PROBLEM", 85, 87]]], ["In Africa the risk of yellow fever is usually much greater than the risk of the vaccine.", [["yellow fever", "DISEASE", 22, 34], ["yellow fever", "PROBLEM", 22, 34], ["the vaccine", "TREATMENT", 76, 87], ["yellow", "OBSERVATION_MODIFIER", 22, 28], ["fever", "OBSERVATION", 29, 34]]], ["The V3SWG may develop more explicit criteria for standardizing the rating of these risks in the future with further experience.Systemic lupus erythematosus on corticosteroidsThe resulting template is submitted as a guideline for evaluating the current issues in development of vaccines based on the yellow fever virus vaccine backbone.", [["Systemic lupus erythematosus", "DISEASE", 127, 155], ["corticosteroids", "CHEMICAL", 159, 174], ["yellow fever", "DISEASE", 299, 311], ["corticosteroids", "CHEMICAL", 159, 174], ["yellow fever virus", "ORGANISM", 299, 317], ["yellow fever virus", "SPECIES", 299, 317], ["yellow fever virus", "SPECIES", 299, 317], ["Systemic lupus erythematosus", "PROBLEM", 127, 155], ["corticosteroids", "TREATMENT", 159, 174], ["vaccines", "TREATMENT", 277, 285], ["the yellow fever virus vaccine backbone", "TREATMENT", 295, 334], ["lupus erythematosus", "OBSERVATION", 136, 155], ["corticosteroids", "OBSERVATION", 159, 174]]]], "PMC7497854": [["IntroductionThe COVID-19 is a renowned disease code worldwide for coronavirus disease 2019, which is caused by novel coronavirus also known as severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2).", [["coronavirus disease", "DISEASE", 66, 85], ["acute respiratory syndrome coronavirus", "DISEASE", 150, 188], ["severe acute respiratory syndrome coronavirus-2", "ORGANISM", 143, 190], ["SARS-CoV-2", "ORGANISM", 192, 202], ["COVID-19", "DNA", 16, 24], ["COVID-19", "SPECIES", 16, 24], ["severe acute respiratory syndrome coronavirus", "SPECIES", 143, 188], ["SARS-CoV-2", "SPECIES", 192, 202], ["coronavirus disease", "PROBLEM", 66, 85], ["novel coronavirus", "PROBLEM", 111, 128], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 143, 188], ["CoV", "TEST", 197, 200], ["coronavirus", "OBSERVATION", 117, 128], ["severe", "OBSERVATION_MODIFIER", 143, 149], ["acute", "OBSERVATION_MODIFIER", 150, 155], ["respiratory syndrome", "OBSERVATION", 156, 176]]], ["This pandemic is the third outbreak of coronavirus family in two decades after Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS) (Gorbalenya et al. 2020).", [["coronavirus", "DISEASE", 39, 50], ["Acute Respiratory Syndrome", "DISEASE", 86, 112], ["SARS", "DISEASE", 114, 118], ["Middle East Respiratory Syndrome", "DISEASE", 124, 156], ["MERS", "DISEASE", 158, 162], ["coronavirus", "ORGANISM", 39, 50], ["Middle East Respiratory Syndrome (MERS)", "SPECIES", 124, 163], ["Severe Acute Respiratory Syndrome", "PROBLEM", 79, 112], ["SARS)", "PROBLEM", 114, 119], ["Middle East Respiratory Syndrome", "PROBLEM", 124, 156], ["Severe", "OBSERVATION_MODIFIER", 79, 85], ["Acute", "OBSERVATION_MODIFIER", 86, 91], ["Respiratory Syndrome", "OBSERVATION", 92, 112], ["Middle", "ANATOMY_MODIFIER", 124, 130], ["Respiratory Syndrome", "OBSERVATION", 136, 156]]], ["Now, it's like a plague of the twenty-first century, which has affected almost all the countries of the world with more than eight million confirmed cases and 0.44 million deaths as of June 15, 2020 (WHO 2020a).", [["deaths", "DISEASE", 172, 178]]], ["The rapid spread of this contagious disease includes pneumonia-like symptomatic or asymptomatic manifestations (80% infections) (WHO 2020b).", [["pneumonia", "DISEASE", 53, 62], ["infections", "DISEASE", 116, 126], ["this contagious disease", "PROBLEM", 20, 43], ["pneumonia", "PROBLEM", 53, 62], ["asymptomatic manifestations", "PROBLEM", 83, 110], ["80% infections", "PROBLEM", 112, 126], ["rapid", "OBSERVATION_MODIFIER", 4, 9], ["spread", "OBSERVATION_MODIFIER", 10, 16], ["contagious", "OBSERVATION_MODIFIER", 25, 35], ["disease", "OBSERVATION", 36, 43], ["pneumonia", "OBSERVATION", 53, 62], ["symptomatic", "OBSERVATION_MODIFIER", 68, 79], ["asymptomatic", "OBSERVATION_MODIFIER", 83, 95]]], ["The incubation period of this novel coronavirus is 1\u201314 days after infection; most commonly, the symptoms start to appear within 5\u20138 days (Linton et al. 2020; Shakoor et al. 2020).", [["coronavirus", "DISEASE", 36, 47], ["infection", "DISEASE", 67, 76], ["coronavirus", "ORGANISM", 36, 47], ["this novel coronavirus", "PROBLEM", 25, 47], ["infection", "PROBLEM", 67, 76], ["the symptoms", "PROBLEM", 93, 105]]], ["The infected person could experience mild to severe symptoms mainly including fever (most frequent), cough, shortness of breath.", [["fever", "DISEASE", 78, 83], ["cough", "DISEASE", 101, 106], ["shortness of breath", "DISEASE", 108, 127], ["person", "ORGANISM", 13, 19], ["person", "SPECIES", 13, 19], ["mild to severe symptoms", "PROBLEM", 37, 60], ["fever", "PROBLEM", 78, 83], ["cough", "PROBLEM", 101, 106], ["shortness of breath", "PROBLEM", 108, 127], ["infected", "OBSERVATION", 4, 12], ["mild", "OBSERVATION_MODIFIER", 37, 41], ["severe", "OBSERVATION_MODIFIER", 45, 51]]], ["The most ruthless form of this novel disease can cause pneumonia, kidney failure, sore throat, fatigue, severe damages to the respiratory system and even death (Cheng et al. 2020; Michelen et al. 2020).", [["kidney", "ANATOMY", 66, 72], ["respiratory system", "ANATOMY", 126, 144], ["pneumonia", "DISEASE", 55, 64], ["kidney failure", "DISEASE", 66, 80], ["sore throat", "DISEASE", 82, 93], ["fatigue", "DISEASE", 95, 102], ["damages to the respiratory system", "DISEASE", 111, 144], ["death", "DISEASE", 154, 159], ["kidney", "ORGAN", 66, 72], ["this novel disease", "PROBLEM", 26, 44], ["pneumonia", "PROBLEM", 55, 64], ["kidney failure", "PROBLEM", 66, 80], ["sore throat", "PROBLEM", 82, 93], ["fatigue", "PROBLEM", 95, 102], ["severe damages to the respiratory system", "PROBLEM", 104, 144], ["pneumonia", "OBSERVATION", 55, 64], ["kidney", "ANATOMY", 66, 72], ["failure", "OBSERVATION", 73, 80], ["sore throat", "ANATOMY", 82, 93], ["severe", "OBSERVATION_MODIFIER", 104, 110], ["damages", "OBSERVATION", 111, 118], ["respiratory system", "ANATOMY", 126, 144]]], ["The dangerous aspect is its fast-human to human transmission rate.", [["human", "ORGANISM", 33, 38], ["human", "ORGANISM", 42, 47], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 42, 47], ["dangerous", "OBSERVATION_MODIFIER", 4, 13]]], ["Epidemiology of this novel disease is mainly affected by three factors, i.e., the host, transmission media, and the environment (Bilal et al. 2020; Sobral et al. 2020).IntroductionIn Pakistan, the first two cases were reported in Karachi, Sindh province, on February 26, 2020 (Dawn News, 2020).", [["this novel disease", "PROBLEM", 16, 34], ["disease", "OBSERVATION", 27, 34]]], ["The total number of confirmed cases were 148,921 and 2839 deaths as of June 15, 2020 in Pakistan.", [["deaths", "DISEASE", 58, 64], ["total", "OBSERVATION_MODIFIER", 4, 9]]], ["A rapid rise in the number of daily confirmed cases and deaths was seen from May 7, 2020, onwards.", [["deaths", "DISEASE", 56, 62], ["A rapid rise", "PROBLEM", 0, 12], ["rapid", "OBSERVATION_MODIFIER", 2, 7], ["rise", "OBSERVATION_MODIFIER", 8, 12]]], ["As of June 15, 2020, Pakistan ranked 14th on the globe.", [["globe", "ANATOMY", 49, 54]]], ["The situation of COVID-19 in Pakistan can be checked through official national and international websites like covid.gov.pk, covid19.who.int, and worldometers.info.IntroductionSeveral studies have shown the impacts of environmental and weather conditions on spread of viral diseases.", [["viral diseases", "DISEASE", 268, 282], ["covid19", "GENE_OR_GENE_PRODUCT", 125, 132], ["covid19", "DNA", 125, 132], ["COVID", "TEST", 17, 22], ["covid19", "TEST", 125, 132], ["Several studies", "TEST", 176, 191], ["viral diseases", "PROBLEM", 268, 282], ["viral diseases", "OBSERVATION", 268, 282]]], ["For instance, certain weather and climatic conditions possibly play a vital role in restricting the spread of contagious diseases (Wang et al. 2010; D\u2019Amato et al. 2014).", [["climatic conditions", "PROBLEM", 34, 53], ["contagious diseases", "PROBLEM", 110, 129]]], ["A recent study in Norway, Oslo concluded that temperature was positively and precipitation negatively correlated with the COVID-19 disease (Menebo 2020).", [["A recent study", "TEST", 0, 14], ["the COVID-19 disease", "PROBLEM", 118, 138]]], ["Similar kinds of results have been found in another study conducted in New York City, USA (Bashir et al. 2020).", [["another study", "TEST", 44, 57]]], ["A global study also showed the association between COVID-19 cases and the climatic indicators (Sobral et al. 2020).", [["A global study", "TEST", 0, 14], ["COVID", "TEST", 51, 56]]], ["By taking all the above mentioned scenarios into account, this study is aimed to investigate the association between meteorological parameters like temperature, precipitation, and humidity with COVID-19 cases and deaths.Materials and methodsPakistan is situated in South Asia and bordered with India, Afghanistan, China, and Iran.", [["deaths", "DISEASE", 213, 219], ["this study", "TEST", 58, 68], ["meteorological parameters", "TEST", 117, 142], ["precipitation", "TREATMENT", 161, 174], ["COVID", "TREATMENT", 194, 199]]], ["Islamabad, the capital of Pakistan, having a total population of 1.095 million, covers an area of 906.5 km2.", [["a total population", "TREATMENT", 43, 61]]], ["Pakistan, as a developing country, has limited resources to combat COVID-19 disease.", [["COVID-19", "CANCER", 67, 75], ["disease", "PROBLEM", 76, 83]]], ["The data set of COVID-19 regarding confirmed cases and deaths in Islamabad (on a daily basis) was taken from the official website of Pakistan (covid.gov.pk).", [["deaths", "DISEASE", 55, 61], ["COVID", "TEST", 16, 21]]], ["While the data set of meteorological parameters such as temperature and humidity (on a daily basis) was taken from a USA based website of National Oceanic and Atmospheric Administration (NOAA) (noaa.gov).", [["meteorological parameters", "TEST", 22, 47], ["National Oceanic", "TREATMENT", 138, 154], ["Atmospheric Administration", "TREATMENT", 159, 185]]], ["The datasets of both meteorological parameters and COVID-19 daily new cases and deaths were taken within the time era of May 1, 2020, to June 15, 2020.", [["deaths", "DISEASE", 80, 86], ["COVID", "TEST", 51, 56]]], ["The correlation tests were used to determine the association between the COVID-19 pandemic and the meteorological parameters.", [["The correlation tests", "TEST", 0, 21], ["the COVID", "TEST", 69, 78], ["the meteorological parameters", "TEST", 95, 124]]], ["The pictorial graphs were made of the meteorological COVID-19 data by using OriginPro software, and SPSS was used for correlation and data analysis.", [["the meteorological COVID", "TEST", 34, 58], ["OriginPro software", "TEST", 76, 94], ["SPSS", "TEST", 100, 104], ["data analysis", "TEST", 134, 147]]], ["Figure 1 shows the total number of cases and deaths of COVID-19 on August 10, 2020, in Pakistan.Results and discussionThe daily confirmed COVID-19 patients of Islamabad city were within the hundred numbers until mid of May, 2020.", [["deaths", "DISEASE", 45, 51], ["patients", "ORGANISM", 147, 155], ["patients", "SPECIES", 147, 155], ["COVID", "TEST", 55, 60], ["COVID", "TEST", 138, 143]]], ["After then, the daily new cases escalated very swiftly (Fig. S1).", [["S1", "GENE_OR_GENE_PRODUCT", 61, 63], ["S1", "PROTEIN", 61, 63]]], ["The total number of confirmed cases in Islamabad were 8857 as of June 15, 2020.", [["total", "OBSERVATION_MODIFIER", 4, 9]]], ["In the span of May 1, 2020, to June 15, 2020, minimum cases as 21 and maximum cases as 771 were reported on May 5, and June 13, 2020, respectively.", [["minimum cases", "TEST", 46, 59]]], ["The deaths started to report from May 9, with the total number of fatalities as 83 until June 15, 2020 (Fig. S2).", [["deaths", "DISEASE", 4, 10], ["fatalities", "DISEASE", 66, 76], ["S2", "PROTEIN", 109, 111]]], ["The weather data of Islamabad showed temperature ranges from 26 \u00b0C (highest minimum temperature) to 40 \u00b0C (highest maximum temperature) with an average of 32 \u00b0C (highest average temperature) (Fig. S3); likewise, humidity ranged from 57% (highest minimum humidity) to 100% (highest maximum humidity) with an average of 89% (highest average humidity) (Fig. S4).", [["temperature ranges", "TEST", 37, 55], ["maximum temperature", "TEST", 115, 134], ["humidity", "TEST", 212, 220]]], ["The rainfall data showed 11 days of rainfall recorded with a maximum of 160 mm within the period taken for this study (Fig. S5).Results and discussionTable 1 illustrates the Pearson, Spearman, and Kendall\u2019s correlations between COVID-19 new cases, deaths and the weather parameters (minimum temperature, maximum temperature, average temperature, minimum humidity, maximum humidity, average humidity and minimum rainfall, maximum rainfall, average rainfall).", [["deaths", "DISEASE", 248, 254], ["S5", "GENE_OR_GENE_PRODUCT", 124, 126], ["S5", "PROTEIN", 124, 126], ["The rainfall data", "TEST", 0, 17], ["this study", "TEST", 107, 117], ["COVID", "TEST", 228, 233], ["the weather parameters", "TEST", 259, 281], ["minimum temperature", "TEST", 283, 302], ["maximum temperature", "TEST", 304, 323], ["average temperature", "TEST", 325, 344], ["minimum humidity", "TEST", 346, 362], ["maximum humidity", "TEST", 364, 380]]], ["While, Fig. 2 shows correlations between COVID-19 new cases, deaths and the weather parameters.", [["deaths", "DISEASE", 61, 67], ["COVID", "TEST", 41, 46], ["the weather parameters", "TEST", 72, 94]]], ["All three types of correlations results showed that new COVID-19 cases and deaths were significantly correlated with temperature minimum at p < 0.01 with a high level as the correlation coefficients were greater than 0.5.", [["deaths", "DISEASE", 75, 81], ["new COVID", "TEST", 52, 61], ["temperature minimum", "TEST", 117, 136], ["the correlation coefficients", "TEST", 170, 198]]], ["Also, new cases were mediumly correlated with temperature average at p < 0.05.", [["temperature average", "TEST", 46, 65]]], ["However, temperature maximum, humidity minimum, humidity maximum, humidity average, and rainfall were not significantly correlated with new COVID-19 cases and deaths (Table 1).Results and discussionThe current study provides information in support of the spread of COVID-19 and fatalities in Islamabad with relation to various metrological parameters.", [["deaths", "DISEASE", 159, 165], ["temperature maximum", "TEST", 9, 28], ["humidity minimum", "TEST", 30, 46], ["humidity maximum", "TEST", 48, 64], ["The current study", "TEST", 198, 215], ["COVID", "TEST", 265, 270]]], ["While the findings showed that the spread of COVID-19 has an association with temperature minimum with the lowest minimum temperature of 15 \u00b0C and the highest minimum temperature of 26 \u00b0C; also, with the temperature average having the lowest average temperature 20 \u00b0C and highest average temperature 32 \u00b0C. An argument on positive relationship between COVID-19 and temperature around 15\u201325 with pleasant sunny days could be the breaking of lock-down rules resulting in the spread of COVID-19.", [["COVID-19", "CHEMICAL", 45, 53], ["COVID-19", "CHEMICAL", 45, 53], ["COVID", "TEST", 45, 50], ["the temperature", "TEST", 200, 215], ["temperature", "TEST", 288, 299], ["COVID", "TEST", 352, 357], ["temperature", "TEST", 365, 376], ["COVID", "TEST", 483, 488], ["positive relationship", "OBSERVATION_MODIFIER", 322, 343]]], ["In contrast, people are less prone to go outside in high temperature and rainfall days.", [["people", "ORGANISM", 13, 19], ["people", "SPECIES", 13, 19], ["high temperature", "OBSERVATION_MODIFIER", 52, 68]]], ["Several studies argued that COVID-19 is a cold virus having high stability at lower temperatures, while sensitive to high temperature (Shi et al. 2020).", [["COVID-19", "CHEMICAL", 28, 36], ["COVID-19", "ORGANISM", 28, 36], ["Several studies", "TEST", 0, 15], ["COVID", "TEST", 28, 33], ["a cold virus", "PROBLEM", 40, 52], ["high stability at lower temperatures", "PROBLEM", 60, 96], ["high temperature", "PROBLEM", 117, 133], ["high stability", "OBSERVATION_MODIFIER", 60, 74], ["lower temperatures", "OBSERVATION_MODIFIER", 78, 96]]], ["However, the spread of contagious diseases like COVID-19 and its relation to weather transmission and other meteorological parameters like temperature, humidity, wind speed, precipitation etc. was reported previously with the severe acute respiratory syndrome (SARS), Respiratory Syncytial Virus (RSV), and West Nile virus infection (Tan et al. 2005; Wang et al. 2010; Vandini et al. 2013).Results and discussionIn the early days of the emergence of this disease in Wuhan, a study indicated the correlation between weather temperature and the spread of COVID-19.", [["COVID-19", "CHEMICAL", 48, 56], ["acute respiratory syndrome", "DISEASE", 233, 259], ["SARS", "DISEASE", 261, 265], ["Respiratory Syncytial Virus (RSV)", "DISEASE", 268, 301], ["West Nile virus infection", "DISEASE", 307, 332], ["Respiratory Syncytial Virus", "ORGANISM", 268, 295], ["RSV", "ORGANISM", 297, 300], ["West Nile virus", "ORGANISM", 307, 322], ["West Nile virus", "SPECIES", 307, 322], ["Respiratory Syncytial Virus", "SPECIES", 268, 295], ["RSV", "SPECIES", 297, 300], ["West Nile virus", "SPECIES", 307, 322], ["contagious diseases", "PROBLEM", 23, 42], ["COVID", "TEST", 48, 53], ["meteorological parameters", "TEST", 108, 133], ["the severe acute respiratory syndrome", "PROBLEM", 222, 259], ["SARS)", "PROBLEM", 261, 266], ["Respiratory Syncytial Virus (RSV)", "PROBLEM", 268, 301], ["West Nile virus infection", "PROBLEM", 307, 332], ["this disease", "PROBLEM", 450, 462], ["a study", "TEST", 473, 480], ["weather temperature", "TEST", 515, 534], ["COVID", "TEST", 553, 558], ["spread", "OBSERVATION_MODIFIER", 13, 19], ["contagious", "OBSERVATION_MODIFIER", 23, 33], ["diseases", "OBSERVATION", 34, 42], ["severe", "OBSERVATION_MODIFIER", 226, 232], ["acute", "OBSERVATION_MODIFIER", 233, 238], ["respiratory syndrome", "OBSERVATION", 239, 259], ["Respiratory Syncytial", "ANATOMY", 268, 289]]], ["It concluded that the disease conquers with the rise in environmental temperature (Guo et al. 2020).", [["the disease conquers", "PROBLEM", 18, 38], ["disease", "OBSERVATION", 22, 29], ["rise", "OBSERVATION_MODIFIER", 48, 52]]], ["Nonetheless, the temperature in Islamabad is going further up in the ongoing summer, while the number of cases daily reports is also increasing.", [["increasing", "OBSERVATION_MODIFIER", 133, 143]]], ["This study also showed no association with temperature maximum.", [["This study", "TEST", 0, 10], ["no association with", "UNCERTAINTY", 23, 42]]], ["However, the spread of this virus might be influenced by other factors like population density, people's attitude towards taking precautionary measures, lockdown implementation, population mobility, testing facilities and capacity, and development of herd immunity.Results and discussionThis study can assist the cognitive policymakers regarding COVID-19 spread and its association with meteorological parameters.", [["herd", "ORGANISM_SUBDIVISION", 251, 255], ["COVID-19", "CELL", 346, 354], ["people", "SPECIES", 96, 102], ["this virus", "PROBLEM", 23, 33], ["precautionary measures", "TREATMENT", 129, 151], ["This study", "TEST", 287, 297], ["COVID", "TEST", 346, 351], ["meteorological parameters", "TEST", 387, 412]]], ["Despite this, the study may have some limitations.", [["the study", "TEST", 14, 23]]], ["First, the date of test conduction and the time of result intimation may not imply the infection date, and the incubation of this virus is yet another factor to influence.", [["infection", "DISEASE", 87, 96], ["test conduction", "TEST", 19, 34], ["the infection", "PROBLEM", 83, 96], ["this virus", "PROBLEM", 125, 135], ["infection", "OBSERVATION", 87, 96]]], ["Secondly, the limited daily testing capacity may also influence the number of confirmed new cases.", [["the limited daily testing capacity", "TEST", 10, 44]]], ["Thirdly, this study is based on the dataset of one and a half months (May 1 to June 15), the solid conclusions require more time because the spread of this disease is not as yet over in Pakistan.ConclusionPrevious literature on similar global pandemics proved the association between meteorological parameters and the spread of contagious diseases.", [["this study", "TEST", 9, 19], ["this disease", "PROBLEM", 151, 163], ["meteorological parameters", "TEST", 284, 309], ["contagious diseases", "PROBLEM", 328, 347], ["disease", "OBSERVATION", 156, 163], ["spread", "OBSERVATION_MODIFIER", 318, 324], ["contagious diseases", "OBSERVATION", 328, 347]]], ["This study concluded that temperature minimum and temperature average were significantly correlated with COVID-19, nevertheless humidity and rainfall do not have any relation with COVID-19 proliferation in Islamabad, Pakistan.", [["This study", "TEST", 0, 10], ["temperature minimum", "TEST", 26, 45], ["temperature average", "TEST", 50, 69], ["COVID", "TEST", 105, 110], ["COVID", "TREATMENT", 180, 185]]], ["However, various other factors like population density and social distancing etc. may also affect the spread of this disease.", [["population density", "PROBLEM", 36, 54], ["this disease", "PROBLEM", 112, 124], ["population", "OBSERVATION_MODIFIER", 36, 46], ["density", "OBSERVATION", 47, 54], ["spread", "OBSERVATION_MODIFIER", 102, 108], ["disease", "OBSERVATION", 117, 124]]]], "PMC7108019": [["EPIDEMICSEpidemics of infections are predictable to occur, but largely unpredictable in time, place, microbe, and consequences.", [["infections", "DISEASE", 22, 32], ["infections", "PROBLEM", 22, 32], ["infections", "OBSERVATION", 22, 32], ["unpredictable", "OBSERVATION_MODIFIER", 71, 84]]]], "22c9417168261106e727e559b0a3e425b7f1b560": [["How to avoid nosocomial spread during tracheostomy for COVID-19 patients", [["patients", "ORGANISM", 64, 72], ["patients", "SPECIES", 64, 72], ["nosocomial spread", "PROBLEM", 13, 30], ["tracheostomy", "TREATMENT", 38, 50]]]], "1e25adaeb1a47cce8e742b25e9d168580e150f2d": [["Vanwege de pandemie van het SARS-CoV-2-virus is in de chronische (diabetes)zorg in korte tijd veel gebeurd om de face-to-facezorg te transformeren tot zorg op afstand (remote) per telefoon en/of beeld.", [["diabetes", "DISEASE", 66, 74], ["CoV-2-virus", "ORGANISM", 33, 44], ["Vanwege de pandemie van het SARS-CoV-2-virus", "SPECIES", 0, 44], ["korte tijd veel gebeurd om de face-to-facezorg te transformeren tot zorg op afstand", "SPECIES", 83, 166], ["CoV", "TEST", 33, 36], ["virus", "PROBLEM", 39, 44], ["diabetes", "PROBLEM", 66, 74]]], ["In de literatuur wordt deze terminologie al jarenlang gebruikt voor allerlei initiatieven waarin internet of zorg op afstand worden gebruikt, zowel voor type 1-als type 2-diabetes.", [["diabetes", "DISEASE", 171, 179], ["diabetes", "PROBLEM", 171, 179], ["diabetes", "OBSERVATION", 171, 179]]], ["Achter deze aanbevelingen zit uiteraard de ambitie om de uitkomst van zorg \u2212 uitgedrukt in glucose metrics en PROM's (patient reported outcome measures) \u2212 te optimaliseren met een gestroomlijnde data-uitwisseling die voor zowel voor de pati\u00ebnt als de hulpverlener goed te hanteren is.", [["glucose", "CHEMICAL", 91, 98], ["patient", "ORGANISM", 118, 125], ["patient", "SPECIES", 118, 125], ["glucose metrics en PROM's", "TREATMENT", 91, 116]]], ["Daarmee kan een digitale kliniek bijdragen aan een verbetering van waarde van de zorg voor de pati\u00ebnt.TECHNOLOGIE EN UITKOMSTHet gebruik van technologie voor en door diabetespati\u00ebnten is de afgelopen jaren enorm toegenomen.", [["Daarmee kan een", "TREATMENT", 0, 15]]], ["In de T1D Exchange-studie werd, ondanks stijging van technologiegebruik, zelfs een verslechtering gezien.", [["T1D", "DISEASE", 6, 9]]], ["Van de jongeren met type 1-diabetes heeft in 2018 17% een HbA1c < 7.5% en 21% van de volwassenen heeft een HbA1c < 7%.", [["diabetes heeft", "DISEASE", 27, 41], ["diabetes", "PROBLEM", 27, 35], ["een", "TEST", 54, 57], ["HbA1c", "TEST", 58, 63], ["een HbA1c", "TEST", 103, 112]]], ["2 In de populatie met type 2-diabetes is pomp-en sensorbehandeling minder uitgebreid ge\u00ebvalueerd, al werd in een recente meta-analyse gerapporteerd dat FGM-gebruik ook in deze groep verbetering van regulatie bewerkstelligt.", [["diabetes", "DISEASE", 29, 37], ["diabetes", "PROBLEM", 29, 37]]], ["4 \u2022 Doel van een digitale kliniek is de pati\u00ebnt te steunen in zelfmanagement.TECHNOLOGIE EN UITKOMST\u2022 Het eigenaarschap van de data moet gereguleerd worden op mondiaal niveau; de pati\u00ebnt besluit wie mag meekijken. \u2022 In een digitale kliniek kunnen sommige face-to-facecontacten vervangen worden door digitale contactmomenten.", [["Doel van een digitale kliniek", "TREATMENT", 4, 33]]], ["Dit zorgt voor frequentere tussentijdse interactie. \u2022 Het is belangrijk dat de data van alle devices (zoals pompdata met sensordata) gemakkelijk overdraagbaar zijn, om ze te kunnen integreren, interpreteren en van een goed advies te voorzien.TECHNOLOGIE EN UITKOMSTj a a rg a n g 1 8 | n r.", [["van alle devices", "TREATMENT", 84, 100], ["te voorzien", "TREATMENT", 230, 241], ["a n g", "TEST", 274, 279]]], ["2 | j u n i 2 0 2 0DIGITAAL ECOSYSTEEMEen algemene conclusie ligt voor de hand: 'Technologie is niet alles. '", [["j u n i", "TEST", 4, 11], ["0DIGITAAL", "TEST", 18, 27], ["ECOSYSTEEMEen", "TEST", 28, 41], ["algemene", "TEST", 42, 50]]], ["Tevens zal het data-uploaden bij nieuwe systemen niet meer \u2212 zoals nu \u2212 een actie van de pati\u00ebnt zijn, maar gaan de data automatisch naar een cloud.", [["een cloud", "OBSERVATION", 138, 147]]], ["Kostte het in het jaar 2000 2 \u00e0 3 minuten om de uitkomsten schriftelijk vast te leggen, nu kost elektronische monitoring 16 tot 19 minuten.", [["vast te leggen", "TREATMENT", 72, 86], ["nu kost elektronische monitoring", "TREATMENT", 88, 120]]], ["5 Het nakijken van de schriftelijke bloedglucosewaarden nam 11 minuten in beslag; het uitlezen van pompdata neemt nu gemiddeld 18 minuten in beslag en het analyseren van de boluscalculator nog eens 15 minuten.", [["Het nakijken van de schriftelijke bloedglucosewaarden nam 11 minuten in beslag; het uitlezen van pompdata neemt nu gemiddeld 18 minuten in beslag en het analyseren van de boluscalculator nog eens 15 minuten", "SPECIES", 2, 208]]], ["Bovenstaande cijfers zijn uiteraard erg afhankelijk van de organisatie van de zorg, de ervaring van de hulpverleners, de beschikbare ITmogelijkheden voor het ontvangen van informatie en de manier van terugkoppeling naar de pati\u00ebnt.", [["Bovenstaande cijfers", "TREATMENT", 0, 20]]], ["Hoe het ook zij, de cijfers geven aan dat een toename van data zonder automatisering niet zomaar een verbetering in zorguitkomsten zal geven.", [["Hoe het ook zij", "SPECIES", 0, 15], ["een verbetering", "TREATMENT", 97, 112]]], ["Een gevaar daarbij is dat die inzet \u2212 los van de noodzaak diverse alarmen te zetten om het tijdig ingrijpen mogelijk te maken \u2212 kan leiden tot zogenoemde alarm fatigue en burn-outverschijnselen.", [["alarm fatigue", "DISEASE", 154, 167], ["zetten om het tijdig ingrijpen mogelijk te maken \u2212 kan leiden tot zogenoemde alarm fatigue en burn-outverschijnselen", "SPECIES", 77, 193], ["van de noodzaak diverse alarmen", "TREATMENT", 42, 73], ["mogelijk te", "TREATMENT", 108, 119], ["fatigue", "PROBLEM", 160, 167]]], ["In de VS zegt 54% van de artsen ten minste \u00e9\u00e9n burn-outsymptoom te ervaren, waarbij met name de administratieve lastendruk \u2212 inclusief het invoeren en verwerken van data \u2212 een risicofactor is.", [["een risicofactor", "TREATMENT", 172, 188]]], ["Het aanleveren van gegevens is daarvoor cruciaal.", [["Het aanleveren van gegevens", "SPECIES", 0, 27]]], ["Momenteel gebeurt dat nog te weinig: uit onderzoek in de VS blijkt dat 50-71% van de pati\u00ebnten tussen de consulten door de data nooit doorstuurt (uploadt) naar de zorgverlener.", [["dat", "TEST", 67, 70]]], ["Ten derde geven zij aan behoefte te hebben aan realtime afstemming bij hun zelfmanagement.", [["bij hun zelfmanagement", "TREATMENT", 67, 89]]], ["In de ADVICE4U-studie onderzochten Nimri et al 11 j a a rg a n g 1 8 | n r.", [["r.", "ANATOMY", 73, 75]]], ["2 | j u n i 2 0 2 0 IT-faciliteiten -Realtime data van pompen en sensoren, transmissie via cloud zonder een uploadvereiste, en waar nodig nog uploadmogelijkheden thuis en uitleesmogelijkheden voor alle overige devices (pomp, sensor, bloedglucosemeters) -Pati\u00ebntmanagementsysteem dat data van devices kan integreren en onderdeel uitmaakt van het persoonlijke dossier, koppeling met PGO -Decision support-systemen -Spreekuurmanagement: automatische uitnodigingen en reminders op basis van data, alsmede op verzoek pati\u00ebnt -Voldoende bandbreedte en apparatuur voor video-/beeldconsultatie Bedrijfsvoering -Passende staffing: kwantitatief en kwalitatief (medisch, technisch, datamanagement) -Effici\u00ebnte verhouding tussen het aantal hulpverleners en de pati\u00ebnten -Heldere afspraken over wie en wat met e-health kan worden geholpen en wie beter een face-to-faceconsult kan hebben -Passend declaratiesysteem van zorgkosten Educatie -Over werkwijze, verwachtingen Tabel 3.", [["kan integreren en onderdeel uitmaakt van het persoonlijke dossier, koppeling met PGO -Decision support-systemen -Spreekuurmanagement: automatische uitnodigingen en reminders op basis van data, alsmede op verzoek pati\u00ebnt -Voldoende bandbreedte en apparatuur voor video-/beeldconsultatie Bedrijfsvoering -Passende staffing: kwantitatief en kwalitatief (medisch, technisch, datamanagement) -Effici\u00ebnte verhouding tussen het aantal hulpverleners en de pati\u00ebnten -Heldere afspraken over wie en wat met e-health kan worden geholpen en wie beter een face-to-faceconsult kan hebben -Passend declaratiesysteem van zorgkosten Educatie -Over werkwijze", "SPECIES", 300, 940], ["IT", "TEST", 20, 22], ["faciliteiten", "TEST", 23, 35], ["een face", "TREATMENT", 839, 847]]]], "PMC7108186": [["The ID subspecialty fellowship includes integrated training to provide patient care and ensure population health.", [["patient", "ORGANISM", 71, 78], ["patient", "SPECIES", 71, 78], ["integrated training", "TREATMENT", 40, 59]]], ["The clinical training includes diagnosis, management, and treatment of patients with ID; expertise in techniques for preventing healthcare-associated infections and antimicrobial resistance; prevention strategies; and research approaches to address ID-related questions.The Diverse Practice Settings of ID Specialists ::: THE UNIQUE EXPERTISE OF THE ID PHYSICIANIn 2015, 8515 ID physicians were practicing in the United States [5], often combining clinical care with work as educators, epidemiologists, public health leaders, antimicrobial stewardship or infection prevention and control directors, researchers, administrators, and policymakers.The Diverse Practice Settings of ID Specialists ::: THE UNIQUE EXPERTISE OF THE ID PHYSICIANMultiple studies have demonstrated the cost-effectiveness and patient benefit of ID physician care for hospitalized patients with ID [6\u20139].", [["ID", "DISEASE", 85, 87], ["infections", "DISEASE", 150, 160], ["infection", "DISEASE", 555, 564], ["patients", "ORGANISM", 71, 79], ["patient", "ORGANISM", 799, 806], ["patients", "ORGANISM", 853, 861], ["patients", "SPECIES", 71, 79], ["patient", "SPECIES", 799, 806], ["patients", "SPECIES", 853, 861], ["management", "TREATMENT", 42, 52], ["treatment", "TREATMENT", 58, 67], ["healthcare-associated infections", "PROBLEM", 128, 160], ["antimicrobial resistance", "TREATMENT", 165, 189], ["prevention strategies", "TREATMENT", 191, 212], ["antimicrobial stewardship", "TREATMENT", 526, 551], ["infection prevention", "TREATMENT", 555, 575], ["THE ID PHYSICIANMultiple studies", "TEST", 721, 753], ["infections", "OBSERVATION", 150, 160], ["antimicrobial resistance", "OBSERVATION", 165, 189]]], ["Further, the work of ID physicians provides broader public protection against infectious threats through community and healthcare facility\u2013based infection control and prevention activities, surveillance, outbreak response, and other public health activities.Infection Prevention and Control in Healthcare Settings ::: ID PHYSICIANS AS LEADERS OF POPULATION HEALTHInfection prevention and control activities in healthcare settings involve a range of interventions.", [["infection", "DISEASE", 145, 154], ["healthcare facility\u2013based infection control", "TREATMENT", 119, 162], ["surveillance", "TEST", 190, 202], ["Infection Prevention", "TREATMENT", 258, 278], ["POPULATION HEALTHInfection prevention", "TREATMENT", 346, 383], ["interventions", "TREATMENT", 449, 462], ["infection", "OBSERVATION", 145, 154]]], ["Methods include providing oversight of programs that conduct surveillance and identify risks, providing education regarding the use of appropriate isolation procedures and personal protective equipment, developing policies to respond to novel infections, and ensuring that the healthcare environment and medical devices are properly cleaned and maintained.", [["infections", "DISEASE", 243, 253], ["conduct surveillance", "TEST", 53, 73], ["appropriate isolation procedures", "TREATMENT", 135, 167], ["personal protective equipment", "TREATMENT", 172, 201], ["novel infections", "PROBLEM", 237, 253], ["medical devices", "TREATMENT", 304, 319], ["infections", "OBSERVATION", 243, 253]]], ["Studies have shown that development and implementation of these activities by ID physicians have resulted in improved outcomes and reductions in hospital-acquired infections in a variety of healthcare settings [19].", [["infections", "DISEASE", 163, 173], ["Studies", "TEST", 0, 7], ["acquired infections", "PROBLEM", 154, 173]]], ["Prevention of healthcare-associated infections leads to savings of approximately $1000 to more than $40 000 per patient depending on the specific infection in a variety of healthcare settings [20].Infection Prevention and Control in Healthcare Settings ::: ID PHYSICIANS AS LEADERS OF POPULATION HEALTHExamples of ID physician leadership in infection control and prevention and healthcare epidemiology are described here.", [["infections", "DISEASE", 36, 46], ["infection", "DISEASE", 146, 155], ["infection", "DISEASE", 341, 350], ["patient", "ORGANISM", 112, 119], ["patient", "SPECIES", 112, 119], ["healthcare-associated infections", "PROBLEM", 14, 46], ["the specific infection", "PROBLEM", 133, 155], ["Infection Prevention", "TREATMENT", 197, 217], ["infection control", "TREATMENT", 341, 358], ["infections", "OBSERVATION", 36, 46], ["infection", "OBSERVATION", 146, 155], ["infection", "OBSERVATION", 341, 350]]], ["During the West Africa Ebola crisis in 2014 and 2015, ID physicians served as leaders of special biocontainment units at the National Institutes of Health, University of Nebraska, Emory University, and Bellevue Hospital.", [["Ebola", "DISEASE", 23, 28]]], ["These units and their staff developed novel, sophisticated infection prevention strategies to care for patients with potentially deadly infections.", [["infection", "DISEASE", 59, 68], ["infections", "DISEASE", 136, 146], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["sophisticated infection prevention strategies", "TREATMENT", 45, 90], ["deadly infections", "PROBLEM", 129, 146], ["infection", "OBSERVATION", 59, 68]]], ["They reassured medical providers, political leaders, and our nation\u2019s public by providing safe, state-of-the-art care.", [["the-art care", "TREATMENT", 105, 117]]], ["In Seattle, Washington, an ID physician reported an outbreak of deadly, multidrug-resistant carbapenem-resistant Enterobacteriaceae infections were attributed to contaminated, faulty duodenoscopes.", [["carbapenem", "CHEMICAL", 92, 102], ["Enterobacteriaceae infections", "DISEASE", 113, 142], ["carbapenem", "CHEMICAL", 92, 102], ["carbapenem", "SIMPLE_CHEMICAL", 92, 102], ["Enterobacteriaceae", "ORGANISM", 113, 131], ["multidrug-resistant carbapenem", "TREATMENT", 72, 102], ["resistant Enterobacteriaceae infections", "PROBLEM", 103, 142], ["contaminated, faulty duodenoscopes", "PROBLEM", 162, 196], ["Enterobacteriaceae infections", "OBSERVATION", 113, 142]]], ["This investigation helped lead to changes in guidance on endoscope reprocessing and safety [21, 22].", [["endoscope reprocessing", "TREATMENT", 57, 79]]], ["An ID physician at Vanderbilt University identified contaminated steroids as the source of a fungal meningitis outbreak that ultimately caused more than 700 infections and 46 deaths across 20 states before the cause was established [23, 24].Antimicrobial Stewardship ::: ID PHYSICIANS AS LEADERS OF POPULATION HEALTHAntimicrobial resistance is one of the most urgent public health threats of our time.", [["steroids", "CHEMICAL", 65, 73], ["fungal meningitis", "DISEASE", 93, 110], ["infections", "DISEASE", 157, 167], ["deaths", "DISEASE", 175, 181], ["steroids", "CHEMICAL", 65, 73], ["contaminated steroids", "TREATMENT", 52, 73], ["a fungal meningitis outbreak", "PROBLEM", 91, 119], ["fungal", "OBSERVATION_MODIFIER", 93, 99], ["meningitis", "OBSERVATION", 100, 110]]], ["Infections caused by antimicrobial-resistant organisms kill more than 23 000 people and result in $20 billion in unnecessary healthcare costs each year in the United States [18].", [["Infections", "DISEASE", 0, 10], ["people", "ORGANISM", 77, 83], ["people", "SPECIES", 77, 83], ["Infections", "PROBLEM", 0, 10], ["resistant organisms", "PROBLEM", 35, 54], ["antimicrobial", "OBSERVATION_MODIFIER", 21, 34]]], ["Newer antimicrobials will be precious resources, and ID physician\u2013driven expertise will be vital to ensure that they are being used appropriately.", [["Newer antimicrobials", "TREATMENT", 0, 20]]], ["A recent Clinical Infectious Diseases article highlighted the unique skill set and training ID physicians have to lead antimicrobial stewardship programs (ASPs) in order to ensure that correct antimicrobials are used judiciously [25].", [["Infectious Diseases", "DISEASE", 18, 37], ["A recent Clinical Infectious Diseases", "PROBLEM", 0, 37], ["antimicrobial stewardship programs", "TREATMENT", 119, 153], ["correct antimicrobials", "TREATMENT", 185, 207], ["Infectious", "OBSERVATION_MODIFIER", 18, 28]]], ["The Centers for Disease Control and Prevention (CDC) have acknowledged the impact and importance of ASPs in their release of the Core Elements of Hospital Antibiotic Stewardship Programs in 2014 [26], and the Joint Commission released their antimicrobial stewardship standard for healthcare settings in 2017.", [["Disease Control", "TREATMENT", 16, 31], ["Joint", "ANATOMY", 209, 214]]], ["Adoption of a federal government requirement that other states follow suit would help to ensure that all patients can benefit from the positive impact of ASPs.", [["patients", "ORGANISM", 105, 113], ["ASPs", "SIMPLE_CHEMICAL", 154, 158], ["patients", "SPECIES", 105, 113], ["a federal government requirement", "TREATMENT", 12, 44], ["ASPs", "PROBLEM", 154, 158]]], ["ASPs will become increasingly vital in preventing a post-antibiotic era where common infections become untreatable due to resistant organisms.", [["infections", "DISEASE", 85, 95], ["ASPs", "PROBLEM", 0, 4], ["a post-antibiotic era", "TREATMENT", 50, 71], ["common infections", "PROBLEM", 78, 95], ["resistant organisms", "PROBLEM", 122, 141]]], ["ID physicians need to take an active role in ensuring their facilities have adequate ASPs that meet the standards laid out by the CDC and Joint Commission.", [["Joint", "ANATOMY", 138, 143]]], ["Well-run ASPs not only help preserve the efficacy of antimicrobials but also improve patient outcomes.", [["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92], ["antimicrobials", "TREATMENT", 53, 67]]], ["In fact, studies have indicated that ASPs generated several hundred thousand dollars a year in cost savings while also reducing rates of Clostridium difficile infections [28, 29].", [["Clostridium difficile infections", "DISEASE", 137, 169], ["Clostridium difficile", "ORGANISM", 137, 158], ["Clostridium difficile", "SPECIES", 137, 158], ["Clostridium difficile", "SPECIES", 137, 158], ["ASPs", "PROBLEM", 37, 41], ["cost savings", "TREATMENT", 95, 107], ["Clostridium difficile infections", "PROBLEM", 137, 169]]], ["It is vital that the government continue to support the implementation of ID-led ASPs in all healthcare settings to slow the development of resistance and to keep our current antimicrobials useful for as long as possible.Emergency Preparedness and Response ::: ID PHYSICIANS AS LEADERS OF POPULATION HEALTHIn response to the 2001 anthrax bioterrorism attacks and the looming threat of pandemic influenza, hospitals began extensive preparations for natural and human-made bioemergencies.", [["anthrax bioterrorism attacks", "DISEASE", 330, 358], ["influenza", "DISEASE", 394, 403], ["human", "ORGANISM", 460, 465], ["human", "SPECIES", 460, 465], ["human", "SPECIES", 460, 465], ["ID-led ASPs", "TREATMENT", 74, 85], ["our current antimicrobials", "TREATMENT", 163, 189], ["pandemic influenza", "PROBLEM", 385, 403], ["bioemergencies", "TREATMENT", 471, 485]]], ["These activities substantially increased with the appearance of the SARS, MERS\u2013coronavirus, and Ebola virus epidemics.", [["SARS", "DISEASE", 68, 72], ["MERS\u2013coronavirus", "DISEASE", 74, 90], ["Ebola virus epidemics", "DISEASE", 96, 117], ["Ebola virus", "ORGANISM", 96, 107], ["Ebola virus", "SPECIES", 96, 107], ["Ebola virus", "SPECIES", 96, 107], ["the SARS", "PROBLEM", 64, 72], ["MERS\u2013coronavirus", "PROBLEM", 74, 90], ["Ebola virus epidemics", "PROBLEM", 96, 117], ["increased", "OBSERVATION_MODIFIER", 31, 40], ["Ebola virus", "OBSERVATION", 96, 107]]], ["ID physicians provided scientific and clinical expertise that shaped prevention, control, detection, and treatment efforts.", [["treatment efforts", "TREATMENT", 105, 122]]], ["Natural disasters also carry an increased risk of outbreaks of unusual, serious infections, as seen in connection with the hurricanes and flooding in Texas, Florida, Puerto Rico, and the US Virgin Islands, which led to more than 70 reported cases of leptospirosis and other waterborne and vectorborne diseases [30].", [["infections", "DISEASE", 80, 90], ["leptospirosis", "DISEASE", 250, 263], ["waterborne and vectorborne diseases", "DISEASE", 274, 309], ["serious infections", "PROBLEM", 72, 90], ["leptospirosis", "PROBLEM", 250, 263], ["vectorborne diseases", "PROBLEM", 289, 309], ["increased", "OBSERVATION_MODIFIER", 32, 41], ["serious", "OBSERVATION_MODIFIER", 72, 79], ["infections", "OBSERVATION", 80, 90], ["leptospirosis", "OBSERVATION", 250, 263]]], ["ID physicians also played a leading role in infection prevention at large-scale shelters for people who had been displaced by storms and flooding.", [["infection", "DISEASE", 44, 53], ["people", "ORGANISM", 93, 99], ["people", "SPECIES", 93, 99], ["infection prevention", "TREATMENT", 44, 64], ["infection", "OBSERVATION", 44, 53]]], ["Hospital and healthcare system emergency preparedness requires an intimate knowledge of hospital infection control procedures and capacities, regional collaboration with other facilities, planning with public health authorities, and development of communication strategies within the hospital community, with public health departments, and with the general public.ID PHYSICIANS AS LEADERS IN GLOBAL HEALTHA review of recent international ID outbreaks emphasizes the global dimensions of public health protection\u2014the SARS epidemic originated in Hong Kong, the Ebola virus outbreak started in West Africa, and the Zika virus epidemic spread from Brazil throughout South America and the Caribbean.", [["infection", "DISEASE", 97, 106], ["SARS", "DISEASE", 516, 520], ["Ebola virus", "DISEASE", 559, 570], ["Ebola virus", "ORGANISM", 559, 570], ["Zika virus", "ORGANISM", 612, 622], ["Ebola virus", "SPECIES", 559, 570], ["Ebola virus", "SPECIES", 559, 570], ["Zika virus", "SPECIES", 612, 622], ["hospital infection control procedures", "TREATMENT", 88, 125], ["recent international ID outbreaks", "PROBLEM", 417, 450], ["the SARS epidemic", "PROBLEM", 512, 529], ["the Ebola virus outbreak", "PROBLEM", 555, 579], ["the Zika virus", "PROBLEM", 608, 622], ["Ebola virus", "OBSERVATION", 559, 570]]], ["A bacterial plasmid that conferred resistance to colistin, often the last antimicrobial line of defense against gram-negative organisms, emerged from bacteria that were colonizing domestic animal populations in China and is now seen in patients on 6 continents.", [["plasmid", "ANATOMY", 12, 19], ["colistin", "CHEMICAL", 49, 57], ["colistin", "CHEMICAL", 49, 57], ["colistin", "SIMPLE_CHEMICAL", 49, 57], ["patients", "ORGANISM", 236, 244], ["bacterial plasmid", "DNA", 2, 19], ["patients", "SPECIES", 236, 244], ["A bacterial plasmid", "TREATMENT", 0, 19], ["colistin", "TREATMENT", 49, 57], ["the last antimicrobial line", "TREATMENT", 65, 92], ["gram-negative organisms", "PROBLEM", 112, 135], ["bacteria", "PROBLEM", 150, 158], ["bacterial plasmid", "OBSERVATION", 2, 19], ["negative organisms", "OBSERVATION", 117, 135], ["populations", "OBSERVATION_MODIFIER", 196, 207]]], ["Older epidemics, of course, continue; tuberculosis and HIV\u2013AIDS remain scourges in many countries.", [["tuberculosis", "DISEASE", 38, 50], ["HIV\u2013AIDS", "DISEASE", 55, 63], ["HIV", "SPECIES", 55, 58], ["HIV", "SPECIES", 55, 58], ["tuberculosis", "PROBLEM", 38, 50], ["HIV", "PROBLEM", 55, 58]]], ["Emerging and reemerging infections with global consequences have reemphasized efforts to address global health security.ID PHYSICIANS AS LEADERS IN GLOBAL HEALTHThe global SARS epidemic illustrated how increased international travel and trade introduce new risks for the rapid worldwide spread of new infectious pathogens.", [["infections", "DISEASE", 24, 34], ["SARS", "DISEASE", 172, 176], ["The global SARS epidemic", "PROBLEM", 161, 185], ["new infectious pathogens", "PROBLEM", 297, 321], ["infections", "OBSERVATION", 24, 34], ["global", "OBSERVATION_MODIFIER", 165, 171], ["SARS", "OBSERVATION", 172, 176], ["new", "OBSERVATION_MODIFIER", 297, 300], ["infectious", "OBSERVATION", 301, 311]]], ["ID physicians remain crucial to ongoing IHR implementation efforts, including disease outbreak recognition, in-country training, and collaborative partnership in epidemic disease control, diagnostics, and preparedness.ID PHYSICIANS AS LEADERS IN GLOBAL HEALTHWith prescient timing, the CDC\u2019s Global Health Security Agenda (GHSA) was launched just months before the Ebola crisis surfaced in West Africa.", [["Ebola", "DISEASE", 365, 370], ["epidemic disease control", "TREATMENT", 162, 186], ["the Ebola crisis", "PROBLEM", 361, 377], ["Ebola crisis", "OBSERVATION", 365, 377]]], ["ID physicians provide critical support to all 3 arms.", [["critical support", "TREATMENT", 22, 38]]], ["ID training and expertise establish the necessary foundations for the prevention goal to address issues such as antimicrobial resistance, biosafety and biosecurity, and immunization needs.", [["ID training", "TREATMENT", 0, 11], ["antimicrobial resistance", "TREATMENT", 112, 136], ["biosecurity", "TREATMENT", 152, 163], ["immunization needs", "TREATMENT", 169, 187]]], ["Greater use of diagnostic tests in countries currently lacking such resources is critical for containing emerging and reemerging infections, preventing outbreaks, and halting the development of antimicrobial resistance.", [["infections", "DISEASE", 129, 139], ["diagnostic tests", "TEST", 15, 31], ["reemerging infections", "PROBLEM", 118, 139], ["outbreaks", "PROBLEM", 152, 161], ["antimicrobial resistance", "PROBLEM", 194, 218], ["infections", "OBSERVATION", 129, 139], ["antimicrobial resistance", "OBSERVATION", 194, 218]]], ["The response goal would establish emergency operations centers that link public health with other rapid-response agencies, all of which draw on ID physician expertise.WORKING TOWARD APPROPRIATE COMPENSATION FOR ID PHYSICIANSMultiple studies have demonstrated that consulting an ID physician improves treatment outcomes and lowers patient care costs.", [["patient", "ORGANISM", 330, 337], ["patient", "SPECIES", 330, 337], ["emergency operations", "TREATMENT", 34, 54], ["ID PHYSICIANSMultiple studies", "TEST", 211, 240], ["treatment outcomes", "TREATMENT", 300, 318], ["lowers patient care costs", "TREATMENT", 323, 348]]], ["This benefit has been documented for ID consultation in general [33], in specific patient populations such as intensive care unit patients [34], and for specific illnesses such as staphylococcal bloodstream infections and other multidrug-resistant organism infections [9, 35].WORKING TOWARD APPROPRIATE COMPENSATION FOR ID PHYSICIANSID physicians also improve outcomes and reduce costs through antimicrobial stewardship and infection prevention [8, 36].", [["bloodstream", "ANATOMY", 195, 206], ["staphylococcal bloodstream infections", "DISEASE", 180, 217], ["multidrug-resistant organism infections", "DISEASE", 228, 267], ["infection", "DISEASE", 424, 433], ["patient", "ORGANISM", 82, 89], ["patients", "ORGANISM", 130, 138], ["patient", "SPECIES", 82, 89], ["patients", "SPECIES", 130, 138], ["specific illnesses", "PROBLEM", 153, 171], ["staphylococcal bloodstream infections", "PROBLEM", 180, 217], ["other multidrug-resistant organism infections", "PROBLEM", 222, 267], ["antimicrobial stewardship", "TREATMENT", 394, 419], ["infection prevention", "TREATMENT", 424, 444]]], ["In addition, many complex procedures and treatments (such as bone marrow and solid organ transplantation) could not be safely conducted without input from ID specialists.WORKING TOWARD APPROPRIATE COMPENSATION FOR ID PHYSICIANSThe IDSA has implemented several initiatives in an effort to reinvigorate the pipeline of ID applicants.", [["bone marrow", "ANATOMY", 61, 72], ["solid organ", "ANATOMY", 77, 88], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 61, 72], ["organ", "ORGAN", 83, 88], ["many complex procedures", "TREATMENT", 13, 36], ["treatments", "TREATMENT", 41, 51], ["bone marrow", "TREATMENT", 61, 72], ["solid organ transplantation", "TREATMENT", 77, 104], ["many", "OBSERVATION_MODIFIER", 13, 17], ["complex", "OBSERVATION_MODIFIER", 18, 25], ["procedures", "OBSERVATION", 26, 36]]], ["However, other potential options should be considered in order to properly compensate ID physicians for the public health benefit of their work.RECOMMENDATIONSRecommendations for federal, state, local, and institutional policymakers include the following:RECOMMENDATIONSAppropriate compensation for ID service in all of these forms will have significant positive effects on individual patient care, nosocomial infections, and community public health, ensuring that the future ID workforce has enough of an incentive to pursue this vital field.", [["nosocomial infections", "DISEASE", 399, 420], ["patient", "ORGANISM", 385, 392], ["patient", "SPECIES", 385, 392], ["nosocomial infections", "PROBLEM", 399, 420]]]], "6cf5095850e83d633002293144c1162712cf2644": [["IntroductionViral vectors are highly evolved gene delivery systems for therapeutic interventions.", [["IntroductionViral vectors", "TREATMENT", 0, 25], ["gene delivery systems", "TREATMENT", 45, 66], ["therapeutic interventions", "TREATMENT", 71, 96]]], ["Over the last ten years, adeno-associated viruses (AAV) emerged as one of the most promising vectors for gene therapy and vaccine.", [["adeno-associated viruses", "ORGANISM", 25, 49], ["AAV", "ORGANISM", 51, 54], ["AAV", "SPECIES", 51, 54], ["adeno-associated viruses", "PROBLEM", 25, 49], ["gene therapy", "TREATMENT", 105, 117], ["vaccine", "TREATMENT", 122, 129], ["viruses", "OBSERVATION", 42, 49]]], ["Phase I and Phase II clinical trials utilizing AAV have been carried out worldwide that have jumped to 92 in 2012 (http://www.wiley.com//legacy/wileychi/genmed/clinical, access date: December 4, 2012) from 47 in 2007 (Edelstein et al., 2007) .", [["AAV", "ORGANISM", 47, 50], ["AAV", "TREATMENT", 47, 50]]], ["Safety and efficacy of AAV vectors (AAV serotype 1, 2, 6 and 8) have been evaluated in clinical trials for the treatment of different diseases, including Parkinson's disease (Eberling et al., 2008; LeWitt et al., 2011) , cystic fibrosis (Moss et al., 2007; Wagner et al., 2002) , hemophilia B (Manno et al., 2006 (Manno et al., , 2003 , rheumatoid arthritis (Mease et al., 2010) , Leber's congenital amaurosis (Hauswirth et al., 2008; Maguire et al., 2008; Simonelli et al., 2010) and treatment of lipoprotein lipase deficiency (Mingozzi et al., 2009; Stroes et al., 2008) .", [["Parkinson's disease", "DISEASE", 154, 173], ["cystic fibrosis", "DISEASE", 221, 236], ["hemophilia B", "DISEASE", 280, 292], ["rheumatoid arthritis", "DISEASE", 337, 357], ["Leber's", "DISEASE", 381, 388], ["congenital amaurosis", "DISEASE", 389, 409], ["AAV", "ORGANISM", 23, 26], ["AAV serotype 1", "ORGANISM", 36, 50], ["cystic", "ORGAN", 221, 227], ["lipoprotein lipase", "GENE_OR_GENE_PRODUCT", 498, 516], ["lipoprotein lipase", "PROTEIN", 498, 516], ["AAV", "SPECIES", 23, 26], ["AAV vectors", "TREATMENT", 23, 34], ["AAV serotype", "TREATMENT", 36, 48], ["different diseases", "PROBLEM", 124, 142], ["Parkinson's disease", "PROBLEM", 154, 173], ["cystic fibrosis", "PROBLEM", 221, 236], ["hemophilia B", "PROBLEM", 280, 292], ["rheumatoid arthritis", "PROBLEM", 337, 357], ["Leber's congenital amaurosis", "PROBLEM", 381, 409], ["lipoprotein lipase deficiency", "PROBLEM", 498, 527], ["cystic", "OBSERVATION_MODIFIER", 221, 227], ["fibrosis", "OBSERVATION", 228, 236], ["hemophilia", "OBSERVATION", 280, 290], ["rheumatoid arthritis", "OBSERVATION", 337, 357], ["congenital amaurosis", "OBSERVATION", 389, 409]]], ["Recently, the European Medicines Agency recommended approval of the Western world's first AAV-mediated gene therapy product (Yla-Herttuala, 2012) .", [["AAV", "ORGANISM", 90, 93], ["AAV-mediated gene therapy product", "TREATMENT", 90, 123]]], ["In animal studies, AAV has been shown to have potential to be used as a vaccine either by * Corresponding author.", [["AAV", "ORGANISM", 19, 22], ["AAV", "SPECIES", 19, 22], ["animal studies", "TEST", 3, 17]]], ["Tel.: +1 514 496 2264; fax: +1 514 496 6785.IntroductionE-mail addresses: amine.kamen@gmail.com, Amine.", [["Amine", "SIMPLE_CHEMICAL", 97, 102]]], ["Kamen@cnrc-nrc.gc.ca (A.A. Kamen). having attached antigen on the AAV capsids (Nieto et al., 2012; Rybniker et al., 2012) or by introducing a gene for a particular antigen (Sipo et al., 2011; Xin et al., 2001) to induce humoral response.", [["AAV", "ORGANISM", 66, 69], ["humoral response", "OBSERVATION", 220, 236]]], ["Logan and Alexander (2012) have reviewed the potential of AAV to be used as a tool for the manipulation of immune system response.", [["immune system", "ANATOMY", 107, 120], ["AAV", "ORGANISM", 58, 61], ["immune system", "ANATOMICAL_SYSTEM", 107, 120], ["AAV", "TREATMENT", 58, 61]]], ["Mice challenged with human papillomavirus HPV16PsV were protected by vaccinating them with adeno-associated virus like particles (AAVLPs) consisting of VP3 containing L2 epitopes from HPV16 and HPV31 inserted at position 587 and 453, respectively (Nieto et al., 2012) .", [["Mice", "ORGANISM", 0, 4], ["human", "ORGANISM", 21, 26], ["papillomavirus HPV16PsV", "ORGANISM", 27, 50], ["adeno-associated virus like particles", "ORGANISM", 91, 128], ["AAVLPs", "CANCER", 130, 136], ["VP3", "GENE_OR_GENE_PRODUCT", 152, 155], ["HPV16", "ORGANISM", 184, 189], ["HPV31", "GENE_OR_GENE_PRODUCT", 194, 199], ["VP3", "PROTEIN", 152, 155], ["L2 epitopes", "PROTEIN", 167, 178], ["HPV31", "PROTEIN", 194, 199], ["Mice", "SPECIES", 0, 4], ["human", "SPECIES", 21, 26], ["human papillomavirus HPV16PsV", "SPECIES", 21, 50], ["adeno-associated virus", "SPECIES", 91, 113], ["HPV16", "SPECIES", 184, 189], ["human papillomavirus HPV16PsV", "TREATMENT", 21, 50], ["adeno-associated virus like particles", "PROBLEM", 91, 128], ["VP3 containing L2 epitopes", "TREATMENT", 152, 178], ["HPV16", "TEST", 184, 189], ["HPV31", "TEST", 194, 199], ["L2", "ANATOMY_MODIFIER", 167, 169]]], ["AAV-HIV vector expressing HIV-1 env, tat and rev genes showed positive results when used in BALB/c mice when given as HIV vaccination (Xin et al., 2001) .", [["AAV-HIV", "ORGANISM", 0, 7], ["HIV-1", "ORGANISM", 26, 31], ["env", "ORGANISM", 32, 35], ["tat", "GENE_OR_GENE_PRODUCT", 37, 40], ["rev", "GENE_OR_GENE_PRODUCT", 45, 48], ["BALB/c mice", "ORGANISM", 92, 103], ["HIV", "ORGANISM", 118, 121], ["AAV-HIV vector", "DNA", 0, 14], ["HIV-1 env, tat and rev genes", "DNA", 26, 54], ["HIV", "SPECIES", 4, 7], ["HIV-1", "SPECIES", 26, 31], ["mice", "SPECIES", 99, 103], ["HIV", "SPECIES", 4, 7], ["HIV-1", "SPECIES", 26, 31], ["mice", "SPECIES", 99, 103], ["HIV", "SPECIES", 118, 121], ["HIV", "PROBLEM", 26, 29], ["tat and rev genes", "TEST", 37, 54], ["HIV vaccination", "TREATMENT", 118, 133]]], ["A vaccine against SARS coronavirus (SARS-CoV) has been developed and tested in BALB/c mice by cloning receptor binding domain in AAV vector (Du et al., 2006) .IntroductionOver 100 different variant (naturally occurring or synthesized) capsid sequences of AAV have been reported.", [["SARS coronavirus", "DISEASE", 18, 34], ["SARS", "DISEASE", 36, 40], ["SARS coronavirus", "ORGANISM", 18, 34], ["SARS-CoV", "ORGANISM", 36, 44], ["BALB/c mice", "ORGANISM", 79, 90], ["AAV", "ORGANISM", 129, 132], ["AAV", "ORGANISM", 255, 258], ["cloning receptor binding domain", "PROTEIN", 94, 125], ["capsid sequences", "PROTEIN", 235, 251], ["SARS coronavirus", "SPECIES", 18, 34], ["mice", "SPECIES", 86, 90], ["SARS coronavirus", "SPECIES", 18, 34], ["SARS-CoV", "SPECIES", 36, 44], ["mice", "SPECIES", 86, 90], ["A vaccine", "TREATMENT", 0, 9], ["SARS coronavirus", "PROBLEM", 18, 34], ["IntroductionOver", "TREATMENT", 159, 175], ["capsid sequences of AAV", "TREATMENT", 235, 258]]], ["However, the most commonly studied are the eleven AAV serotypes (AAV1 to AAV11) isolated from human, simian, and rhesus and cynomolgus monkeys.", [["AAV", "ORGANISM", 50, 53], ["AAV1", "GENE_OR_GENE_PRODUCT", 65, 69], ["AAV11", "GENE_OR_GENE_PRODUCT", 73, 78], ["human", "ORGANISM", 94, 99], ["simian", "ORGANISM", 101, 107], ["rhesus", "ORGANISM", 113, 119], ["cynomolgus monkeys", "ORGANISM", 124, 142], ["human", "SPECIES", 94, 99], ["simian", "SPECIES", 101, 107], ["rhesus", "SPECIES", 113, 119], ["cynomolgus monkeys", "SPECIES", 124, 142], ["human", "SPECIES", 94, 99], ["cynomolgus monkeys", "SPECIES", 124, 142], ["the eleven AAV serotypes", "PROBLEM", 39, 63], ["cynomolgus monkeys", "OBSERVATION", 124, 142]]], ["Serotype AAV6 (Rutledge et al., 1998; Xiao et al., 1999) is believed to be a recombinant product of AAV2 and AAV1.", [["AAV2", "ORGANISM", 100, 104], ["AAV1", "GENE_OR_GENE_PRODUCT", 109, 113], ["AAV1", "PROTEIN", 109, 113], ["AAV2", "SPECIES", 100, 104], ["believed to be", "UNCERTAINTY", 60, 74], ["AAV2", "OBSERVATION", 100, 104]]], ["AAV serotype 2 has been extensively studied for delivering genes to treat a variety of diseases.", [["AAV serotype 2", "ORGANISM", 0, 14], ["AAV serotype 2", "TREATMENT", 0, 14], ["a variety of diseases", "PROBLEM", 74, 95], ["diseases", "OBSERVATION", 87, 95]]], ["They are unable to replicate in the absence of helper viruses and to date, no known human pathogenicity have been associated with wild-type AAV infections.", [["AAV infections", "DISEASE", 140, 154], ["human", "ORGANISM", 84, 89], ["AAV", "ORGANISM", 140, 143], ["human", "SPECIES", 84, 89], ["human", "SPECIES", 84, 89], ["helper viruses", "PROBLEM", 47, 61], ["known human pathogenicity", "PROBLEM", 78, 103], ["type AAV infections", "PROBLEM", 135, 154], ["infections", "OBSERVATION", 144, 154]]], ["Also persistent long-term transgene expression levels are achieved (Xiao et al., 1996) when transducing dividing and non-dividing cells.", [["cells", "ANATOMY", 130, 135], ["cells", "CELL", 130, 135], ["dividing and non-dividing cells", "CELL_TYPE", 104, 135], ["persistent long-term transgene expression levels", "PROBLEM", 5, 53], ["persistent", "OBSERVATION_MODIFIER", 5, 15], ["long-term", "OBSERVATION_MODIFIER", 16, 25], ["non-dividing cells", "OBSERVATION", 117, 135]]], ["It has been reported that humoral responses of infection by AAV2 is common and neutralizing AAV2 antibodies are present in the range of 35-80% of the human population throughout the world depending on the age group and the country, suggesting the limitation on the potential of AAV2 as delivery system Erles et al., 1999; Moskalenko et al., 2000) .", [["infection", "DISEASE", 47, 56], ["AAV2", "ORGANISM", 60, 64], ["AAV2", "ORGANISM", 92, 96], ["human", "ORGANISM", 150, 155], ["AAV2", "ORGANISM", 278, 282], ["AAV2 antibodies", "PROTEIN", 92, 107], ["human", "SPECIES", 150, 155], ["AAV2", "SPECIES", 60, 64], ["AAV2", "SPECIES", 92, 96], ["human", "SPECIES", 150, 155], ["infection", "PROBLEM", 47, 56], ["neutralizing AAV2 antibodies", "TEST", 79, 107], ["infection", "OBSERVATION", 47, 56]]], ["Boutin et al. (2010) investigated humoral responses to natural exposure of AAV types 1, 2, 5, 6, 8 and 9 and reported that all four IgG subclasses were produced.", [[", 2, 5, 6, 8 and 9", "CHEMICAL", 86, 104], ["AAV", "ORGANISM", 75, 78], ["IgG", "GENE_OR_GENE_PRODUCT", 132, 135], ["IgG subclasses", "PROTEIN", 132, 146], ["AAV", "ANATOMY", 75, 78], ["IgG subclasses", "OBSERVATION", 132, 146]]], ["They concluded that vectors based on AAV5, AAV8 and AAV9 are the best candidates for gene therapy in humans.", [["AAV5", "GENE_OR_GENE_PRODUCT", 37, 41], ["AAV8", "GENE_OR_GENE_PRODUCT", 43, 47], ["AAV9", "GENE_OR_GENE_PRODUCT", 52, 56], ["humans", "ORGANISM", 101, 107], ["AAV5", "DNA", 37, 41], ["AAV8", "DNA", 43, 47], ["AAV9", "DNA", 52, 56], ["humans", "SPECIES", 101, 107], ["humans", "SPECIES", 101, 107], ["AAV5", "TREATMENT", 37, 41], ["AAV8", "TREATMENT", 43, 47], ["AAV9", "TREATMENT", 52, 56], ["gene therapy", "TREATMENT", 85, 97]]], ["Many researchers considered the use of different serotypes of AAV to circumvent the pre-existing immune response.", [["AAV", "ORGANISM", 62, 65], ["AAV", "SPECIES", 62, 65], ["different serotypes", "TREATMENT", 39, 58], ["AAV", "TREATMENT", 62, 65], ["immune response", "OBSERVATION", 97, 112]]], ["More importantly, it has been observed that serotypes of AAV transduce cells from different organs with various efficiencies.", [["cells", "ANATOMY", 71, 76], ["organs", "ANATOMY", 92, 98], ["AAV", "ORGANISM", 57, 60], ["cells", "CELL", 71, 76], ["organs", "ORGAN", 92, 98], ["AAV", "SPECIES", 57, 60], ["AAV transduce cells", "TREATMENT", 57, 76], ["various efficiencies", "PROBLEM", 104, 124], ["AAV transduce cells", "OBSERVATION", 57, 76], ["various efficiencies", "OBSERVATION", 104, 124]]], ["Therefore, a specific AAV serotype could be selected for efficient gene delivery into target tissues.", [["tissues", "ANATOMY", 93, 100], ["AAV", "ORGANISM", 22, 25], ["tissues", "TISSUE", 93, 100], ["AAV", "SPECIES", 22, 25], ["a specific AAV serotype", "TREATMENT", 11, 34], ["efficient gene delivery", "TREATMENT", 57, 80]]], ["Van Vliet et al. (2008) have summarized the tissue specific transduction efficiencies.", [["tissue", "ANATOMY", 44, 50], ["tissue", "TISSUE", 44, 50], ["the tissue specific transduction efficiencies", "PROBLEM", 40, 85], ["transduction efficiencies", "OBSERVATION", 60, 85]]], ["Asokan et al. (2012) reviewed advances in the use of AAV for gene therapy application.", [["AAV", "ORGANISM", 53, 56], ["AAV", "TREATMENT", 53, 56], ["gene therapy application", "TREATMENT", 61, 85]]], ["They summarized the best combinations of AAV serotypes with organs, e.g., liver (AAV8), cardiac and musculoskeletal (AAV1, AAV6 and AAV9), central nervous system (e.g., for Parkinson, Alzheimer's Batten's epilepsy, lysosome storage disorder: AAV5 and AAV9), and eye (AAV8).", [["organs", "ANATOMY", 60, 66], ["liver", "ANATOMY", 74, 79], ["cardiac", "ANATOMY", 88, 95], ["musculoskeletal", "ANATOMY", 100, 115], ["central nervous system", "ANATOMY", 139, 161], ["lysosome", "ANATOMY", 215, 223], ["eye", "ANATOMY", 262, 265], ["Parkinson", "DISEASE", 173, 182], ["Alzheimer's Batten's epilepsy", "DISEASE", 184, 213], ["lysosome storage disorder", "DISEASE", 215, 240], ["AAV", "ORGANISM", 41, 44], ["organs", "ORGAN", 60, 66], ["liver", "ORGAN", 74, 79], ["cardiac", "ORGAN", 88, 95], ["AAV1", "GENE_OR_GENE_PRODUCT", 117, 121], ["AAV6", "GENE_OR_GENE_PRODUCT", 123, 127], ["AAV9", "GENE_OR_GENE_PRODUCT", 132, 136], ["central nervous system", "ANATOMICAL_SYSTEM", 139, 161], ["lysosome", "CELLULAR_COMPONENT", 215, 223], ["eye", "ORGAN", 262, 265], ["AAV serotypes", "PROBLEM", 41, 54], ["cardiac and musculoskeletal (AAV1, AAV6 and AAV9)", "PROBLEM", 88, 137], ["central nervous system", "PROBLEM", 139, 161], ["Parkinson, Alzheimer's Batten's epilepsy", "PROBLEM", 173, 213], ["lysosome storage disorder", "PROBLEM", 215, 240], ["AAV5", "PROBLEM", 242, 246], ["liver", "ANATOMY", 74, 79], ["cardiac", "ANATOMY", 88, 95], ["musculoskeletal", "ANATOMY", 100, 115], ["AAV9", "ANATOMY", 132, 136], ["central", "ANATOMY_MODIFIER", 139, 146], ["nervous system", "ANATOMY", 147, 161], ["eye", "ANATOMY", 262, 265]]], ["The serotypes AAV1 to 8 were investigated to transduce rat myocardium (Palomeque et al., 2007) out of which AAV1 and AAV6 were identified as the best candidates; the efficacy of AAV1, 2 and 5 was compared for the delivery of gene to different regions of the nervous system (Burger et al., 2004) ; for gene delivery to heart when compared to AAV1, 6, 7, and 8, AAV9 was the most efficient (Bish et al., 2008) ; and AAV6 was shown to be more efficient in delivering gene to cornea in vitro when compared to AAV8 and AAV9 (Sharma et al., 2010) .", [["myocardium", "ANATOMY", 59, 69], ["nervous system", "ANATOMY", 258, 272], ["heart", "ANATOMY", 318, 323], ["cornea", "ANATOMY", 472, 478], ["rat", "ORGANISM", 55, 58], ["myocardium", "MULTI-TISSUE_STRUCTURE", 59, 69], ["AAV1", "GENE_OR_GENE_PRODUCT", 108, 112], ["AAV6", "GENE_OR_GENE_PRODUCT", 117, 121], ["AAV1", "GENE_OR_GENE_PRODUCT", 178, 182], ["5", "ORGANISM", 190, 191], ["nervous system", "ANATOMICAL_SYSTEM", 258, 272], ["heart", "ORGAN", 318, 323], ["AAV9", "GENE_OR_GENE_PRODUCT", 360, 364], ["AAV6", "GENE_OR_GENE_PRODUCT", 414, 418], ["cornea", "ORGAN", 472, 478], ["AAV1", "PROTEIN", 108, 112], ["AAV6", "PROTEIN", 117, 121], ["AAV1, 2 and 5", "DNA", 178, 191], ["AAV6", "PROTEIN", 414, 418], ["rat", "SPECIES", 55, 58], ["rat", "SPECIES", 55, 58], ["AAV8", "SPECIES", 505, 509], ["The serotypes AAV1", "TEST", 0, 18], ["AAV1", "TEST", 108, 112], ["AAV6", "TEST", 117, 121], ["AAV1", "TEST", 178, 182], ["the delivery of gene", "TREATMENT", 209, 229], ["gene delivery", "TREATMENT", 301, 314], ["AAV1", "TEST", 341, 345], ["AAV9", "TEST", 360, 364], ["AAV6", "TEST", 414, 418], ["AAV8", "TEST", 505, 509], ["rat myocardium", "ANATOMY", 55, 69], ["nervous system", "ANATOMY", 258, 272], ["heart", "ANATOMY", 318, 323]]], ["AAV serotypes 1, 5, 7 and 8 among the serotypes 1-8 tested showed most effective cell mediated immunity response in muscle when compared to AAV2 (Xin et al., 2006) .", [["cell", "ANATOMY", 81, 85], ["muscle", "ANATOMY", 116, 122], ["AAV serotypes 1", "ORGANISM", 0, 15], ["5", "GENE_OR_GENE_PRODUCT", 17, 18], ["7", "GENE_OR_GENE_PRODUCT", 20, 21], ["8", "GENE_OR_GENE_PRODUCT", 26, 27], ["cell", "CELL", 81, 85], ["muscle", "ORGAN", 116, 122], ["AAV2", "ORGANISM", 140, 144], ["AAV2", "SPECIES", 140, 144], ["AAV serotypes", "TEST", 0, 13], ["the serotypes", "TEST", 34, 47], ["immunity response", "OBSERVATION", 95, 112], ["muscle", "ANATOMY", 116, 122]]], ["Attempts have been made in constructing laboratoryderived serotypes to target single tissue type to minimize the AAV dosage required for a treatment.", [["tissue", "ANATOMY", 85, 91], ["tissue", "TISSUE", 85, 91], ["AAV", "ORGANISM", 113, 116], ["constructing laboratoryderived serotypes", "TREATMENT", 27, 67], ["the AAV dosage", "TREATMENT", 109, 123], ["a treatment", "TREATMENT", 137, 148]]], ["For example, Asokan et al. (2010) engineered AAV2i8 from AAV2 and AAV8 to change the properties of the new virus construct.", [["AAV2i8", "GENE_OR_GENE_PRODUCT", 45, 51], ["AAV2", "ORGANISM", 57, 61], ["AAV8", "GENE_OR_GENE_PRODUCT", 66, 70], ["AAV2", "SPECIES", 57, 61], ["AAV2", "TREATMENT", 57, 61], ["AAV8", "TREATMENT", 66, 70], ["the new virus construct", "PROBLEM", 99, 122], ["new", "OBSERVATION_MODIFIER", 103, 106], ["virus construct", "OBSERVATION", 107, 122]]], ["This construct reduced the gene expression in mouse liver by 40 folds (in contrast to AAV8) while high levels of expressions were observed in the muscle cells (in contrast to AAV2).", [["liver", "ANATOMY", 52, 57], ["muscle cells", "ANATOMY", 146, 158], ["mouse", "ORGANISM", 46, 51], ["liver", "ORGAN", 52, 57], ["AAV8", "GENE_OR_GENE_PRODUCT", 86, 90], ["muscle cells", "CELL", 146, 158], ["AAV2", "ORGANISM", 175, 179], ["AAV8", "PROTEIN", 86, 90], ["muscle cells", "CELL_TYPE", 146, 158], ["mouse", "SPECIES", 46, 51], ["mouse", "SPECIES", 46, 51], ["AAV8", "TEST", 86, 90], ["high levels of expressions", "PROBLEM", 98, 124], ["gene expression", "OBSERVATION", 27, 42], ["liver", "ANATOMY", 52, 57], ["muscle cells", "ANATOMY", 146, 158]]], ["Relatively very low levels of expressions were observed in Brain.", [["Brain", "ANATOMY", 59, 64], ["Brain", "ORGAN", 59, 64], ["very", "OBSERVATION_MODIFIER", 11, 15], ["low levels", "OBSERVATION_MODIFIER", 16, 26], ["Brain", "ANATOMY", 59, 64]]], ["Lin et al. (2009) showed that recombining different capsids increased the responses to HIV-1 gag which is a further advancement to the use of AAV as vaccine.", [["HIV-1", "ORGANISM", 87, 92], ["gag", "ORGANISM", 93, 96], ["AAV", "ORGANISM", 142, 145], ["HIV-1", "SPECIES", 87, 92], ["HIV-1", "SPECIES", 87, 92], ["AAV", "SPECIES", 142, 145], ["recombining different capsids", "PROBLEM", 30, 59], ["AAV as vaccine", "TREATMENT", 142, 156]]], ["This showed that by mixing different serotypes, the properties of AAV could be engineered to maximize the expression in the target tissue.", [["tissue", "ANATOMY", 131, 137], ["AAV", "ORGANISM", 66, 69], ["tissue", "TISSUE", 131, 137], ["AAV", "SPECIES", 66, 69], ["mixing different serotypes", "PROBLEM", 20, 46], ["AAV", "TREATMENT", 66, 69], ["different", "OBSERVATION_MODIFIER", 27, 36], ["serotypes", "OBSERVATION", 37, 46], ["AAV", "OBSERVATION", 66, 69], ["target tissue", "OBSERVATION", 124, 137]]], ["The delivery of AAV vaccine by selecting intranasal, subcutaneous or muscular route has different effect on immune response (Xin et al., 2001) .IntroductionMajor advancements have been realized in the molecular engineering, structural analyses and processing of AAV vectors.", [["subcutaneous", "ANATOMY", 53, 65], ["muscular", "ANATOMY", 69, 77], ["AAV", "ORGANISM", 16, 19], ["AAV", "ORGANISM", 262, 265], ["AAV", "SPECIES", 16, 19], ["The delivery of AAV vaccine", "TREATMENT", 0, 27], ["selecting intranasal, subcutaneous or muscular route", "TREATMENT", 31, 83], ["AAV vectors", "TREATMENT", 262, 273]]], ["Grieger et al. (2006) published a detailed protocol on the production and characterization of AAV vectors.", [["AAV", "ORGANISM", 94, 97], ["a detailed protocol", "TREATMENT", 32, 51], ["AAV vectors", "TREATMENT", 94, 105]]], ["The use of serum-free medium has also advanced the commercial manufacturing of the AAV vectors for human use.", [["serum", "ANATOMY", 11, 16], ["serum", "ORGANISM_SUBSTANCE", 11, 16], ["AAV", "ORGANISM", 83, 86], ["human", "ORGANISM", 99, 104], ["human", "SPECIES", 99, 104], ["AAV", "SPECIES", 83, 86], ["human", "SPECIES", 99, 104], ["the AAV vectors", "TREATMENT", 79, 94]]], ["Aside from these improvements, the supply of AAV vectors for clinical studies for the proof of concept remains challenging, thus limiting the number and duration of clinical trials.", [["AAV", "ORGANISM", 45, 48], ["AAV vectors", "TREATMENT", 45, 56], ["clinical studies", "TEST", 61, 77], ["improvements", "OBSERVATION_MODIFIER", 17, 29]]], ["The need for different serotypes to target specific tissues has further added complexity to the production, purification and analytical procedures.IntroductionThere are different modes of AAV production.", [["tissues", "ANATOMY", 52, 59], ["tissues", "TISSUE", 52, 59], ["AAV", "ORGANISM", 188, 191], ["different serotypes", "TREATMENT", 13, 32], ["purification", "TREATMENT", 108, 120], ["analytical procedures", "TREATMENT", 125, 146], ["AAV production", "TREATMENT", 188, 202], ["AAV production", "OBSERVATION", 188, 202]]], ["AAV has been produced successfully in producer cell lines and packaging cell lines (Chadeuf et al., 2000; Clark et al., 1995; Farson et al., 2004; Gao et al., 2002; Liu et al., 2000; Thorne et al., 2009; Yuan et al., 2007) where the cells could be anchorage dependent or in suspension.", [["cell lines", "ANATOMY", 47, 57], ["cell lines", "ANATOMY", 72, 82], ["cells", "ANATOMY", 233, 238], ["AAV", "ORGANISM", 0, 3], ["producer cell lines", "CELL", 38, 57], ["packaging cell lines", "CELL", 62, 82], ["cells", "CELL", 233, 238], ["producer cell lines", "CELL_LINE", 38, 57], ["packaging cell lines", "CELL_LINE", 62, 82], ["AAV", "TREATMENT", 0, 3], ["producer cell lines", "TREATMENT", 38, 57], ["anchorage dependent", "PROBLEM", 248, 267], ["successfully", "OBSERVATION_MODIFIER", 22, 34], ["producer cell lines", "OBSERVATION", 38, 57], ["packaging cell lines", "OBSERVATION", 62, 82]]], ["Producer cell lines contain all AAV production components (e.g., vector genome and AAV Rep & Cap) and helper virus (e.g., Adenovirus type 5) is used to induce.", [["cell lines", "ANATOMY", 9, 19], ["cell lines", "CELL", 9, 19], ["AAV", "ORGANISM", 32, 35], ["AAV", "ORGANISM", 83, 86], ["Rep", "GENE_OR_GENE_PRODUCT", 87, 90], ["Cap", "GENE_OR_GENE_PRODUCT", 93, 96], ["Adenovirus type 5", "ORGANISM", 122, 139], ["Producer cell lines", "CELL_LINE", 0, 19], ["AAV production components", "PROTEIN", 32, 57], ["vector genome", "DNA", 65, 78], ["Rep", "PROTEIN", 87, 90], ["Cap", "PROTEIN", 93, 96], ["Adenovirus type 5", "SPECIES", 122, 139], ["Producer cell lines", "TREATMENT", 0, 19], ["all AAV production components", "TREATMENT", 28, 57], ["vector genome", "TREATMENT", 65, 78], ["AAV Rep & Cap)", "TREATMENT", 83, 97], ["helper virus (e.g., Adenovirus type", "TREATMENT", 102, 137], ["cell lines", "OBSERVATION", 9, 19], ["all", "OBSERVATION_MODIFIER", 28, 31], ["AAV production", "OBSERVATION", 32, 46]]], ["Packaging cell lines use two viruses, one to induce the AAV rep-cap genes present in the packaging cell line and the other to supply the gene of interest to be encapsidated.", [["cell lines", "ANATOMY", 10, 20], ["cell line", "ANATOMY", 99, 108], ["cell lines", "CELL", 10, 20], ["AAV", "ORGANISM", 56, 59], ["cell line", "CELL", 99, 108], ["Packaging cell lines", "CELL_LINE", 0, 20], ["AAV rep-cap genes", "DNA", 56, 73], ["packaging cell line", "CELL_LINE", 89, 108], ["Packaging cell lines", "TREATMENT", 0, 20], ["the AAV rep-cap genes", "TREATMENT", 52, 73], ["cell lines", "OBSERVATION", 10, 20], ["viruses", "OBSERVATION", 29, 36], ["AAV", "OBSERVATION", 56, 59], ["packaging cell line", "OBSERVATION", 89, 108], ["encapsidated", "OBSERVATION", 160, 172]]], ["Stable cell lines (Clark et al., 1995; Liu et al., 2000) are more practical for large-scale manufacturing with consistently high yields after the success of the proof of concept.", [["cell lines", "ANATOMY", 7, 17], ["cell lines", "CELL", 7, 17], ["Stable cell lines", "CELL_LINE", 0, 17], ["large-scale manufacturing", "TREATMENT", 80, 105], ["cell lines", "OBSERVATION", 7, 17]]], ["Transient transfection technology, however, offers a rapid generation of material for the proof of concept.", [["a rapid generation of material", "PROBLEM", 51, 81]]], ["For transient transfection the components required for AAV production are supplied by plasmids, or in a combination of plasmids and a helper virus.", [["plasmids", "ANATOMY", 86, 94], ["plasmids", "ANATOMY", 119, 127], ["AAV", "ORGANISM", 55, 58], ["plasmids", "DNA", 86, 94], ["plasmids", "DNA", 119, 127], ["transient transfection the components", "PROBLEM", 4, 41], ["AAV production", "TREATMENT", 55, 69], ["plasmids", "TREATMENT", 119, 127], ["a helper virus", "PROBLEM", 132, 146], ["transient", "OBSERVATION_MODIFIER", 4, 13], ["transfection", "OBSERVATION", 14, 26]]], ["Transient transfection has been done using adherent cells in cell plates (Salvetti et al., 1998; Zolotukhin et al., 1999) , cell factories (Drittanti et al., 2001) or roller bottles (Liu et al., 2003) .", [["cells", "ANATOMY", 52, 57], ["cell", "ANATOMY", 61, 65], ["cell", "ANATOMY", 124, 128], ["cells", "CELL", 52, 57], ["cell", "CELL", 61, 65], ["cell", "CELL", 124, 128], ["adherent cells", "CELL_TYPE", 43, 57], ["Transient transfection", "PROBLEM", 0, 22], ["adherent cells in cell plates", "TREATMENT", 43, 72], ["transfection", "OBSERVATION", 10, 22]]], ["When the scaling up of the process is desired in a short period of time to generate pre-clinical/clinical material or material required for the proof of concept, methods using adherent cells may need more incubator space and are timeconsuming and labor-intensive processes.", [["cells", "ANATOMY", 185, 190], ["cells", "CELL", 185, 190], ["adherent cells", "CELL_TYPE", 176, 190], ["pre-clinical/clinical material", "TREATMENT", 84, 114], ["adherent cells", "TREATMENT", 176, 190], ["more incubator space", "TREATMENT", 200, 220], ["labor", "PROBLEM", 247, 252]]], ["Technology is advancing to support the anchorage dependent cell growth as well by providing up to 100 layered CellCube \u00ae units (Corning Life Sciences, Tewksbury, MA, USA) with liquid volume of 6000 mL which can support more than 10 10 cells.", [["cell", "ANATOMY", 59, 63], ["cells", "ANATOMY", 235, 240], ["cell", "CELL", 59, 63], ["cells", "CELL", 235, 240], ["the anchorage dependent cell growth", "PROBLEM", 35, 70], ["liquid volume", "TREATMENT", 176, 189], ["anchorage dependent", "OBSERVATION_MODIFIER", 39, 58], ["cell growth", "OBSERVATION", 59, 70]]], ["Selecting cells that are able to grow in suspension is an alternative for scaling up in conventional bioreactors (Durocher et al., 2007; Park et al., 2006; Reed et al., 2006) .", [["cells", "ANATOMY", 10, 15], ["cells", "CELL", 10, 15]]], ["A major advantage of transient transfection is that serotype-specific vectors of AAV can be easily generated in a short period of time by supplying a capsid/replication plasmid of choice, along with the transgene and helper plasmids.", [["plasmid", "ANATOMY", 169, 176], ["plasmids", "ANATOMY", 224, 232], ["AAV", "ORGANISM", 81, 84], ["capsid/replication plasmid", "DNA", 150, 176], ["transgene and helper plasmids", "DNA", 203, 232], ["AAV", "SPECIES", 81, 84], ["transient transfection", "TREATMENT", 21, 43], ["serotype-specific vectors of AAV", "TREATMENT", 52, 84], ["a capsid/replication plasmid of choice", "TREATMENT", 148, 186], ["the transgene and helper plasmids", "TREATMENT", 199, 232], ["transient", "OBSERVATION_MODIFIER", 21, 30], ["transfection", "OBSERVATION", 31, 43]]], ["Therefore, transfection is the most chosen mode for AAV production to rapidly generate preclinical material.", [["AAV", "ORGANISM", 52, 55], ["transfection", "TREATMENT", 11, 23], ["AAV production", "PROBLEM", 52, 66]]], ["Another approach using the insect cell-baculovirus system for AAV manufacturing has recently attracted attention and has shown great potential for the large-scale manufacturing of clinical material (Meghrous et al., 2005; Mena et al., 2010; Urabe et al., 2002) .", [["cell", "ANATOMY", 34, 38], ["insect cell", "CELL", 27, 38], ["baculovirus", "ORGANISM", 39, 50], ["AAV", "ORGANISM", 62, 65], ["baculovirus", "SPECIES", 39, 50], ["AAV", "SPECIES", 62, 65], ["Another approach", "TREATMENT", 0, 16], ["the insect cell-baculovirus system", "TREATMENT", 23, 57], ["AAV manufacturing", "TREATMENT", 62, 79], ["large", "OBSERVATION_MODIFIER", 151, 156]]], ["The advantages and challenges of the different methods have been extensively reviewed elsewhere (Aucoin et al., 2008) .IntroductionTo scale-up the production of any clinical grade biological material, it is very important to have a cell line that maintains a high yield of the product.", [["cell line", "ANATOMY", 232, 241], ["cell line", "CELL", 232, 241], ["cell line", "CELL_LINE", 232, 241], ["the different methods", "TREATMENT", 33, 54], ["any clinical grade biological material", "PROBLEM", 161, 199], ["a cell line", "TREATMENT", 230, 241], ["cell line", "OBSERVATION", 232, 241]]], ["The cell line used for the production must be generated in a sufficient quantity as a Master Cell Bank (MCB) with full characterization.", [["cell line", "ANATOMY", 4, 13], ["Cell", "ANATOMY", 93, 97], ["cell line", "CELL", 4, 13], ["Master Cell", "CELL", 86, 97], ["cell line", "CELL_LINE", 4, 13], ["The cell line", "TREATMENT", 0, 13], ["full characterization", "TEST", 114, 135], ["cell line", "OBSERVATION", 4, 13]]], ["NRC-Montreal facility has generated and is maintaining such a cell line, the human embryonic kidney (HEK) 293SF-3F6 cell line, which meets the requirements of MCB for manufacturing under GMP guidelines.", [["cell line", "ANATOMY", 62, 71], ["embryonic kidney", "ANATOMY", 83, 99], ["HEK) 293SF-3F6 cell line", "ANATOMY", 101, 125], ["GMP", "CHEMICAL", 187, 190], ["GMP", "CHEMICAL", 187, 190], ["cell line", "CELL", 62, 71], ["human", "ORGANISM", 77, 82], ["embryonic kidney", "CELL", 83, 99], ["HEK) 293SF-3F6 cell line", "CELL", 101, 125], ["MCB", "SIMPLE_CHEMICAL", 159, 162], ["GMP", "SIMPLE_CHEMICAL", 187, 190], ["cell line", "CELL_LINE", 62, 71], ["human embryonic kidney (HEK) 293SF-3F6 cell line", "CELL_LINE", 77, 125], ["human", "SPECIES", 77, 82], ["human", "SPECIES", 77, 82], ["a cell line", "TREATMENT", 60, 71], ["3F6 cell line", "TREATMENT", 112, 125], ["GMP guidelines", "TREATMENT", 187, 201], ["cell line", "OBSERVATION", 62, 71], ["kidney", "ANATOMY", 93, 99], ["cell line", "OBSERVATION", 116, 125]]], ["In this work, it is demonstrated that this cell line is capable of producing sufficient quantities of different AAV serotypes.IntroductionThe plasmid/mammalian cell system described in the present study is based on transfection of HEK293SF-3F6 by three plasmids employing polyethylenimine (PEI) as the DNA transporter in a serum-free medium.", [["cell line", "ANATOMY", 43, 52], ["plasmid", "ANATOMY", 142, 149], ["cell", "ANATOMY", 160, 164], ["plasmids", "ANATOMY", 253, 261], ["serum", "ANATOMY", 323, 328], ["HEK293SF-3F6", "CHEMICAL", 231, 243], ["polyethylenimine", "CHEMICAL", 272, 288], ["PEI", "CHEMICAL", 290, 293], ["polyethylenimine", "CHEMICAL", 272, 288], ["PEI", "CHEMICAL", 290, 293], ["cell line", "CELL", 43, 52], ["AAV", "ORGANISM", 112, 115], ["mammalian cell", "CELL", 150, 164], ["HEK293SF-3F6", "CELL", 231, 243], ["polyethylenimine", "SIMPLE_CHEMICAL", 272, 288], ["PEI", "SIMPLE_CHEMICAL", 290, 293], ["DNA", "CELLULAR_COMPONENT", 302, 305], ["serum", "ORGANISM_SUBSTANCE", 323, 328], ["cell line", "CELL_LINE", 43, 52], ["plasmid", "DNA", 142, 149], ["HEK293SF", "PROTEIN", 231, 239], ["3F6", "DNA", 240, 243], ["plasmids", "DNA", 253, 261], ["this cell line", "TREATMENT", 38, 52], ["different AAV serotypes", "PROBLEM", 102, 125], ["The plasmid/mammalian cell system", "TREATMENT", 138, 171], ["HEK293SF", "TEST", 231, 239], ["polyethylenimine (PEI", "TREATMENT", 272, 293], ["the DNA transporter", "TEST", 298, 317], ["cell line", "OBSERVATION", 43, 52], ["different AAV serotypes", "OBSERVATION", 102, 125], ["mammalian cell system", "OBSERVATION", 150, 171]]], ["The system was used for the production of different serotypes of AAV.", [["AAV", "ORGANISM", 65, 68], ["different serotypes of AAV", "TREATMENT", 42, 68], ["AAV", "OBSERVATION", 65, 68]]], ["Among the plasmids supplied to produce different serotypes of AAV, the AdV helper and transgene plasmids remained the same in all productions.", [["plasmids", "ANATOMY", 10, 18], ["AAV", "ORGANISM", 62, 65], ["AdV", "ORGANISM", 71, 74], ["plasmids", "DNA", 10, 18], ["AdV helper and transgene plasmids", "DNA", 71, 104], ["AAV", "SPECIES", 62, 65], ["AdV", "SPECIES", 71, 74], ["the plasmids", "TREATMENT", 6, 18], ["AAV", "TREATMENT", 62, 65], ["the AdV helper", "TREATMENT", 67, 81], ["transgene plasmids", "TREATMENT", 86, 104], ["AAV", "OBSERVATION", 62, 65]]], ["The plasmid containing the capsid proteins supplied for the production of AAV dictated the serotype produced.", [["plasmid", "ANATOMY", 4, 11], ["AAV", "ORGANISM", 74, 77], ["plasmid", "DNA", 4, 11], ["capsid proteins", "PROTEIN", 27, 42], ["The plasmid", "TREATMENT", 0, 11], ["the capsid proteins", "TREATMENT", 23, 42], ["plasmid", "OBSERVATION", 4, 11], ["capsid proteins", "OBSERVATION", 27, 42]]], ["Assuming that the production of different serotypes may be less dependent on the type of capsid plasmid used, selecting one serotype as a model has minimized the number of experiments necessary to evaluate parameter optimization; therefore, generalizing the production protocol, which would be suitable to produce all serotypes available.", [["capsid plasmid", "DNA", 89, 103], ["different serotypes", "PROBLEM", 32, 51], ["capsid plasmid", "TREATMENT", 89, 103], ["parameter optimization", "TEST", 206, 228], ["generalizing the production protocol", "TEST", 241, 277], ["less dependent", "OBSERVATION_MODIFIER", 59, 73]]], ["From the available serotypes, AAV2 was selected as a model AAV for the investigation of production parameters.", [["AAV2", "ORGANISM", 30, 34], ["AAV", "ORGANISM", 59, 62], ["AAV2", "SPECIES", 30, 34], ["AAV2", "TREATMENT", 30, 34], ["a model AAV", "TREATMENT", 51, 62], ["production parameters", "PROBLEM", 88, 109]]], ["The effects of plasmid DNA concentration at different cell densities on the transfection efficiency for the production of AAV were investigated.", [["plasmid", "ANATOMY", 15, 22], ["cell", "ANATOMY", 54, 58], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["cell", "CELL", 54, 58], ["AAV", "ORGANISM", 122, 125], ["plasmid DNA", "DNA", 15, 26], ["plasmid DNA concentration", "TREATMENT", 15, 40], ["different cell densities", "PROBLEM", 44, 68], ["the transfection efficiency", "TREATMENT", 72, 99], ["the production of AAV", "TREATMENT", 104, 125], ["plasmid DNA", "OBSERVATION", 15, 26], ["concentration", "OBSERVATION_MODIFIER", 27, 40], ["different cell densities", "OBSERVATION", 44, 68], ["transfection efficiency", "OBSERVATION", 76, 99], ["AAV", "ANATOMY", 122, 125]]], ["Using optimal transfection conditions, nine serotypes of AAV (AAV1-9) were produced in shake flasks to demonstrate the production of multiple serotypes in the cGMP HEK293SF-3F6 cell line.", [["cGMP HEK293SF-3F6 cell line", "ANATOMY", 159, 186], ["AAV1-9", "CHEMICAL", 62, 68], ["cGMP", "CHEMICAL", 159, 163], ["AAV", "ORGANISM", 57, 60], ["AAV1-9", "CELL", 62, 68], ["cGMP HEK293SF-3F6 cell line", "CELL", 159, 186], ["cGMP HEK293SF-3F6 cell line", "CELL_LINE", 159, 186], ["AAV", "SPECIES", 57, 60], ["optimal transfection conditions", "TREATMENT", 6, 37], ["AAV (AAV1", "TEST", 57, 66], ["multiple serotypes", "PROBLEM", 133, 151], ["the cGMP HEK293SF", "TEST", 155, 172], ["AAV", "ANATOMY", 57, 60], ["multiple", "OBSERVATION_MODIFIER", 133, 141], ["serotypes", "OBSERVATION", 142, 151], ["3F6 cell line", "OBSERVATION", 173, 186]]], ["Scalability was evaluated by producing two serotypes (AAV2 and AAV6) in three runs of 3-L bioreactor.Plasmid constructsTriple plasmids used at a weight ratio of 1:1:1 contained the Rep/Cap plasmid of adeno-associated virus type 1-9, which comprised the gene sequences for replication and structural proteins.", [["plasmids", "ANATOMY", 126, 134], ["adeno-associated virus type 1-9", "CHEMICAL", 200, 231], ["AAV2", "ORGANISM", 54, 58], ["Rep", "GENE_OR_GENE_PRODUCT", 181, 184], ["Cap", "GENE_OR_GENE_PRODUCT", 185, 188], ["adeno-associated virus type 1", "ORGANISM", 200, 229], ["Plasmid constructs", "DNA", 101, 119], ["Triple plasmids", "DNA", 119, 134], ["Rep/Cap plasmid", "DNA", 181, 196], ["structural proteins", "PROTEIN", 288, 307], ["AAV2", "SPECIES", 54, 58], ["3-L bioreactor", "TREATMENT", 86, 100], ["Plasmid constructs", "TREATMENT", 101, 119], ["Triple plasmids", "TREATMENT", 119, 134], ["a weight ratio", "TEST", 143, 157], ["the Rep/Cap plasmid", "TREATMENT", 177, 196], ["adeno-associated virus type", "TEST", 200, 227], ["structural proteins", "PROBLEM", 288, 307], ["plasmids", "OBSERVATION", 126, 134]]], ["The transgene plasmid of ITRCMV-eGFP (single stranded), which harbored the transgene for enhanced green fluorescent protein (eGFP), was driven by the cytomegalovirus promoter (CMV) between AAV inverted terminal repeats (ITRs).", [["ITRCMV-eGFP", "GENE_OR_GENE_PRODUCT", 25, 36], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 98, 123], ["eGFP", "GENE_OR_GENE_PRODUCT", 125, 129], ["cytomegalovirus", "ORGANISM", 150, 165], ["CMV", "ORGANISM", 176, 179], ["AAV", "ORGANISM", 189, 192], ["transgene plasmid", "DNA", 4, 21], ["ITRCMV", "DNA", 25, 31], ["eGFP", "DNA", 32, 36], ["enhanced green fluorescent protein", "PROTEIN", 89, 123], ["eGFP", "PROTEIN", 125, 129], ["cytomegalovirus promoter", "DNA", 150, 174], ["AAV inverted terminal repeats", "DNA", 189, 218], ["ITRs", "DNA", 220, 224], ["ITRCMV-eGFP", "TREATMENT", 25, 36], ["enhanced green fluorescent protein (eGFP", "PROBLEM", 89, 129], ["the cytomegalovirus promoter", "TREATMENT", 146, 174], ["AAV inverted terminal repeats", "TREATMENT", 189, 218]]], ["The adenovirus helper-functions were supplied by pXX6-80 plasmid that contains genes for E1A, E1B, E4 and E2A proteins and VA RNAs.", [["adenovirus", "ORGANISM", 4, 14], ["pXX6", "GENE_OR_GENE_PRODUCT", 49, 53], ["E1A", "GENE_OR_GENE_PRODUCT", 89, 92], ["E1B", "GENE_OR_GENE_PRODUCT", 94, 97], ["E4", "GENE_OR_GENE_PRODUCT", 99, 101], ["E2A", "GENE_OR_GENE_PRODUCT", 106, 109], ["pXX6-80 plasmid", "DNA", 49, 64], ["E1A", "DNA", 89, 92], ["E1B", "DNA", 94, 97], ["E4", "PROTEIN", 99, 101], ["E2A proteins", "PROTEIN", 106, 118], ["VA RNAs", "RNA", 123, 130], ["The adenovirus helper", "TREATMENT", 0, 21], ["pXX6", "TEST", 49, 53], ["E1A", "PROBLEM", 89, 92], ["VA RNAs", "OBSERVATION", 123, 130]]], ["The AAV pseudotypes 1, 2, 3, 4, 5, 6, 7, 8 and 9 are pseudo-packages of rAAV-containing capsids of AAV1, AAV2, AAV3, AAV4, AAV5, AAV6, AAV7, AAV8 and AAV9, respectively, with the ITRs of AAV2.", [["AAV pseudotypes 1", "ORGANISM", 4, 21], ["2", "GENE_OR_GENE_PRODUCT", 23, 24], ["3", "GENE_OR_GENE_PRODUCT", 26, 27], ["4", "GENE_OR_GENE_PRODUCT", 29, 30], ["5", "GENE_OR_GENE_PRODUCT", 32, 33], ["6", "GENE_OR_GENE_PRODUCT", 35, 36], ["7", "GENE_OR_GENE_PRODUCT", 38, 39], ["8", "GENE_OR_GENE_PRODUCT", 41, 42], ["9", "GENE_OR_GENE_PRODUCT", 47, 48], ["rAAV", "ORGANISM", 72, 76], ["AAV1", "GENE_OR_GENE_PRODUCT", 99, 103], ["AAV2", "GENE_OR_GENE_PRODUCT", 105, 109], ["AAV3", "GENE_OR_GENE_PRODUCT", 111, 115], ["AAV4", "GENE_OR_GENE_PRODUCT", 117, 121], ["AAV5", "GENE_OR_GENE_PRODUCT", 123, 127], ["AAV6", "GENE_OR_GENE_PRODUCT", 129, 133], ["AAV7", "GENE_OR_GENE_PRODUCT", 135, 139], ["AAV8", "GENE_OR_GENE_PRODUCT", 141, 145], ["AAV9", "GENE_OR_GENE_PRODUCT", 150, 154], ["AAV2", "ORGANISM", 187, 191], ["AAV pseudotypes 1, 2, 3, 4, 5, 6, 7, 8 and 9", "DNA", 4, 48], ["AAV1", "PROTEIN", 99, 103], ["AAV3", "PROTEIN", 111, 115], ["AAV4", "PROTEIN", 117, 121], ["AAV5", "PROTEIN", 123, 127], ["AAV6", "PROTEIN", 129, 133], ["AAV7", "PROTEIN", 135, 139], ["AAV8", "PROTEIN", 141, 145], ["AAV9", "PROTEIN", 150, 154], ["ITRs", "PROTEIN", 179, 183], ["AAV2", "SPECIES", 187, 191], ["The AAV pseudotypes", "TEST", 0, 19], ["pseudo", "TEST", 53, 59], ["rAAV", "TEST", 72, 76], ["AAV1", "TEST", 99, 103], ["AAV2", "TEST", 105, 109], ["AAV3", "TEST", 111, 115], ["AAV4", "TEST", 117, 121], ["AAV5", "TEST", 123, 127], ["AAV6", "TEST", 129, 133], ["AAV7", "TEST", 135, 139], ["AAV8", "TEST", 141, 145], ["AAV9", "TEST", 150, 154], ["the ITRs of AAV2", "PROBLEM", 175, 191], ["AAV", "ANATOMY", 4, 7], ["pseudotypes", "OBSERVATION", 8, 19], ["pseudo", "OBSERVATION", 53, 59], ["rAAV", "OBSERVATION", 72, 76], ["containing capsids", "ANATOMY_MODIFIER", 77, 95], ["AAV1", "ANATOMY_MODIFIER", 99, 103], ["AAV2", "ANATOMY_MODIFIER", 105, 109], ["AAV3", "ANATOMY_MODIFIER", 111, 115], ["AAV4", "ANATOMY_MODIFIER", 117, 121], ["AAV5", "ANATOMY_MODIFIER", 123, 127], ["AAV6", "ANATOMY_MODIFIER", 129, 133], ["AAV7", "ANATOMY_MODIFIER", 135, 139], ["AAV8", "ANATOMY_MODIFIER", 141, 145], ["AAV9", "ANATOMY_MODIFIER", 150, 154], ["AAV2", "ANATOMY_MODIFIER", 187, 191]]], ["The transgene plasmids, pXX6-80 and serotype-specific plasmids (AAV1-6, 8 and 9) were provided by Jude Samulski from Samulski Laboratory, Gene Therapy Center, University of North Carolina at Chapel Hill (http://genetherapy. unc.edu/services.htm) with the exception of the plasmid for serotype 7 (pAAV2/7) that was obtained from The Penn Vector Core, University of Pennsylvania, Philadelphia, PA (http://www.med. upenn.edu/gtp/vectorcore/ServicesRates.shtml).Plasmid constructsAll transfections were done using 25-kDa linear polyethylenimine (PEI) from Polysciences Inc. (Warrington, PA, USA) as a DNA transporter.Cell linesHEK293SF-3F6 (cGMP cell line from National Research Council Canada, Montreal, Qc, Canada, www.nrc-cnrc.gc.ca/eng/ rd/hht/index.html) used for AAV production, were grown and maintained as a suspension culture in serum-free HyClone Thermo Scientific HyQ SFM4Transfx-293 medium supplemented with 1 g/L Pluronic F-68, 4 mM l-glutamine and 2 g/L NaHCO 3 .", [["plasmids", "ANATOMY", 14, 22], ["plasmids", "ANATOMY", 54, 62], ["Cell linesHEK293SF-3F6", "ANATOMY", 613, 635], ["cGMP cell line", "ANATOMY", 637, 651], ["serum", "ANATOMY", 834, 839], ["polyethylenimine", "CHEMICAL", 524, 540], ["PEI", "CHEMICAL", 542, 545], ["linesHEK293SF-3F6", "CHEMICAL", 618, 635], ["cGMP", "CHEMICAL", 637, 641], ["html", "CHEMICAL", 750, 754], ["HyQ SFM4Transfx-293", "CHEMICAL", 871, 890], ["Pluronic F-68", "CHEMICAL", 922, 935], ["l-glutamine", "CHEMICAL", 942, 953], ["polyethylenimine", "CHEMICAL", 524, 540], ["PEI", "CHEMICAL", 542, 545], ["cGMP", "CHEMICAL", 637, 641], ["Pluronic F-68", "CHEMICAL", 922, 935], ["l-glutamine", "CHEMICAL", 942, 953], ["NaHCO 3", "CHEMICAL", 964, 971], ["pXX6-80", "GENE_OR_GENE_PRODUCT", 24, 31], ["AAV1-6", "ORGANISM", 64, 70], ["serotype 7", "ORGANISM", 284, 294], ["pAAV2", "ORGANISM", 296, 301], ["gtp", "GENE_OR_GENE_PRODUCT", 422, 425], ["polyethylenimine", "SIMPLE_CHEMICAL", 524, 540], ["PEI", "SIMPLE_CHEMICAL", 542, 545], ["DNA", "CELLULAR_COMPONENT", 597, 600], ["Cell linesHEK293SF-3F6", "CELL", 613, 635], ["cGMP cell line", "CELL", 637, 651], ["nrc-", "GENE_OR_GENE_PRODUCT", 717, 721], ["html", "GENE_OR_GENE_PRODUCT", 750, 754], ["AAV", "ORGANISM", 765, 768], ["serum", "ORGANISM_SUBSTANCE", 834, 839], ["Pluronic F-68", "SIMPLE_CHEMICAL", 922, 935], ["l-glutamine", "SIMPLE_CHEMICAL", 942, 953], ["transgene plasmids", "DNA", 4, 22], ["pXX6", "DNA", 24, 28], ["serotype-specific plasmids", "DNA", 36, 62], ["AAV1-6, 8 and 9", "DNA", 64, 79], ["plasmid", "DNA", 272, 279], ["edu", "PROTEIN", 418, 421], ["gtp", "DNA", 422, 425], ["vectorcore/ServicesRates.shtml", "PROTEIN", 426, 456], ["Plasmid constructs", "DNA", 458, 476], ["DNA transporter", "PROTEIN", 597, 612], ["linesHEK293SF-3F6 (cGMP cell line", "CELL_LINE", 618, 651], ["cnrc.gc.ca", "PROTEIN", 721, 731], ["eng", "PROTEIN", 732, 735], ["rd", "DNA", 737, 739], ["html", "PROTEIN", 750, 754], ["The transgene plasmids", "TREATMENT", 0, 22], ["pXX6", "TEST", 24, 28], ["serotype-specific plasmids", "TREATMENT", 36, 62], ["AAV1", "TEST", 64, 68], ["genetherapy", "TREATMENT", 211, 222], ["the plasmid", "TREATMENT", 268, 279], ["serotype", "TREATMENT", 284, 292], ["gtp/vectorcore/ServicesRates.shtml", "TREATMENT", 422, 456], ["Plasmid constructs", "TREATMENT", 458, 476], ["All transfections", "TEST", 476, 493], ["25-kDa linear polyethylenimine (PEI", "TREATMENT", 510, 545], ["Cell linesHEK293SF", "TEST", 613, 631], ["cGMP cell line", "TREATMENT", 637, 651], ["nrc-", "TEST", 717, 721], ["cnrc.gc.ca", "TEST", 721, 731], ["AAV production", "PROBLEM", 765, 779], ["a suspension culture", "TEST", 810, 830], ["serum", "TEST", 834, 839], ["glutamine", "TREATMENT", 944, 953], ["2 g/L NaHCO", "TREATMENT", 958, 969], ["transgene plasmids", "OBSERVATION", 4, 22], ["cell line", "OBSERVATION", 642, 651], ["hht", "ANATOMY", 740, 743]]], ["HeLa cells were maintained in DMEM containing 10% FBS.", [["HeLa cells", "ANATOMY", 0, 10], ["FBS", "ANATOMY", 50, 53], ["HeLa cells", "CELL", 0, 10], ["FBS", "ORGANISM_SUBSTANCE", 50, 53], ["HeLa cells", "CELL_LINE", 0, 10], ["HeLa cells", "TREATMENT", 0, 10]]], ["Both cell lines were propagated at 37 \u2022 C in 5% CO 2 .AAV production protocolsHEK293SF-3F6 cells were grown in 19 mL of serum-free HyQ SFM4Transfx293 medium and transfected with 1 mL transfection mixture in 125-mL shake flasks.", [["cell lines", "ANATOMY", 5, 15], ["protocolsHEK293SF-3F6 cells", "ANATOMY", 69, 96], ["serum", "ANATOMY", 120, 125], ["HyQ SFM4Transfx293", "CHEMICAL", 131, 149], ["CO 2", "CHEMICAL", 48, 52], ["cell lines", "CELL", 5, 15], ["AAV", "ORGANISM", 54, 57], ["protocolsHEK293SF-3F6 cells", "CELL", 69, 96], ["serum", "ORGANISM_SUBSTANCE", 120, 125], ["HyQ", "SIMPLE_CHEMICAL", 131, 134], ["cell lines", "CELL_LINE", 5, 15], ["protocolsHEK293SF-3F6 cells", "CELL_LINE", 69, 96], ["Both cell lines", "TREATMENT", 0, 15], ["AAV production protocolsHEK293SF", "TEST", 54, 86], ["serum", "TEST", 120, 125], ["1 mL transfection mixture", "TREATMENT", 178, 203], ["cell lines", "OBSERVATION", 5, 15]]], ["After 48 h of production, 10% (v/v) of lysing buffer concentrate (20 mM MgCl 2 , 1% Triton X-100 in 500 mM Tris buffered solution, pH 7.5) and 1% (v/v) of freshly diluted Benzonase \u00ae (Merck KGaA, Darmstadt, Germany) to supply a final concentration of 50 units benzonase/mL to digest host-cell DNA and unpackaged virus DNA were added to the harvested cell culture.", [["cell", "ANATOMY", 288, 292], ["cell", "ANATOMY", 350, 354], ["Triton X-100", "CHEMICAL", 84, 96], ["benzonase", "CHEMICAL", 260, 269], ["MgCl 2", "CHEMICAL", 72, 78], ["Tris", "CHEMICAL", 107, 111], ["benzonase", "CHEMICAL", 260, 269], ["Triton X-100", "SIMPLE_CHEMICAL", 84, 96], ["Benzonase \u00ae", "SIMPLE_CHEMICAL", 171, 182], ["benzonase", "SIMPLE_CHEMICAL", 260, 269], ["cell", "ORGANISM_SUBSTANCE", 288, 292], ["DNA", "CELLULAR_COMPONENT", 293, 296], ["DNA", "CELLULAR_COMPONENT", 318, 321], ["cell", "CELL", 350, 354], ["host-cell DNA", "DNA", 283, 296], ["unpackaged virus DNA", "DNA", 301, 321], ["harvested cell culture", "CELL_LINE", 340, 362], ["lysing buffer concentrate", "TREATMENT", 39, 64], ["pH", "TEST", 131, 133], ["freshly diluted Benzonase", "TREATMENT", 155, 180], ["benzonase", "TREATMENT", 260, 269], ["host-cell DNA", "TREATMENT", 283, 296], ["unpackaged virus DNA", "TREATMENT", 301, 321], ["the harvested cell culture", "TEST", 336, 362], ["cell DNA", "OBSERVATION", 288, 296], ["harvested cell", "OBSERVATION", 340, 354]]], ["After 1 h of incubation at 37 \u2022 C with agitation, concentrated MgSO 4 was added to obtain a final concentration of 37.5 mM; the solution was incubated further for 30 min .", [["agitation", "DISEASE", 39, 48], ["MgSO 4", "CHEMICAL", 63, 69], ["MgSO 4", "CHEMICAL", 63, 69], ["MgSO 4", "SIMPLE_CHEMICAL", 63, 69], ["incubation", "TREATMENT", 13, 23], ["agitation", "PROBLEM", 39, 48], ["concentrated MgSO", "TREATMENT", 50, 67], ["the solution", "TREATMENT", 124, 136]]], ["The addition of MgSO 4 was necessary to avoid AAV aggregation and AAV binding to other cellular components released during lysis.AAV production protocolsTo study the effect of different media on AAV yield, when the cells under maintenance (in SFM4Transfx-293 medium) reached a cell density of 1 \u00d7 10 6 cells per mL, 20 mL of cell culture were centrifuged at 385 \u00d7 g for 10 min and then resuspended either in F17 (Invitrogen, Burlington, Ontario, Canada) or in SFM4Transfx-293 (Thermo Scientific Hyclone, Logan, UT, USA) fresh medium.", [["cellular", "ANATOMY", 87, 95], ["cells", "ANATOMY", 215, 220], ["cell", "ANATOMY", 277, 281], ["cells", "ANATOMY", 302, 307], ["cell culture", "ANATOMY", 325, 337], ["MgSO 4", "CHEMICAL", 16, 22], ["SFM4Transfx-293", "CHEMICAL", 243, 258], ["SFM4Transfx-293", "CHEMICAL", 460, 475], ["MgSO 4", "CHEMICAL", 16, 22], ["MgSO 4", "SIMPLE_CHEMICAL", 16, 22], ["AAV", "ORGANISM", 46, 49], ["AAV", "ORGANISM", 66, 69], ["cellular", "CELL", 87, 95], ["AAV", "ORGANISM", 129, 132], ["AAV", "ORGANISM", 195, 198], ["cells", "CELL", 215, 220], ["SFM4Transfx-293", "CELL", 243, 258], ["cell", "CELL", 277, 281], ["cells", "CELL", 302, 307], ["cell culture", "CELL", 325, 337], ["MgSO 4", "PROTEIN", 16, 22], ["SFM4Transfx-293", "SPECIES", 460, 475], ["MgSO 4", "TREATMENT", 16, 22], ["AAV aggregation", "PROBLEM", 46, 61], ["AAV binding", "TREATMENT", 66, 77], ["lysis", "TREATMENT", 123, 128], ["AAV production protocols", "TREATMENT", 129, 153], ["AAV yield", "TREATMENT", 195, 204], ["a cell density", "TEST", 275, 289], ["cell culture", "TEST", 325, 337], ["cell density", "OBSERVATION", 277, 289]]], ["Earlier experiments had indicated (data not shown) that SFM4Transfx-293 and F17 media were good for cell growth but the AAV yield was less in F17 medium.", [["SFM4Transfx-293", "ANATOMY", 56, 71], ["cell", "ANATOMY", 100, 104], ["SFM4Transfx-293", "CHEMICAL", 56, 71], ["SFM4Transfx-293", "CELL", 56, 71], ["cell", "CELL", 100, 104], ["AAV", "ORGANISM", 120, 123], ["SFM4Transfx", "TEST", 56, 67], ["cell growth", "PROBLEM", 100, 111], ["the AAV yield", "TEST", 116, 129]]], ["Therefore, it was decided to see if the cell cultures maintained under SFM4Transfx-293 medium and then replacing with F17 medium at the time of infection would be beneficial for AAV production.", [["cell cultures", "ANATOMY", 40, 53], ["SFM4Transfx-293", "CHEMICAL", 71, 86], ["F17 medium", "CHEMICAL", 118, 128], ["infection", "DISEASE", 144, 153], ["cell cultures", "CELL", 40, 53], ["SFM4Transfx-293", "CELL", 71, 86], ["AAV", "ORGANISM", 178, 181], ["cell cultures", "CELL_LINE", 40, 53], ["AAV", "SPECIES", 178, 181], ["the cell cultures", "TEST", 36, 53], ["F17 medium", "TREATMENT", 118, 128], ["infection", "PROBLEM", 144, 153], ["AAV production", "PROBLEM", 178, 192], ["infection", "OBSERVATION", 144, 153]]], ["The harvested samples were purified by iodixanol gradient before assaying for genomic and infective viral particles.AAV production protocolsTo verify the effect of cell density and amount of DNA supplied, cells at different cell densities were transfected with either 1 g/mL or 1 g/million cells basis.", [["samples", "ANATOMY", 14, 21], ["cell", "ANATOMY", 164, 168], ["cells", "ANATOMY", 205, 210], ["cell", "ANATOMY", 224, 228], ["cells", "ANATOMY", 290, 295], ["iodixanol", "CHEMICAL", 39, 48], ["iodixanol", "CHEMICAL", 39, 48], ["iodixanol", "SIMPLE_CHEMICAL", 39, 48], ["AAV", "ORGANISM", 116, 119], ["cell", "CELL", 164, 168], ["DNA", "CELLULAR_COMPONENT", 191, 194], ["cells", "CELL", 205, 210], ["cell", "CELL", 224, 228], ["cells", "CELL", 290, 295], ["The harvested samples", "TEST", 0, 21], ["iodixanol gradient", "TREATMENT", 39, 57], ["genomic and infective viral particles", "PROBLEM", 78, 115], ["AAV production protocols", "TREATMENT", 116, 140], ["cell density", "TREATMENT", 164, 176], ["DNA", "PROBLEM", 191, 194], ["cells at different cell densities", "PROBLEM", 205, 238], ["harvested", "OBSERVATION", 4, 13], ["infective", "OBSERVATION_MODIFIER", 90, 99], ["viral particles", "OBSERVATION", 100, 115], ["cell density", "OBSERVATION", 164, 176], ["amount", "OBSERVATION_MODIFIER", 181, 187], ["cell densities", "OBSERVATION", 224, 238]]], ["Cells were grown up to about 1 \u00d7 10 6 cells/mL and appropriate volume was then centrifuged and cells were resuspended in fresh medium to obtain about 1, 2, 4 or 8 million cells/mL.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 38, 43], ["cells", "ANATOMY", 95, 100], ["cells", "ANATOMY", 171, 176], ["Cells", "CELL", 0, 5], ["cells", "CELL", 95, 100], ["cells", "CELL", 171, 176], ["Cells", "TEST", 0, 5], ["appropriate volume", "TEST", 51, 69], ["cells", "TEST", 95, 100]]], ["These cell densities were transfected in 20 mL cell culture volume with PEI to DNA ratio of 2:1.", [["cell", "ANATOMY", 6, 10], ["cell", "ANATOMY", 47, 51], ["PEI", "CHEMICAL", 72, 75], ["PEI", "CHEMICAL", 72, 75], ["cell", "CELL", 6, 10], ["cell", "CELL", 47, 51], ["PEI", "SIMPLE_CHEMICAL", 72, 75], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["These cell densities", "PROBLEM", 0, 20], ["culture volume", "TEST", 52, 66], ["PEI", "TREATMENT", 72, 75], ["DNA ratio", "TEST", 79, 88], ["cell densities", "OBSERVATION", 6, 20]]], ["Samples were taken every 12 h post transfection (hpt).AAV production protocolsTo evaluate the potential positive effect of histone deacetylase, sodium butyrate and butyric acid (neutralized by sodium hydroxide to a neutral pH; referred to as butyric acid) were added to the cell culture at a cell density of 1 million cells/mL.", [["Samples", "ANATOMY", 0, 7], ["cell", "ANATOMY", 274, 278], ["cell", "ANATOMY", 292, 296], ["cells", "ANATOMY", 318, 323], ["sodium butyrate", "CHEMICAL", 144, 159], ["butyric acid", "CHEMICAL", 164, 176], ["sodium hydroxide", "CHEMICAL", 193, 209], ["butyric acid", "CHEMICAL", 242, 254], ["sodium butyrate", "CHEMICAL", 144, 159], ["butyric acid", "CHEMICAL", 164, 176], ["sodium hydroxide", "CHEMICAL", 193, 209], ["butyric acid", "CHEMICAL", 242, 254], ["AAV", "ORGANISM", 54, 57], ["histone deacetylase", "GENE_OR_GENE_PRODUCT", 123, 142], ["sodium butyrate", "SIMPLE_CHEMICAL", 144, 159], ["butyric acid", "SIMPLE_CHEMICAL", 164, 176], ["sodium hydroxide", "SIMPLE_CHEMICAL", 193, 209], ["butyric acid", "SIMPLE_CHEMICAL", 242, 254], ["cell", "CELL", 274, 278], ["cell", "CELL", 292, 296], ["cells", "CELL", 318, 323], ["histone deacetylase", "PROTEIN", 123, 142], ["Samples", "TEST", 0, 7], ["AAV production protocols", "TREATMENT", 54, 78], ["histone deacetylase", "TREATMENT", 123, 142], ["sodium butyrate", "TREATMENT", 144, 159], ["butyric acid", "TREATMENT", 164, 176], ["sodium hydroxide", "TREATMENT", 193, 209], ["a neutral pH", "PROBLEM", 213, 225], ["butyric acid)", "TREATMENT", 242, 255], ["the cell culture", "TEST", 270, 286]]], ["The final concentration of these additives was 0 (as control), 1, 2.5, 5, or 10 mM from 1 M stock solutions.", [["these additives", "TREATMENT", 27, 42]]], ["After 48 hpt, a portion of the cell culture was monitored by FACS for percent transfected cells and relative amount of GFP signal from the GFP positive cells.", [["cell", "ANATOMY", 31, 35], ["cells", "ANATOMY", 90, 95], ["cells", "ANATOMY", 152, 157], ["cell", "CELL", 31, 35], ["cells", "CELL", 90, 95], ["GFP", "GENE_OR_GENE_PRODUCT", 119, 122], ["GFP", "GENE_OR_GENE_PRODUCT", 139, 142], ["cells", "CELL", 152, 157], ["cell culture", "CELL_LINE", 31, 43], ["transfected cells", "CELL_LINE", 78, 95], ["GFP positive cells", "CELL_LINE", 139, 157], ["the cell culture", "TEST", 27, 43], ["percent transfected cells", "PROBLEM", 70, 95], ["GFP signal", "TEST", 119, 129], ["the GFP positive cells", "PROBLEM", 135, 157], ["transfected cells", "OBSERVATION", 78, 95], ["amount", "OBSERVATION_MODIFIER", 109, 115], ["GFP signal", "OBSERVATION", 119, 129], ["GFP positive cells", "OBSERVATION", 139, 157]]], ["The other portion of the cell culture was lysed to determine the concentrations of the infectious viral particles (IVP/mL).Bioreactor production of AAVA 3-L Chemap CF-2000 bioreactor (Mannedorf, Switzerland), equipped with two 45 \u2022 pitched blade impellers and three vertical surface baffles, was used to investigate the scalability of the process through production of the following two serotypes: AAV2, and AAV6.", [["cell", "ANATOMY", 25, 29], ["surface", "ANATOMY", 275, 282], ["cell", "CELL", 25, 29], ["AAV2", "ORGANISM", 398, 402], ["AAV6", "GENE_OR_GENE_PRODUCT", 408, 412], ["cell culture", "CELL_LINE", 25, 37], ["AAV2", "SPECIES", 398, 402], ["the cell culture", "TEST", 21, 37], ["the infectious viral particles", "TREATMENT", 83, 113], ["AAVA", "TEST", 148, 152], ["two 45 \u2022 pitched blade impellers", "TREATMENT", 223, 255], ["three vertical surface baffles", "TREATMENT", 260, 290], ["AAV2", "TREATMENT", 398, 402], ["AAV6", "PROBLEM", 408, 412], ["cell culture", "OBSERVATION", 25, 37], ["infectious", "OBSERVATION", 87, 97], ["AAV2", "OBSERVATION", 398, 402], ["AAV6", "ANATOMY", 408, 412]]], ["The listed serotypes were selected because of subsequent studies required at larger scales.", [["The listed serotypes", "TREATMENT", 0, 20], ["subsequent studies", "TEST", 46, 64], ["serotypes", "OBSERVATION", 11, 20]]], ["The final working volume was adjusted to 2.0 L. The agitation was set to 80 rpm, and the temperature was maintained at 37 \u2022 C. A pH of 7.2 was monitored and controlled by CO 2 supplementation during the experiment.", [["agitation", "DISEASE", 52, 61], ["CO 2", "CHEMICAL", 171, 175], ["CO 2", "SIMPLE_CHEMICAL", 171, 175], ["The agitation", "PROBLEM", 48, 61], ["the temperature", "TEST", 85, 100], ["A pH", "TEST", 127, 131]]], ["Dissolved oxygen was maintained at 40% by supplementing the inlet gas with oxygen using computer-controlled mass-flow controllers and FIX-MMI software (Intellution, Norwood, MA).", [["oxygen", "CHEMICAL", 10, 16], ["oxygen", "CHEMICAL", 75, 81], ["oxygen", "CHEMICAL", 10, 16], ["oxygen", "CHEMICAL", 75, 81], ["oxygen", "SIMPLE_CHEMICAL", 10, 16], ["oxygen", "SIMPLE_CHEMICAL", 75, 81], ["FIX", "PROTEIN", 134, 137], ["Dissolved oxygen", "TREATMENT", 0, 16], ["the inlet gas", "TREATMENT", 56, 69], ["oxygen", "TREATMENT", 75, 81], ["computer-controlled mass-flow controllers", "TREATMENT", 88, 129], ["mass", "OBSERVATION", 108, 112]]], ["The bioreactor was inoculated at a cell density of approximately 0.5 \u00d7 10 6 cells/mL with viability greater than 95%.", [["cell", "ANATOMY", 35, 39], ["cells", "ANATOMY", 76, 81], ["cell", "CELL", 35, 39], ["The bioreactor", "TREATMENT", 0, 14], ["a cell density", "TEST", 33, 47], ["viability", "TEST", 90, 99], ["bioreactor", "OBSERVATION_MODIFIER", 4, 14], ["inoculated", "OBSERVATION_MODIFIER", 19, 29], ["cell density", "OBSERVATION", 35, 47], ["viability", "OBSERVATION_MODIFIER", 90, 99], ["greater", "OBSERVATION_MODIFIER", 100, 107]]], ["When the cell density reached approximately 1.0 \u00d7 10 6 cells/mL, the cells were transfected with the PEI/DNA complexes (polyplexes) with a PEI to DNA ratio of 2:1.", [["cell", "ANATOMY", 9, 13], ["cells", "ANATOMY", 55, 60], ["cells", "ANATOMY", 69, 74], ["PEI", "CHEMICAL", 101, 104], ["PEI", "CHEMICAL", 101, 104], ["polyplexes", "CHEMICAL", 120, 130], ["PEI", "CHEMICAL", 139, 142], ["cell", "CELL", 9, 13], ["cells", "CELL", 55, 60], ["cells", "CELL", 69, 74], ["PEI", "GENE_OR_GENE_PRODUCT", 101, 104], ["DNA", "CELLULAR_COMPONENT", 105, 108], ["polyplexes", "SIMPLE_CHEMICAL", 120, 130], ["PEI", "SIMPLE_CHEMICAL", 139, 142], ["DNA", "CELLULAR_COMPONENT", 146, 149], ["PEI/DNA complexes", "PROTEIN", 101, 118], ["the cell density", "TEST", 5, 21], ["the cells", "PROBLEM", 65, 74], ["the PEI/DNA complexes (polyplexes", "TREATMENT", 97, 130], ["a PEI", "TREATMENT", 137, 142], ["DNA ratio", "TEST", 146, 155], ["cell density", "OBSERVATION", 9, 21]]], ["At the time of harvest, AAV from the cell culture in the bioreactor was released using the Triton X-100 method.", [["cell", "ANATOMY", 37, 41], ["Triton X-100", "CHEMICAL", 91, 103], ["Triton X-100", "CHEMICAL", 91, 103], ["AAV", "ORGANISM", 24, 27], ["cell", "CELL", 37, 41], ["Triton X-100", "SIMPLE_CHEMICAL", 91, 103], ["harvest", "TREATMENT", 15, 22], ["AAV", "TREATMENT", 24, 27], ["the cell culture", "TEST", 33, 49], ["the Triton", "TREATMENT", 87, 97], ["harvest", "OBSERVATION", 15, 22], ["cell culture", "OBSERVATION", 37, 49]]], ["All solutions were added directly to the bioreactor, and the lysate was centrifuged at 4000 \u00d7 g for 20 min.", [["lysate", "ANATOMY", 61, 67], ["All solutions", "TREATMENT", 0, 13], ["the lysate", "TREATMENT", 57, 67]]], ["The supernatant was stored at \u221280 \u2022 C for further processing.Purification of AAV by iodixanol step gradient protocolAAV samples (12.3 mL) were purified by overlaying them on top of series of step gradients using 15, 25, 40 and 54% iodixanol concentrations (adapted from Zolotukhin et al., 1999) containing 5, 5, 7 and 5 mL, respectively.", [["supernatant", "ANATOMY", 4, 15], ["samples", "ANATOMY", 120, 127], ["iodixanol", "CHEMICAL", 84, 93], ["iodixanol", "CHEMICAL", 231, 240], ["iodixanol", "CHEMICAL", 84, 93], ["iodixanol", "CHEMICAL", 231, 240], ["AAV", "ORGANISM", 77, 80], ["iodixanol", "SIMPLE_CHEMICAL", 84, 93], ["AAV", "ORGANISM", 116, 119], ["iodixanol", "SIMPLE_CHEMICAL", 231, 240], ["AAV", "TREATMENT", 77, 80], ["iodixanol step gradient protocol", "TREATMENT", 84, 116], ["AAV samples", "TEST", 116, 127], ["54% iodixanol concentrations", "TREATMENT", 227, 255]]], ["The 15% iodixanol concentration also contained 1 M NaCl to avoid aggregation of AAV with other cellular proteins and negatively charged nuclear components.", [["cellular", "ANATOMY", 95, 103], ["nuclear", "ANATOMY", 136, 143], ["iodixanol", "CHEMICAL", 8, 17], ["NaCl", "CHEMICAL", 51, 55], ["iodixanol", "CHEMICAL", 8, 17], ["NaCl", "CHEMICAL", 51, 55], ["iodixanol", "SIMPLE_CHEMICAL", 8, 17], ["AAV", "ORGANISM", 80, 83], ["cellular", "CELL", 95, 103], ["cellular proteins", "PROTEIN", 95, 112], ["The 15% iodixanol concentration", "TREATMENT", 0, 31], ["1 M NaCl", "TREATMENT", 47, 55], ["aggregation of AAV", "PROBLEM", 65, 83], ["other cellular proteins", "PROBLEM", 89, 112], ["AAV", "ANATOMY", 80, 83], ["cellular proteins", "OBSERVATION", 95, 112]]], ["After the completion of centrifugation, 5 mL were withdrawn from 2 mm below the 40/54 interface marked before starting the ultracentrifugation at 385,000 \u00d7 g for 1 h 45 min in Sorvals T-865 rotor in Sorval Ultracentrifuge.Quantitation of viral vectorsAAV infectivity was determined by the gene transfer assay (GTA) using GFP as a reporter gene in all cases.", [["Sorvals T-865", "CHEMICAL", 176, 189], ["AAV", "ORGANISM", 251, 254], ["GFP", "GENE_OR_GENE_PRODUCT", 321, 324], ["GFP", "DNA", 321, 324], ["reporter gene", "DNA", 330, 343], ["AAV", "SPECIES", 251, 254], ["centrifugation", "TREATMENT", 24, 38], ["the ultracentrifugation", "TREATMENT", 119, 142], ["viral vectorsAAV infectivity", "PROBLEM", 238, 266], ["viral vectors", "OBSERVATION", 238, 251]]], ["The procedure described by Cheng et al. (1997) was adapted for AAV infectivity assay where sample is diluted before addition to the cells to have the GFP positive cells in the range of 2-20% to assure that only single virus has entered the cell for GFP expression.", [["sample", "ANATOMY", 91, 97], ["cells", "ANATOMY", 132, 137], ["cells", "ANATOMY", 163, 168], ["cell", "ANATOMY", 240, 244], ["AAV", "ORGANISM", 63, 66], ["cells", "CELL", 132, 137], ["GFP", "GENE_OR_GENE_PRODUCT", 150, 153], ["cells", "CELL", 163, 168], ["cell", "CELL", 240, 244], ["GFP", "GENE_OR_GENE_PRODUCT", 249, 252], ["GFP positive cells", "CELL_LINE", 150, 168], ["AAV", "SPECIES", 63, 66], ["The procedure", "TREATMENT", 0, 13], ["AAV infectivity assay", "PROBLEM", 63, 84], ["the cells", "TREATMENT", 128, 137], ["the GFP positive cells", "TEST", 146, 168], ["single virus", "PROBLEM", 211, 223]]], ["The lysed samples either were assayed with or without the purification by iodixanol step gradient ultracentrifugation protocol.", [["samples", "ANATOMY", 10, 17], ["iodixanol", "CHEMICAL", 74, 83], ["iodixanol", "SIMPLE_CHEMICAL", 74, 83], ["The lysed samples", "TEST", 0, 17], ["iodixanol step gradient ultracentrifugation protocol", "TREATMENT", 74, 126]]], ["Infectivity assay is independent of the contaminant DNA, but reveals the percent recovery from the iodixanol purification step.", [["iodixanol", "CHEMICAL", 99, 108], ["iodixanol", "CHEMICAL", 99, 108], ["DNA", "CELLULAR_COMPONENT", 52, 55], ["iodixanol", "SIMPLE_CHEMICAL", 99, 108], ["Infectivity assay", "TEST", 0, 17], ["the contaminant DNA", "PROBLEM", 36, 55], ["the iodixanol purification step", "TREATMENT", 95, 126]]], ["The GFP-positive cells were quantified by FACS using HEK293 cells in suspension as described by Chahal et al. (2007) or HeLa cells as anchorage dependent cells but with the similar protocol.", [["GFP-positive cells", "ANATOMY", 4, 22], ["HEK293 cells", "ANATOMY", 53, 65], ["HeLa cells", "ANATOMY", 120, 130], ["cells", "ANATOMY", 154, 159], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["HEK293 cells", "CELL", 53, 65], ["HeLa cells", "CELL", 120, 130], ["cells", "CELL", 154, 159], ["GFP-positive cells", "CELL_LINE", 4, 22], ["HEK293 cells", "CELL_LINE", 53, 65], ["HeLa cells", "CELL_LINE", 120, 130], ["anchorage dependent cells", "CELL_TYPE", 134, 159], ["The GFP", "TEST", 0, 7], ["positive cells", "PROBLEM", 8, 22], ["HEK293 cells in suspension", "TREATMENT", 53, 79], ["HeLa cells as anchorage dependent cells", "PROBLEM", 120, 159], ["the similar protocol", "TREATMENT", 169, 189], ["positive cells", "OBSERVATION", 8, 22], ["HEK293 cells", "OBSERVATION", 53, 65]]], ["Briefly, the HeLa cells were co-infected with wild-type Adenovirus similar to HEK293 cells.", [["HeLa cells", "ANATOMY", 13, 23], ["HEK293 cells", "ANATOMY", 78, 90], ["HeLa cells", "CELL", 13, 23], ["Adenovirus", "ORGANISM", 56, 66], ["HEK293 cells", "CELL", 78, 90], ["HeLa cells", "CELL_LINE", 13, 23], ["HEK293 cells", "CELL_LINE", 78, 90], ["the HeLa cells", "PROBLEM", 9, 23], ["type Adenovirus", "PROBLEM", 51, 66], ["HEK293 cells", "OBSERVATION", 78, 90]]], ["After 24 h of infection, the cells were washed with PBS and trypsinized for 15 min at 37 \u2022 C. The cells were suspended in medium containing 10% serum to inactivate the trypsin and the cells were centrifuged and resuspended in 2% formaldehyde solution in PBS.", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 98, 103], ["serum", "ANATOMY", 144, 149], ["cells", "ANATOMY", 184, 189], ["infection", "DISEASE", 14, 23], ["formaldehyde", "CHEMICAL", 229, 241], ["formaldehyde", "CHEMICAL", 229, 241], ["cells", "CELL", 29, 34], ["cells", "CELL", 98, 103], ["serum", "ORGANISM_SUBSTANCE", 144, 149], ["trypsin", "GENE_OR_GENE_PRODUCT", 168, 175], ["cells", "CELL", 184, 189], ["formaldehyde", "SIMPLE_CHEMICAL", 229, 241], ["trypsin", "PROTEIN", 168, 175], ["infection", "PROBLEM", 14, 23], ["PBS", "TREATMENT", 52, 55], ["the trypsin", "TREATMENT", 164, 175], ["2% formaldehyde solution in PBS", "TREATMENT", 226, 257], ["infection", "OBSERVATION", 14, 23]]], ["The GFP-positive cells were quantified by FACS.", [["GFP-positive cells", "ANATOMY", 4, 22], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["GFP-positive cells", "CELL_LINE", 4, 22], ["The GFP", "TEST", 0, 7], ["positive cells", "PROBLEM", 8, 22], ["positive cells", "OBSERVATION", 8, 22]]], ["AAV genomic particles were determined by real-time-qPCR.", [["AAV", "ORGANISM", 0, 3], ["AAV", "SPECIES", 0, 3], ["AAV genomic particles", "PROBLEM", 0, 21], ["particles", "OBSERVATION_MODIFIER", 12, 21]]], ["Lysed samples treated with Benzonase \u00ae were purified by iodixanol step-gradient protocol.", [["samples", "ANATOMY", 6, 13], ["Benzonase \u00ae", "CHEMICAL", 27, 38], ["iodixanol", "CHEMICAL", 56, 65], ["Benzonase \u00ae", "CHEMICAL", 27, 38], ["iodixanol", "CHEMICAL", 56, 65], ["Benzonase \u00ae", "SIMPLE_CHEMICAL", 27, 38], ["iodixanol", "SIMPLE_CHEMICAL", 56, 65], ["Benzonase \u00ae", "TREATMENT", 27, 38], ["iodixanol step-gradient protocol", "TREATMENT", 56, 88]]], ["The purified samples were diluted 100fold and retreated with 50 units of Benzonase \u00ae /mL to ensure the removal of host-cell DNA and unpackaged virus DNA.", [["samples", "ANATOMY", 13, 20], ["cell", "ANATOMY", 119, 123], ["Benzonase", "CHEMICAL", 73, 82], ["Benzonase", "SIMPLE_CHEMICAL", 73, 82], ["cell", "ORGANISM_SUBSTANCE", 119, 123], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["DNA", "CELLULAR_COMPONENT", 149, 152], ["host-cell DNA", "DNA", 114, 127], ["unpackaged virus DNA", "DNA", 132, 152], ["The purified samples", "TEST", 0, 20], ["Benzonase", "TREATMENT", 73, 82], ["mL", "TREATMENT", 86, 88], ["the removal", "TREATMENT", 99, 110], ["host-cell DNA", "TREATMENT", 114, 127], ["unpackaged virus DNA", "PROBLEM", 132, 152], ["cell DNA", "OBSERVATION", 119, 127], ["virus DNA", "OBSERVATION", 143, 152]]], ["The High Pure Viral Nucleic Acid kit (Roche Applied-Science, Indianapolis, USA), was used to purify viral nucleic acids from AAV samples before real-time polymerase chain reaction (RT-PCR).", [["samples", "ANATOMY", 129, 136], ["nucleic acids", "CHEMICAL", 106, 119], ["AAV", "ORGANISM", 125, 128], ["The High Pure Viral Nucleic Acid kit", "PROBLEM", 0, 36], ["viral nucleic acids", "TEST", 100, 119], ["AAV samples", "TEST", 125, 136], ["real-time polymerase chain reaction", "PROBLEM", 144, 179], ["RT-PCR", "TEST", 181, 187]]], ["The samples were diluted in water and supplemented with Poly A and Proteinase K solutions.", [["samples", "ANATOMY", 4, 11], ["Poly A", "CHEMICAL", 56, 62], ["Proteinase K", "CHEMICAL", 67, 79], ["Poly A", "CHEMICAL", 56, 62], ["Poly A", "SIMPLE_CHEMICAL", 56, 62], ["Proteinase K solutions", "SIMPLE_CHEMICAL", 67, 89], ["The samples", "TREATMENT", 0, 11], ["Poly A and Proteinase K solutions", "TREATMENT", 56, 89]]], ["A standard curve was generated for each RT-PCR run.", [["A standard curve", "TEST", 0, 16], ["each RT-PCR run", "TREATMENT", 35, 50]]], ["The reaction was performed in the LightCycler 3 instrument (Roche Diagnostics, Qu\u00e9bec, Canada).", [["The reaction", "PROBLEM", 0, 12]]], ["The reactions were performed in a total volume of 20 L containing 18 L of PCR Mix, 12 L H 2 O, 1 L forward primer 5 mM, 1 L reverse primer 5 mM, 4 L Master Mix LightCycler Fast-Start SYBR Green I (Roche Diagnostics, Qu\u00e9bec, Canada) and 2 L of template (serial dilution of standard from 10 3 to 10 8 molecules, unknowns or water for the negative control).", [["a total volume", "TREATMENT", 32, 46], ["PCR Mix", "TREATMENT", 74, 81], ["Fast", "TEST", 172, 176], ["template (serial dilution of standard", "TREATMENT", 243, 280]]], ["The PCR conditions were as follows: pre-incubation at 95 \u2022 C for 10 min; denaturation at 95 \u2022 C for 15 s; annealing cycles at 55 \u2022 C for 35 s; and extension at 72 \u2022 C for 40 s.", [["The PCR conditions", "TEST", 0, 18], ["pre-incubation", "TEST", 36, 50], ["denaturation", "TEST", 73, 85], ["annealing cycles", "TEST", 106, 122], ["extension", "TEST", 147, 156]]], ["The CMV Forward primer (5 -CAAGTACGCCCCCTATTGAC-3 ) and the CMV Reverse primer (5 -AAGTCCCGTTGATTTTGGTG-3 ) were used.", [["CMV", "ORGANISM", 4, 7], ["CMV", "ORGANISM", 60, 63], ["CMV Forward primer", "DNA", 4, 22], ["CMV Reverse primer", "DNA", 60, 78], ["The CMV Forward primer", "TEST", 0, 22], ["CAAGTACGCCCCCTATTGAC", "TEST", 27, 47], ["the CMV Reverse primer", "TREATMENT", 56, 78], ["CMV", "OBSERVATION", 4, 7]]], ["Data analysis was performed using LightCycler 3.5 software (Roche Diagnostics, Qu\u00e9bec, Canada).Effect of type of culture mediumSFM4Transfx-293 medium ranked higher in all respects ( Table 1 ).", [["mediumSFM4Transfx-293", "CHEMICAL", 121, 142], ["mediumSFM4Transfx-293", "CELL", 121, 142], ["Data analysis", "TEST", 0, 13], ["LightCycler", "TEST", 34, 45], ["culture mediumSFM4Transfx", "TEST", 113, 138]]], ["The AAV yields in terms of infective viral particles and viral genomic particles were higher in SFM4Transfx-293 medium than F17 medium when compared on volumetric and cell specific basis.", [["SFM4Transfx-293", "ANATOMY", 96, 111], ["cell", "ANATOMY", 167, 171], ["SFM4Transfx-293", "CHEMICAL", 96, 111], ["AAV", "ORGANISM", 4, 7], ["SFM4Transfx-293", "CELL", 96, 111], ["cell", "CELL", 167, 171], ["SFM4Transfx-293", "SPECIES", 96, 111], ["The AAV yields", "TREATMENT", 0, 14], ["infective viral particles", "PROBLEM", 27, 52], ["viral genomic particles", "PROBLEM", 57, 80], ["AAV", "OBSERVATION", 4, 7], ["infective", "OBSERVATION_MODIFIER", 27, 36], ["viral particles", "OBSERVATION", 37, 52], ["viral genomic particles", "OBSERVATION", 57, 80], ["higher", "OBSERVATION_MODIFIER", 86, 92]]], ["Considering the percent error associated with infective viral particle assay (up to \u00b130%), the Vg/IVP ratio may be considered similar in both cases.", [["Vg", "GENE_OR_GENE_PRODUCT", 95, 97], ["the percent error", "PROBLEM", 12, 29], ["infective viral particle assay", "PROBLEM", 46, 76], ["the Vg/IVP ratio", "TEST", 91, 107], ["infective", "OBSERVATION_MODIFIER", 46, 55], ["viral particle", "OBSERVATION", 56, 70], ["may be considered", "UNCERTAINTY", 108, 125]]], ["SFM4Transfx-293 medium was selected as a medium of choice for AAV production because volumetric and cell specific infective viral particles produced were twice as much as obtained in F17 medium.Effect of the amount of plasmid DNA on transfection efficiency and AAV yieldWhen the cells were transfected with 1 g/mL on volumetric basis, except for 8.0E+06 cells/mL cell culture, the higher the initial cell density, the higher was the transduced cells reflected by GFP positive cells, whereas, IVP yields were consistently approximately 1.0E+08 IVP/mL cell culture (Fig. 1) .", [["cell", "ANATOMY", 100, 104], ["plasmid", "ANATOMY", 218, 225], ["cells", "ANATOMY", 279, 284], ["cells", "ANATOMY", 354, 359], ["cell", "ANATOMY", 363, 367], ["cell", "ANATOMY", 400, 404], ["cells", "ANATOMY", 444, 449], ["cells", "ANATOMY", 476, 481], ["cell", "ANATOMY", 550, 554], ["SFM4Transfx-293", "CHEMICAL", 0, 15], ["SFM4Transfx-293", "CELL", 0, 15], ["AAV", "ORGANISM", 62, 65], ["cell", "CELL", 100, 104], ["DNA", "CELLULAR_COMPONENT", 226, 229], ["AAV", "ORGANISM", 261, 264], ["cells", "CELL", 279, 284], ["cells", "CELL", 354, 359], ["cell", "CELL", 363, 367], ["cell", "CELL", 400, 404], ["cells", "CELL", 444, 449], ["GFP", "GENE_OR_GENE_PRODUCT", 463, 466], ["cells", "CELL", 476, 481], ["plasmid DNA", "DNA", 218, 229], ["8.0E+06 cells", "CELL_LINE", 346, 359], ["transduced cells", "CELL_LINE", 433, 449], ["GFP positive cells", "CELL_LINE", 463, 481], ["SFM4Transfx-293", "SPECIES", 0, 15], ["SFM4Transfx", "TEST", 0, 11], ["AAV production", "PROBLEM", 62, 76], ["volumetric and cell specific infective viral particles", "PROBLEM", 85, 139], ["plasmid DNA", "PROBLEM", 218, 229], ["transfection efficiency", "TREATMENT", 233, 256], ["volumetric basis", "TEST", 317, 333], ["cells", "TEST", 354, 359], ["cell culture", "TEST", 363, 375], ["the higher the initial cell density", "PROBLEM", 377, 412], ["GFP positive cells", "PROBLEM", 463, 481], ["IVP yields", "TEST", 492, 502], ["cell culture", "TEST", 550, 562], ["amount", "OBSERVATION_MODIFIER", 208, 214], ["plasmid DNA", "OBSERVATION", 218, 229], ["transfection efficiency", "OBSERVATION", 233, 256], ["initial cell density", "OBSERVATION", 392, 412], ["positive cells", "OBSERVATION", 467, 481]]], ["The transfected GFP positive cells did not increase proportional to the increase in the initial cell density.", [["cells", "ANATOMY", 29, 34], ["cell", "ANATOMY", 96, 100], ["GFP", "GENE_OR_GENE_PRODUCT", 16, 19], ["cells", "CELL", 29, 34], ["cell", "CELL", 96, 100], ["transfected GFP positive cells", "CELL_LINE", 4, 34], ["The transfected GFP positive cells", "PROBLEM", 0, 34], ["transfected GFP", "OBSERVATION", 4, 19], ["positive cells", "OBSERVATION", 20, 34], ["increase", "OBSERVATION_MODIFIER", 43, 51], ["increase", "OBSERVATION_MODIFIER", 72, 80], ["initial cell density", "OBSERVATION", 88, 108]]], ["When the DNA plasmid was supplied on the basis of 1 g DNA/10 6 cells, percent cells transfected improved relative to 1 \u00d7 10 6 cells/mL cell culture (Fig. 2) .", [["plasmid", "ANATOMY", 13, 20], ["cells", "ANATOMY", 63, 68], ["cells", "ANATOMY", 78, 83], ["cells", "ANATOMY", 126, 131], ["cell", "ANATOMY", 135, 139], ["DNA", "CELLULAR_COMPONENT", 9, 12], ["DNA", "CELLULAR_COMPONENT", 54, 57], ["cells", "CELL", 63, 68], ["cells", "CELL", 78, 83], ["cells", "CELL", 126, 131], ["cell culture", "CELL", 135, 147], ["DNA plasmid", "DNA", 9, 20], ["the DNA plasmid", "TEST", 5, 20], ["DNA", "TEST", 54, 57], ["percent cells", "TEST", 70, 83], ["cell culture", "TEST", 135, 147]]], ["However, again by proportionally increasing the plasmid DNA for higher cell density did not bring similar proportional increase in GFP positive cells as were obtained by 1 \u00d7 10 6 cells/mL cell culture set.Effect of the amount of plasmid DNA on transfection efficiency and AAV yieldGenomic particles purified by iodixanol protocol and infective viral particles in the lysate were consistently approximately 6.0 \u00d7 10 9 Vg/mL cell culture and 7.0 \u00d7 10 8 IVP/mL cell culture, respectively, for all cell densities, even though, the cell densities at 48 hpt were higher for higher initial cell densities (Fig. 3) .", [["plasmid", "ANATOMY", 48, 55], ["cell", "ANATOMY", 71, 75], ["cells", "ANATOMY", 144, 149], ["cells", "ANATOMY", 179, 184], ["cell", "ANATOMY", 188, 192], ["plasmid", "ANATOMY", 229, 236], ["lysate", "ANATOMY", 367, 373], ["cell", "ANATOMY", 423, 427], ["cell culture", "ANATOMY", 458, 470], ["cell", "ANATOMY", 494, 498], ["cell", "ANATOMY", 527, 531], ["cell", "ANATOMY", 583, 587], ["iodixanol", "CHEMICAL", 311, 320], ["iodixanol", "CHEMICAL", 311, 320], ["DNA", "CELLULAR_COMPONENT", 56, 59], ["cell", "CELL", 71, 75], ["GFP", "GENE_OR_GENE_PRODUCT", 131, 134], ["cells", "CELL", 144, 149], ["cells", "CELL", 179, 184], ["cell", "CELL", 188, 192], ["DNA", "CELLULAR_COMPONENT", 237, 240], ["AAV", "ORGANISM", 272, 275], ["iodixanol", "SIMPLE_CHEMICAL", 311, 320], ["cell", "CELL", 423, 427], ["cell", "CELL", 458, 462], ["cell", "CELL", 494, 498], ["cell", "CELL", 527, 531], ["cell", "CELL", 583, 587], ["plasmid DNA", "DNA", 48, 59], ["GFP positive cells", "CELL_LINE", 131, 149], ["plasmid DNA", "DNA", 229, 240], ["the plasmid DNA", "PROBLEM", 44, 59], ["higher cell density", "PROBLEM", 64, 83], ["similar proportional increase in GFP positive cells", "PROBLEM", 98, 149], ["cell culture", "TEST", 188, 200], ["plasmid DNA", "PROBLEM", 229, 240], ["transfection efficiency", "TREATMENT", 244, 267], ["Genomic particles", "PROBLEM", 281, 298], ["iodixanol protocol", "TREATMENT", 311, 329], ["infective viral particles", "PROBLEM", 334, 359], ["the lysate", "TEST", 363, 373], ["Vg/mL cell culture", "TEST", 417, 435], ["IVP/mL cell culture", "TEST", 451, 470], ["all cell densities", "PROBLEM", 490, 508], ["the cell densities", "TEST", 523, 541], ["hpt", "TEST", 548, 551], ["higher initial cell densities", "PROBLEM", 568, 597], ["plasmid DNA", "OBSERVATION", 48, 59], ["higher cell density", "OBSERVATION", 64, 83], ["increase", "OBSERVATION_MODIFIER", 119, 127], ["GFP positive cells", "OBSERVATION", 131, 149], ["amount", "OBSERVATION_MODIFIER", 219, 225], ["plasmid DNA", "OBSERVATION", 229, 240], ["transfection efficiency", "OBSERVATION", 244, 267], ["infective", "OBSERVATION_MODIFIER", 334, 343], ["viral particles", "OBSERVATION", 344, 359], ["cell densities", "OBSERVATION", 494, 508], ["cell densities", "OBSERVATION", 527, 541], ["cell densities", "OBSERVATION", 583, 597]]], ["To reflect the efficiency of the production of AAV by total cells at 48 hpt, the cell specific yield was highest for the 1 \u00d7 10 6 cells/mL cell culture and decreased for higher initial cell densities.", [["cells", "ANATOMY", 60, 65], ["cell", "ANATOMY", 81, 85], ["cells", "ANATOMY", 130, 135], ["cell", "ANATOMY", 139, 143], ["cell", "ANATOMY", 185, 189], ["AAV", "ORGANISM", 47, 50], ["cells", "CELL", 60, 65], ["cell", "CELL", 81, 85], ["cells", "CELL", 130, 135], ["cell", "CELL", 139, 143], ["cell", "CELL", 185, 189], ["AAV", "SPECIES", 47, 50], ["total cells", "TEST", 54, 65], ["the cell specific yield", "TEST", 77, 100], ["cell culture", "TEST", 139, 151], ["higher initial cell densities", "PROBLEM", 170, 199], ["efficiency", "OBSERVATION_MODIFIER", 15, 25], ["decreased", "OBSERVATION_MODIFIER", 156, 165], ["higher initial", "OBSERVATION_MODIFIER", 170, 184], ["cell densities", "OBSERVATION", 185, 199]]], ["About 2500 Vg/cell 2 .", [["cell", "ANATOMY", 14, 18], ["Vg", "PROTEIN", 11, 13]]], ["Cells at various cell densities (1, 2, 4 or 8 million cells/mL) were transfected with 1 g plasmid DNA/million cells in fresh medium.", [["Cells", "ANATOMY", 0, 5], ["cell", "ANATOMY", 17, 21], ["cells", "ANATOMY", 54, 59], ["cells", "ANATOMY", 110, 115], ["Cells", "CELL", 0, 5], ["cell", "CELL", 17, 21], ["cells", "CELL", 54, 59], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["cells", "CELL", 110, 115], ["plasmid DNA", "DNA", 90, 101], ["Cells", "TEST", 0, 5], ["various cell densities", "TEST", 9, 31], ["1 g plasmid DNA/million cells in fresh medium", "TREATMENT", 86, 131], ["various cell densities", "OBSERVATION", 9, 31], ["million cells", "OBSERVATION", 102, 115], ["fresh medium", "OBSERVATION_MODIFIER", 119, 131]]], ["These cell densities were transfected in 20 mL cell culture volume with PEI to DNA ratio of 2:1.", [["cell", "ANATOMY", 6, 10], ["cell", "ANATOMY", 47, 51], ["PEI", "CHEMICAL", 72, 75], ["PEI", "CHEMICAL", 72, 75], ["cell", "CELL", 6, 10], ["cell", "CELL", 47, 51], ["PEI", "SIMPLE_CHEMICAL", 72, 75], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["These cell densities", "PROBLEM", 0, 20], ["culture volume", "TEST", 52, 66], ["PEI", "TREATMENT", 72, 75], ["DNA ratio", "TEST", 79, 88], ["cell densities", "OBSERVATION", 6, 20]]], ["The cell cultures were harvested 48 h post transfection (hpt).", [["cell cultures", "ANATOMY", 4, 17], ["cell cultures", "CELL", 4, 17], ["cell cultures", "CELL_LINE", 4, 17], ["The cell cultures", "TEST", 0, 17]]], ["Comparative data from Fig. 1 has been re-plotted to reflect percent GFP positive cells normalized to GFP positive cells obtained by transfecting at cell density of 1.00E+06 cells/mL. and 310 IVP/cell were obtained at cell density of 1 \u00d7 10 6 cells/mL (Fig. 4) .Effect of butyrates on transfection efficiency and AAV yieldNo increase in the number of transfected cells by the addition of sodium butyrate or butyric acid was observed at the concentrations tested.", [["cells", "ANATOMY", 81, 86], ["cells", "ANATOMY", 114, 119], ["cell", "ANATOMY", 148, 152], ["cells", "ANATOMY", 173, 178], ["cell", "ANATOMY", 195, 199], ["cell", "ANATOMY", 217, 221], ["cells", "ANATOMY", 242, 247], ["cells", "ANATOMY", 362, 367], ["butyrates", "CHEMICAL", 271, 280], ["sodium butyrate", "CHEMICAL", 387, 402], ["butyric acid", "CHEMICAL", 406, 418], ["butyrates", "CHEMICAL", 271, 280], ["sodium butyrate", "CHEMICAL", 387, 402], ["butyric acid", "CHEMICAL", 406, 418], ["GFP", "GENE_OR_GENE_PRODUCT", 68, 71], ["cells", "CELL", 81, 86], ["GFP", "GENE_OR_GENE_PRODUCT", 101, 104], ["cells", "CELL", 114, 119], ["cell", "CELL", 148, 152], ["cell", "CELL", 195, 199], ["cell", "CELL", 217, 221], ["butyrates", "SIMPLE_CHEMICAL", 271, 280], ["AAV", "ORGANISM", 312, 315], ["cells", "CELL", 362, 367], ["sodium butyrate", "SIMPLE_CHEMICAL", 387, 402], ["butyric acid", "SIMPLE_CHEMICAL", 406, 418], ["GFP positive cells", "CELL_LINE", 68, 86], ["GFP positive cells", "CELL_LINE", 101, 119], ["transfected cells", "CELL_LINE", 350, 367], ["Comparative data", "TEST", 0, 16], ["percent GFP positive cells", "PROBLEM", 60, 86], ["GFP positive cells", "TEST", 101, 119], ["cell density", "TEST", 148, 160], ["cells", "TEST", 173, 178], ["mL.", "TEST", 179, 182], ["IVP/cell", "TEST", 191, 199], ["cell density", "TEST", 217, 229], ["Effect of butyrates", "PROBLEM", 261, 280], ["transfection efficiency", "PROBLEM", 284, 307], ["transfected cells", "PROBLEM", 350, 367], ["sodium butyrate", "TREATMENT", 387, 402], ["butyric acid", "PROBLEM", 406, 418], ["transfection efficiency", "OBSERVATION", 284, 307], ["increase", "OBSERVATION_MODIFIER", 324, 332], ["number", "OBSERVATION_MODIFIER", 340, 346], ["transfected cells", "OBSERVATION", 350, 367]]], ["The percentage of transfected cells measured by FACS (at least 10,000 counts) remained at approximately 40% (Fig. 5a) .", [["cells", "ANATOMY", 30, 35], ["cells", "CELL", 30, 35], ["transfected cells", "CELL_LINE", 18, 35], ["transfected cells", "PROBLEM", 18, 35], ["FACS", "TEST", 48, 52], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["transfected cells", "OBSERVATION", 18, 35]]], ["However, the transfected cells showed a higher amount of GFP expression at higher concentrations of sodium butyrate or butyric acid (Fig. 5b) .", [["cells", "ANATOMY", 25, 30], ["sodium butyrate", "CHEMICAL", 100, 115], ["butyric acid", "CHEMICAL", 119, 131], ["sodium butyrate", "CHEMICAL", 100, 115], ["butyric acid", "CHEMICAL", 119, 131], ["cells", "CELL", 25, 30], ["GFP", "GENE_OR_GENE_PRODUCT", 57, 60], ["sodium butyrate", "SIMPLE_CHEMICAL", 100, 115], ["butyric acid", "SIMPLE_CHEMICAL", 119, 131], ["transfected cells", "CELL_LINE", 13, 30], ["GFP", "PROTEIN", 57, 60], ["the transfected cells", "TEST", 9, 30], ["GFP expression", "PROBLEM", 57, 71], ["sodium butyrate", "TREATMENT", 100, 115], ["butyric acid", "TREATMENT", 119, 131], ["higher", "OBSERVATION_MODIFIER", 40, 46], ["amount", "OBSERVATION_MODIFIER", 47, 53], ["GFP expression", "OBSERVATION", 57, 71]]], ["No improvement in the yield of AAV production by the addition of sodium butyrate or butyric acid was observed.", [["sodium butyrate", "CHEMICAL", 65, 80], ["butyric acid", "CHEMICAL", 84, 96], ["sodium butyrate", "CHEMICAL", 65, 80], ["butyric acid", "CHEMICAL", 84, 96], ["AAV", "ORGANISM", 31, 34], ["sodium butyrate", "SIMPLE_CHEMICAL", 65, 80], ["butyric acid", "SIMPLE_CHEMICAL", 84, 96], ["AAV production", "PROBLEM", 31, 45], ["sodium butyrate", "TREATMENT", 65, 80], ["butyric acid", "PROBLEM", 84, 96], ["improvement", "OBSERVATION_MODIFIER", 3, 14]]], ["Infectious vector yields for AAV production experiments containing butyric acid or sodium butyrate were found to be lower when compared to the corresponding controls (Fig. 5c).", [["butyric acid", "CHEMICAL", 67, 79], ["sodium butyrate", "CHEMICAL", 83, 98], ["butyric acid", "CHEMICAL", 67, 79], ["sodium butyrate", "CHEMICAL", 83, 98], ["AAV", "ORGANISM", 29, 32], ["butyric acid", "SIMPLE_CHEMICAL", 67, 79], ["sodium butyrate", "SIMPLE_CHEMICAL", 83, 98], ["Infectious vector", "TREATMENT", 0, 17], ["AAV production experiments", "TREATMENT", 29, 55], ["butyric acid", "TEST", 67, 79], ["sodium butyrate", "TEST", 83, 98]]], ["Cell density and virus yield (in terms of genomic and infective viral particle concentrations) as a function of cell density at transfection.", [["Cell", "ANATOMY", 0, 4], ["cell", "ANATOMY", 112, 116], ["Cell", "CELL", 0, 4], ["cell", "CELL", 112, 116], ["Cell density", "PROBLEM", 0, 12], ["virus yield", "PROBLEM", 17, 28], ["genomic and infective viral particle concentrations", "TREATMENT", 42, 93], ["cell density at transfection", "PROBLEM", 112, 140], ["density", "OBSERVATION", 5, 12], ["virus yield", "OBSERVATION", 17, 28], ["infective", "OBSERVATION_MODIFIER", 54, 63], ["viral particle", "OBSERVATION_MODIFIER", 64, 78], ["cell density", "OBSERVATION", 112, 124]]], ["Production and harvesting conditions is same as in Fig. 1 .", [["Production and harvesting conditions", "PROBLEM", 0, 36], ["harvesting conditions", "OBSERVATION", 15, 36]]], ["The genomic particles and infective viral particles are reported as Vg and IVP per mL cell culture, respectively.Kinetics of AAV2 productionThe production kinetics of AAV2 is shown in Fig. 6 .", [["cell", "ANATOMY", 86, 90], ["Vg", "GENE_OR_GENE_PRODUCT", 68, 70], ["cell", "CELL", 86, 90], ["AAV2", "ORGANISM", 125, 129], ["AAV2", "ORGANISM", 167, 171], ["AAV2", "SPECIES", 125, 129], ["AAV2", "SPECIES", 167, 171], ["The genomic particles", "PROBLEM", 0, 21], ["infective viral particles", "PROBLEM", 26, 51], ["cell culture", "TEST", 86, 98], ["AAV2 production", "TREATMENT", 125, 140], ["The production kinetics of AAV2", "TREATMENT", 140, 171], ["genomic particles", "OBSERVATION", 4, 21], ["infective", "OBSERVATION_MODIFIER", 26, 35], ["viral particles", "OBSERVATION", 36, 51], ["AAV2 production", "OBSERVATION", 125, 140]]], ["Volumetric production of genomic and infective viral particles increased as a function of time.", [["Volumetric production", "TEST", 0, 21], ["genomic and infective viral particles", "PROBLEM", 25, 62], ["infective", "OBSERVATION_MODIFIER", 37, 46], ["viral particles", "OBSERVATION", 47, 62], ["increased", "OBSERVATION_MODIFIER", 63, 72]]], ["On average, iodixanol purification protocol resulted in about 80% recovery of Infective viral particles from cell lysate.", [["cell lysate", "ANATOMY", 109, 120], ["iodixanol", "CHEMICAL", 12, 21], ["iodixanol", "CHEMICAL", 12, 21], ["iodixanol", "SIMPLE_CHEMICAL", 12, 21], ["cell lysate", "ORGANISM_SUBSTANCE", 109, 120], ["iodixanol purification protocol", "TREATMENT", 12, 43], ["Infective viral particles", "PROBLEM", 78, 103], ["cell lysate", "TREATMENT", 109, 120], ["Infective", "OBSERVATION_MODIFIER", 78, 87], ["viral particles", "OBSERVATION", 88, 103], ["cell lysate", "OBSERVATION", 109, 120]]], ["Since it was not possible to estimate genomic particle concentration in cell lysate without purification, it is expected to have similar recovery from the viral genomic particles/mL of iodixanol purified AAV samples as obtained by the infective viral particle recovery by iodixanol purification method.", [["cell lysate", "ANATOMY", 72, 83], ["samples", "ANATOMY", 208, 215], ["iodixanol", "CHEMICAL", 185, 194], ["iodixanol", "CHEMICAL", 272, 281], ["iodixanol", "CHEMICAL", 185, 194], ["cell lysate", "ORGANISM_SUBSTANCE", 72, 83], ["iodixanol", "SIMPLE_CHEMICAL", 185, 194], ["AAV", "ORGANISM", 204, 207], ["iodixanol", "SIMPLE_CHEMICAL", 272, 281], ["genomic particle concentration in cell lysate", "PROBLEM", 38, 83], ["the viral genomic particles", "TREATMENT", 151, 178], ["iodixanol purified AAV samples", "TREATMENT", 185, 215], ["iodixanol purification method", "TREATMENT", 272, 301], ["not possible", "UNCERTAINTY", 13, 25], ["cell lysate", "OBSERVATION", 72, 83], ["infective", "OBSERVATION_MODIFIER", 235, 244], ["viral particle", "OBSERVATION", 245, 259]]], ["However, the results in Fig. 6 are presented as of purified AAV samples without correcting for 80% recovery but backtracked to the volume of cell culture used.", [["samples", "ANATOMY", 64, 71], ["cell", "ANATOMY", 141, 145], ["AAV", "ORGANISM", 60, 63], ["cell", "CELL", 141, 145], ["cell culture", "TEST", 141, 153]]], ["For example, 5 mL of Iodixanol purified AAV came from 12.3 mL of cell culture lysate, therefore a factor of 12.3/5 = 2.46 was used to calculate the nuclease resistant genomic particles of AAV produced in the cell culture.Productions of AAV serotypes in shake flasksTo demonstrate that this production method is generic and applicable to any serotype, the same methodology was applied for the production of other AAV serotypes (AAV1-9) using HEK293SF cells by transfection in 20 mL of serum-free medium in 150-mL shake flasks in duplicate.", [["cell culture lysate", "ANATOMY", 65, 84], ["cell culture", "ANATOMY", 208, 220], ["HEK293SF cells", "ANATOMY", 441, 455], ["serum", "ANATOMY", 484, 489], ["Iodixanol", "CHEMICAL", 21, 30], ["AAV1-9", "CHEMICAL", 427, 433], ["Iodixanol", "CHEMICAL", 21, 30], ["Iodixanol", "SIMPLE_CHEMICAL", 21, 30], ["AAV", "ORGANISM", 40, 43], ["cell", "CELL", 65, 69], ["AAV", "ORGANISM", 188, 191], ["cell", "CELL", 208, 212], ["AAV", "ORGANISM", 236, 239], ["AAV", "ORGANISM", 412, 415], ["AAV1-9", "CELL", 427, 433], ["HEK293SF cells", "CELL", 441, 455], ["serum", "ORGANISM_SUBSTANCE", 484, 489], ["nuclease", "PROTEIN", 148, 156], ["HEK293SF cells", "CELL_LINE", 441, 455], ["Iodixanol purified AAV", "TREATMENT", 21, 43], ["cell culture lysate", "TEST", 65, 84], ["a factor", "TEST", 96, 104], ["the nuclease resistant genomic particles of AAV", "PROBLEM", 144, 191], ["the cell culture", "TEST", 204, 220], ["AAV serotypes", "PROBLEM", 236, 249], ["this production method", "PROBLEM", 285, 307], ["any serotype", "PROBLEM", 337, 349], ["other AAV serotypes", "PROBLEM", 406, 425], ["AAV1", "TEST", 427, 431], ["transfection", "TEST", 459, 471], ["serum", "TEST", 484, 489], ["AAV", "ANATOMY", 40, 43], ["cell culture", "OBSERVATION", 208, 220], ["AAV serotypes", "OBSERVATION", 236, 249], ["shake flasks", "OBSERVATION", 253, 265]]], ["Infective viral particles were assayed using HEK293 and HeLa cells.", [["HEK293", "ANATOMY", 45, 51], ["HeLa cells", "ANATOMY", 56, 66], ["HEK293", "CELL", 45, 51], ["HeLa cells", "CELL", 56, 66], ["HEK293", "CELL_LINE", 45, 51], ["HeLa cells", "CELL_LINE", 56, 66], ["Infective viral particles", "PROBLEM", 0, 25], ["HEK293", "TEST", 45, 51], ["HeLa cells", "TEST", 56, 66], ["viral particles", "OBSERVATION", 10, 25], ["HeLa cells", "OBSERVATION", 56, 66]]], ["Fig. 7 showed that AAV yield varied depending on the serotypes but was independent to the type of cells (HEK293 or HeLa) used for infectivity assay.Productions of AAV serotypes in shake flasksThe similar experiment was repeated but this time the genomic and infective viral particles were assayed from iodixanol purified cell lysates and culture supernatants to see the cell associated (intracellular) and released (extracellular) AAV.", [["cells", "ANATOMY", 98, 103], ["HEK293", "ANATOMY", 105, 111], ["HeLa", "ANATOMY", 115, 119], ["cell lysates", "ANATOMY", 321, 333], ["supernatants", "ANATOMY", 346, 358], ["cell", "ANATOMY", 370, 374], ["intracellular", "ANATOMY", 387, 400], ["extracellular", "ANATOMY", 416, 429], ["iodixanol", "CHEMICAL", 302, 311], ["iodixanol", "CHEMICAL", 302, 311], ["AAV", "ORGANISM", 19, 22], ["cells", "CELL", 98, 103], ["HEK293", "CELL", 105, 111], ["HeLa", "CELL", 115, 119], ["AAV", "ORGANISM", 163, 166], ["iodixanol", "SIMPLE_CHEMICAL", 302, 311], ["cell lysates", "ORGANISM_SUBSTANCE", 321, 333], ["cell", "CELL", 370, 374], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 387, 400], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 416, 429], ["HEK293", "CELL_LINE", 105, 111], ["HeLa", "CELL_LINE", 115, 119], ["AAV yield", "PROBLEM", 19, 28], ["the serotypes", "PROBLEM", 49, 62], ["infectivity assay", "PROBLEM", 130, 147], ["AAV serotypes", "PROBLEM", 163, 176], ["the genomic and infective viral particles", "PROBLEM", 242, 283], ["iodixanol purified cell lysates", "TREATMENT", 302, 333], ["culture supernatants", "TEST", 338, 358], ["AAV serotypes", "OBSERVATION", 163, 176], ["shake flasks", "OBSERVATION", 180, 192], ["infective", "OBSERVATION_MODIFIER", 258, 267], ["viral particles", "OBSERVATION", 268, 283]]], ["Fig. 8 showed that the genomic particles produced after 48 hpt were in the same order of magnitude (\u223c10 10 Vg/mL cell culture) for all AAV serotypes whereas 4-28% were present in supernatant.", [["cell", "ANATOMY", 113, 117], ["supernatant", "ANATOMY", 179, 190], ["cell", "CELL", 113, 117], ["AAV", "ORGANISM", 135, 138], ["AAV", "SPECIES", 135, 138], ["the genomic particles", "PROBLEM", 19, 40], ["magnitude", "TEST", 89, 98], ["cell culture", "TEST", 113, 125], ["all AAV serotypes", "TREATMENT", 131, 148]]], ["Table 2 shows percent AAV in the supernatants of different AAV serotypes production cultures at 48 hpt.", [["supernatants", "ANATOMY", 33, 45], ["AAV", "ORGANISM", 22, 25], ["AAV", "ORGANISM", 59, 62], ["AAV", "SPECIES", 59, 62], ["percent AAV", "TREATMENT", 14, 25], ["different AAV serotypes production cultures", "PROBLEM", 49, 92], ["AAV", "OBSERVATION", 22, 25]]], ["Most of the AAV serotypes produced are cell associated.", [["cell", "ANATOMY", 39, 43], ["AAV", "ORGANISM", 12, 15], ["cell", "CELL", 39, 43], ["AAV", "SPECIES", 12, 15], ["the AAV serotypes", "PROBLEM", 8, 25], ["AAV", "OBSERVATION", 12, 15], ["cell", "OBSERVATION", 39, 43]]], ["At 48 hpt, AAV6, AAV7 and AAV8 showed higher proportion of Vg in supernatant (28, 29 and 19%, respectively) .", [["supernatant", "ANATOMY", 65, 76], ["AAV6", "GENE_OR_GENE_PRODUCT", 11, 15], ["AAV7", "GENE_OR_GENE_PRODUCT", 17, 21], ["AAV8", "GENE_OR_GENE_PRODUCT", 26, 30], ["Vg", "GENE_OR_GENE_PRODUCT", 59, 61], ["AAV6", "PROTEIN", 11, 15], ["AAV7", "PROTEIN", 17, 21], ["AAV8", "PROTEIN", 26, 30], ["Vg", "PROTEIN", 59, 61], ["hpt", "TEST", 6, 9], ["AAV6", "TEST", 11, 15], ["AAV7", "TEST", 17, 21], ["AAV8", "TEST", 26, 30], ["higher", "OBSERVATION_MODIFIER", 38, 44]]], ["AAV serotypes produced different levels of infectious viral particles.", [["AAV", "ORGANISM", 0, 3], ["AAV", "SPECIES", 0, 3], ["AAV serotypes", "PROBLEM", 0, 13], ["infectious viral particles", "PROBLEM", 43, 69], ["different", "OBSERVATION_MODIFIER", 23, 32], ["levels", "OBSERVATION_MODIFIER", 33, 39], ["infectious", "OBSERVATION_MODIFIER", 43, 53], ["viral particles", "OBSERVATION", 54, 69]]], ["It should be noted that AAV infectivity assay is done using either HEK293 (or HeLa cells in Fig. 7) and because AAV serotypes are tissue specific Fig. 7 .", [["HEK293", "ANATOMY", 67, 73], ["HeLa cells", "ANATOMY", 78, 88], ["tissue", "ANATOMY", 130, 136], ["AAV", "ORGANISM", 24, 27], ["HEK293", "CELL", 67, 73], ["HeLa cells", "CELL", 78, 88], ["AAV", "ORGANISM", 112, 115], ["tissue", "TISSUE", 130, 136], ["HEK293", "CELL_LINE", 67, 73], ["HeLa cells", "CELL_LINE", 78, 88], ["AAV", "SPECIES", 112, 115], ["AAV infectivity assay", "TEST", 24, 45], ["HeLa cells", "TEST", 78, 88], ["AAV serotypes", "PROBLEM", 112, 125]]], ["AAV serotypes (AAV1-9) were produced using HEK293SF cells at cell density of 1.00E+06 cells/mL in 20 mL of serum-free medium in 150-mL shake flasks in duplicates.", [["HEK293SF cells", "ANATOMY", 43, 57], ["cell", "ANATOMY", 61, 65], ["cells", "ANATOMY", 86, 91], ["serum", "ANATOMY", 107, 112], ["AAV1-9", "CHEMICAL", 15, 21], ["AAV", "ORGANISM", 0, 3], ["AAV1-9", "CELL", 15, 21], ["HEK293SF cells", "CELL", 43, 57], ["cell", "CELL", 61, 65], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["HEK293SF cells", "CELL_LINE", 43, 57], ["AAV serotypes", "TEST", 0, 13], ["AAV1", "TEST", 15, 19], ["cell density", "TEST", 61, 73], ["cells", "TEST", 86, 91], ["serum", "TEST", 107, 112]]], ["The cell cultures were harvested 48 h post transfection (hpt).", [["cell cultures", "ANATOMY", 4, 17], ["cell cultures", "CELL", 4, 17], ["cell cultures", "CELL_LINE", 4, 17], ["The cell cultures", "TEST", 0, 17]]], ["Infective viral particles were assayed using HEK293 and HeLa cells.", [["HEK293", "ANATOMY", 45, 51], ["HeLa cells", "ANATOMY", 56, 66], ["HEK293", "CELL", 45, 51], ["HeLa cells", "CELL", 56, 66], ["HEK293", "CELL_LINE", 45, 51], ["HeLa cells", "CELL_LINE", 56, 66], ["Infective viral particles", "PROBLEM", 0, 25], ["HEK293", "TEST", 45, 51], ["HeLa cells", "TEST", 56, 66], ["viral particles", "OBSERVATION", 10, 25], ["HeLa cells", "OBSERVATION", 56, 66]]], ["AAV serotypes (AAV1-9) were produced using HEK293SF cells at cell density of 1.00E+06 cells/mL in 20 mL of serum-free medium in 150-mL shake flasks in duplicates.", [["HEK293SF cells", "ANATOMY", 43, 57], ["cell", "ANATOMY", 61, 65], ["cells", "ANATOMY", 86, 91], ["serum", "ANATOMY", 107, 112], ["AAV1-9", "CHEMICAL", 15, 21], ["AAV", "ORGANISM", 0, 3], ["AAV1-9", "CELL", 15, 21], ["HEK293SF cells", "CELL", 43, 57], ["cell", "CELL", 61, 65], ["serum", "ORGANISM_SUBSTANCE", 107, 112], ["HEK293SF cells", "CELL_LINE", 43, 57], ["AAV serotypes", "TEST", 0, 13], ["AAV1", "TEST", 15, 19], ["cell density", "TEST", 61, 73], ["cells", "TEST", 86, 91], ["serum", "TEST", 107, 112]]], ["The cell cultures were harvested 48 h post transfection (hpt).", [["cell cultures", "ANATOMY", 4, 17], ["cell cultures", "CELL", 4, 17], ["cell cultures", "CELL_LINE", 4, 17], ["The cell cultures", "TEST", 0, 17]]], ["The whole cell cultures and supernatant of cell cultures (by removing cell pellet by centrifugation) were purified by iodixanol protocol, and then assayed for genomic (by PCR) and infective viral particle (using HEK293 cells) concentrations. therefore, infective assay does not reflect similar information for comparative purpose, but should be used only as an indicator that the vectors are functionally active to infect cells and are capable of expressing the gene. a The genomic particles obtained by real-time qPCR were back calculated for concentration in cell culture by diving by 2.46 factor (12.3 loaded on tube and 5 mL withdrawn).", [["cell cultures", "ANATOMY", 10, 23], ["supernatant", "ANATOMY", 28, 39], ["cell cultures", "ANATOMY", 43, 56], ["cell pellet", "ANATOMY", 70, 81], ["HEK293 cells", "ANATOMY", 212, 224], ["cells", "ANATOMY", 422, 427], ["cell", "ANATOMY", 561, 565], ["iodixanol", "CHEMICAL", 118, 127], ["iodixanol", "CHEMICAL", 118, 127], ["cell cultures", "CELL", 10, 23], ["cell cultures", "CELL", 43, 56], ["cell", "CELL", 70, 74], ["iodixanol", "SIMPLE_CHEMICAL", 118, 127], ["HEK293 cells", "CELL", 212, 224], ["cells", "CELL", 422, 427], ["cell", "CELL", 561, 565], ["tube", "TISSUE", 615, 619], ["whole cell cultures", "CELL_LINE", 4, 23], ["cell cultures", "CELL_LINE", 43, 56], ["HEK293 cells", "CELL_LINE", 212, 224], ["The whole cell cultures", "TEST", 0, 23], ["cell cultures", "TEST", 43, 56], ["iodixanol protocol", "TREATMENT", 118, 136], ["PCR", "TEST", 171, 174], ["infective viral particle", "PROBLEM", 180, 204], ["infective assay", "TEST", 253, 268], ["The genomic particles", "TEST", 470, 491], ["real-time qPCR", "TEST", 504, 518], ["cell culture", "TEST", 561, 573], ["tube", "TREATMENT", 615, 619], ["infective", "OBSERVATION", 253, 262], ["particles", "OBSERVATION_MODIFIER", 482, 491]]], ["Percent genomic particles present in the supernatant were calculated by dividing the Vg in supernatant/mL cell culture by Vg in whole cell culture/mL (shown in Fig. 8 ) multiplied by 100%.", [["supernatant", "ANATOMY", 41, 52], ["supernatant", "ANATOMY", 91, 102], ["cell", "ANATOMY", 106, 110], ["cell culture", "ANATOMY", 134, 146], ["Vg", "GENE_OR_GENE_PRODUCT", 85, 87], ["cell", "CELL", 106, 110], ["Vg", "CELL", 122, 124], ["cell", "CELL", 134, 138], ["Vg", "PROTEIN", 122, 124], ["Percent genomic particles", "PROBLEM", 0, 25], ["cell culture", "TEST", 106, 118], ["whole cell culture", "TEST", 128, 146], ["genomic particles", "OBSERVATION", 8, 25]]], ["Bioreactor was inoculated at a cell density of 0.35E+06 cells/mL with 97% viability.", [["cell", "ANATOMY", 31, 35], ["cells", "ANATOMY", 56, 61], ["cell", "CELL", 31, 35], ["a cell density", "TEST", 29, 43], ["cell density", "OBSERVATION_MODIFIER", 31, 43]]], ["The cells were transfected with the PEI/DNA complexes (polyplexes) with PEI to DNA ratio of 2:1 in a serum-free medium to produce AAV2.", [["cells", "ANATOMY", 4, 9], ["serum", "ANATOMY", 101, 106], ["PEI", "CHEMICAL", 36, 39], ["PEI", "CHEMICAL", 72, 75], ["PEI", "CHEMICAL", 36, 39], ["polyplexes", "CHEMICAL", 55, 65], ["PEI", "CHEMICAL", 72, 75], ["cells", "CELL", 4, 9], ["PEI", "GENE_OR_GENE_PRODUCT", 36, 39], ["DNA", "CELLULAR_COMPONENT", 40, 43], ["polyplexes", "SIMPLE_CHEMICAL", 55, 65], ["PEI", "SIMPLE_CHEMICAL", 72, 75], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["serum", "ORGANISM_SUBSTANCE", 101, 106], ["AAV2", "ORGANISM", 130, 134], ["PEI/DNA complexes", "PROTEIN", 36, 53], ["AAV2", "SPECIES", 130, 134], ["the PEI/DNA complexes", "TREATMENT", 32, 53], ["PEI", "TREATMENT", 72, 75], ["DNA ratio", "TEST", 79, 88], ["a serum", "TEST", 99, 106], ["AAV2", "PROBLEM", 130, 134], ["AAV2", "OBSERVATION", 130, 134]]], ["The total cell culture volume at the start of transfection was 2000 mL.", [["cell", "ANATOMY", 10, 14], ["cell", "CELL", 10, 14], ["The total cell culture volume", "TEST", 0, 29], ["transfection", "TEST", 46, 58], ["total cell", "OBSERVATION", 4, 14]]], ["Samples were taken every 8 or 12 h intervals up to 96 hpt.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7]]], ["This figure shows the genomic particle yield (in Vg/mL whole cell culture and Vg/mL supernatant of cell culture) and Vg/IVP ratio in (a), the cell specific yields (in terms of Vg/total cell and IVP/total cell) in (b), and total cell counts/mL culture and percent of GFP positive cells in (c).Productions of AAV serotypes in bioreactorsTo demonstrate scalability and potential industrialization of the process, the transfection was performed in a controlled bioreactor.", [["cell", "ANATOMY", 61, 65], ["supernatant", "ANATOMY", 84, 95], ["cell", "ANATOMY", 99, 103], ["cell", "ANATOMY", 142, 146], ["cell", "ANATOMY", 185, 189], ["cell", "ANATOMY", 204, 208], ["cell", "ANATOMY", 228, 232], ["cells", "ANATOMY", 279, 284], ["cell", "CELL", 61, 65], ["cell", "CELL", 99, 103], ["cell", "CELL", 142, 146], ["cell", "CELL", 185, 189], ["cell", "CELL", 204, 208], ["cell", "CELL", 228, 232], ["GFP", "GENE_OR_GENE_PRODUCT", 266, 269], ["cells", "CELL", 279, 284], ["AAV", "ORGANISM", 307, 310], ["Vg", "PROTEIN", 176, 178], ["IVP", "PROTEIN", 194, 197], ["GFP positive cells", "CELL_LINE", 266, 284], ["This figure", "TEST", 0, 11], ["whole cell culture", "TEST", 55, 73], ["Vg", "TEST", 78, 80], ["cell culture", "TEST", 99, 111], ["Vg/IVP ratio", "TEST", 117, 129], ["the cell specific yields", "TEST", 138, 162], ["Vg", "TEST", 176, 178], ["total cell", "TEST", 179, 189], ["IVP/total cell)", "TEST", 194, 209], ["total cell counts", "TEST", 222, 239], ["mL culture", "TEST", 240, 250], ["GFP positive cells", "PROBLEM", 266, 284], ["AAV serotypes", "PROBLEM", 307, 320], ["the transfection", "TREATMENT", 410, 426], ["a controlled bioreactor", "TREATMENT", 444, 467], ["genomic particle", "OBSERVATION", 22, 38], ["positive cells", "OBSERVATION", 270, 284], ["AAV serotypes", "OBSERVATION", 307, 320], ["bioreactors", "OBSERVATION", 324, 335], ["scalability", "OBSERVATION", 350, 361]]], ["The production kinetics were similar for both serotypes (AAV2 and AAV6); therefore, detailed kinetics have been reported only for the production of AAV2 (Fig. 9a , corresponding to Run#01 in Table 3 ).", [["AAV2", "ORGANISM", 57, 61], ["AAV2", "ORGANISM", 148, 152], ["Run#01", "PROTEIN", 181, 187], ["AAV2", "SPECIES", 57, 61], ["AAV2", "SPECIES", 148, 152], ["The production kinetics", "PROBLEM", 0, 23]]], ["The samples were taken at 8-12-h intervals.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11]]], ["The cells continued to grow to a density of 1.87 \u00d7 10 6 cells/mL, and the viability at 72 hpt was 82%.", [["cells", "ANATOMY", 4, 9], ["cells", "ANATOMY", 56, 61], ["cells", "CELL", 4, 9], ["The cells", "PROBLEM", 0, 9], ["a density", "TEST", 31, 40], ["the viability", "TEST", 70, 83], ["hpt", "TEST", 90, 93], ["density", "OBSERVATION_MODIFIER", 33, 40]]], ["About 10-15% Vg and IVP were detected in the supernatant similar to shake flask experiments (Table 2 and Fig. 8) .", [["supernatant", "ANATOMY", 45, 56], ["Vg", "GENE_OR_GENE_PRODUCT", 13, 15], ["IVP", "GENE_OR_GENE_PRODUCT", 20, 23], ["IVP", "TREATMENT", 20, 23]]], ["The cell specific production in terms of Vg/total cells and IVP/total cells (Fig. 9b) were also in the same order of magnitude as obtained in the shake flask experiments (Fig. 6) .", [["cell", "ANATOMY", 4, 8], ["cells", "ANATOMY", 50, 55], ["cells", "ANATOMY", 70, 75], ["cell", "CELL", 4, 8], ["Vg", "GENE_OR_GENE_PRODUCT", 41, 43], ["cells", "CELL", 50, 55], ["cells", "CELL", 70, 75], ["Vg", "PROTEIN", 41, 43], ["total cells", "CELL_TYPE", 44, 55], ["IVP/total cells", "CELL_TYPE", 60, 75], ["Vg/total cells", "TREATMENT", 41, 55], ["IVP/total cells", "TREATMENT", 60, 75], ["cell", "OBSERVATION_MODIFIER", 4, 8], ["specific", "OBSERVATION_MODIFIER", 9, 17], ["production", "OBSERVATION_MODIFIER", 18, 28]]], ["Transfection showed that 40% of the cells were expressing GFP.", [["cells", "ANATOMY", 36, 41], ["cells", "CELL", 36, 41], ["GFP", "GENE_OR_GENE_PRODUCT", 58, 61], ["GFP", "PROTEIN", 58, 61], ["Transfection", "TEST", 0, 12]]], ["After 36 hpt even though the viability started to decrease, the total cell counts were still increasing, therefore, percent GFP positive cells started to show a decline (Fig. 9c) .", [["cell", "ANATOMY", 70, 74], ["cells", "ANATOMY", 137, 142], ["cell", "CELL", 70, 74], ["GFP", "GENE_OR_GENE_PRODUCT", 124, 127], ["cells", "CELL", 137, 142], ["GFP positive cells", "CELL_LINE", 124, 142], ["the viability", "PROBLEM", 25, 38], ["the total cell counts", "TEST", 60, 81], ["percent GFP positive cells", "PROBLEM", 116, 142], ["a decline", "PROBLEM", 159, 168], ["decrease", "OBSERVATION_MODIFIER", 50, 58]]], ["Table 3 Yields of AAV2 and AAV6 obtained in 3-L bioreactors.SerotypesVg/mL (RSD a = 3%) IVP/mL (RSD a = 23%) Vg/IVP Run#01: AAV2 1.0E+10 6.8E+08 15 (std dev \u00b13) Run#02: AAV2 1.2E+10 6.1E+08 20 (std dev \u00b15) Run#03: AAV6 2.0E+09 1.7E+08 12 (std dev \u00b13) a RSD = relative standard deviation (assayed from the same sample).SerotypesThe whole cell culture broth was treated in the bioreactor to maximize the recovery of AAV produced and to streamline the overall process by eliminating steps such as harvesting, centrifugation (or microfiltration) and resuspension of the cell pellet to disrupt the cells for virus extraction.", [["cell", "ANATOMY", 337, 341], ["cell", "ANATOMY", 566, 570], ["cells", "ANATOMY", 593, 598], ["AAV2", "ORGANISM", 18, 22], ["AAV6", "GENE_OR_GENE_PRODUCT", 27, 31], ["AAV2", "ORGANISM", 124, 128], ["AAV2", "ORGANISM", 169, 173], ["cell", "CELL", 337, 341], ["AAV", "ORGANISM", 414, 417], ["cell", "CELL", 566, 570], ["cells", "CELL", 593, 598], ["AAV2", "SPECIES", 18, 22], ["AAV", "SPECIES", 414, 417], ["AAV2 and AAV6", "TREATMENT", 18, 31], ["3-L bioreactors", "TREATMENT", 44, 59], ["SerotypesVg", "TEST", 60, 71], ["RSD", "TEST", 96, 99], ["AAV2", "TEST", 124, 128], ["E", "TEST", 140, 141], ["std dev \u00b1", "TEST", 149, 158], ["Run", "TEST", 161, 164], ["AAV2", "TEST", 169, 173], ["E", "TEST", 177, 178], ["E", "TEST", 185, 186], ["std dev \u00b1", "TEST", 194, 203], ["Run", "TEST", 206, 209], ["AAV6", "TEST", 214, 218], ["E", "TEST", 222, 223], ["E", "TEST", 230, 231], ["std dev \u00b1", "TEST", 239, 248], ["a RSD", "TEST", 251, 256], ["relative standard deviation", "PROBLEM", 259, 286], ["Serotypes", "TREATMENT", 318, 327], ["The whole cell culture broth", "TREATMENT", 327, 355], ["the bioreactor", "TREATMENT", 371, 385], ["AAV", "TREATMENT", 414, 417], ["harvesting", "TREATMENT", 494, 504], ["centrifugation", "TREATMENT", 506, 520], ["microfiltration", "TREATMENT", 525, 540], ["resuspension", "TREATMENT", 546, 558], ["the cell pellet", "TREATMENT", 562, 577], ["virus extraction", "TREATMENT", 603, 619], ["RSD", "ANATOMY", 253, 256], ["standard deviation", "OBSERVATION", 268, 286], ["whole cell", "OBSERVATION_MODIFIER", 331, 341], ["cell pellet", "OBSERVATION", 566, 577]]], ["Concentrations of Triton X-100 lower than 0.4% did not affect the activity of Benzonase \u00ae , which was used to reduce non-viral DNA and non-encapsidated AAV DNA present in the lysate.", [["lysate", "ANATOMY", 175, 181], ["Triton X-100", "CHEMICAL", 18, 30], ["Benzonase \u00ae", "CHEMICAL", 78, 89], ["Triton X-100", "CHEMICAL", 18, 30], ["Benzonase", "CHEMICAL", 78, 87], ["Triton X-100", "SIMPLE_CHEMICAL", 18, 30], ["Benzonase \u00ae", "SIMPLE_CHEMICAL", 78, 89], ["DNA", "CELLULAR_COMPONENT", 127, 130], ["AAV", "ORGANISM", 152, 155], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["lysate", "ORGANISM_SUBSTANCE", 175, 181], ["non-viral DNA", "DNA", 117, 130], ["non-encapsidated AAV DNA", "DNA", 135, 159], ["AAV", "SPECIES", 152, 155], ["Concentrations of Triton", "TREATMENT", 0, 24], ["Benzonase \u00ae", "TREATMENT", 78, 89], ["non-viral DNA", "PROBLEM", 117, 130], ["non-encapsidated AAV DNA", "PROBLEM", 135, 159]]], ["Benzonase addition also resulted in a reduction of the medium viscosity.", [["Benzonase", "CHEMICAL", 0, 9], ["Benzonase", "CHEMICAL", 0, 9], ["Benzonase", "SIMPLE_CHEMICAL", 0, 9], ["Benzonase", "TREATMENT", 0, 9], ["a reduction of the medium viscosity", "PROBLEM", 36, 71], ["reduction", "OBSERVATION_MODIFIER", 38, 47], ["medium viscosity", "OBSERVATION", 55, 71]]], ["The Triton X-100-treated cell culture gave a similar infectious AAV yield compared to the yield by the freeze/thaw method (data not shown).", [["cell", "ANATOMY", 25, 29], ["Triton X-100", "CHEMICAL", 4, 16], ["Triton X-100", "CHEMICAL", 4, 16], ["Triton X-100", "SIMPLE_CHEMICAL", 4, 16], ["cell culture", "CELL", 25, 37], ["AAV", "ORGANISM", 64, 67], ["Triton X-100-treated cell culture", "CELL_LINE", 4, 37], ["The Triton X", "TREATMENT", 0, 12], ["cell culture", "TEST", 25, 37], ["a similar infectious AAV yield", "PROBLEM", 43, 73], ["infectious", "OBSERVATION", 53, 63]]], ["A maximum of 2 \u00d7 10 13 Vg and 1.3 \u00d7 10 12 IVP of AAV2 were produced from 2 L of cell culture produced in 3 L bioreactor in less than 64 hpt.", [["cell", "ANATOMY", 80, 84], ["AAV2", "ORGANISM", 49, 53], ["cell culture", "CELL", 80, 92], ["AAV2", "SPECIES", 49, 53], ["Vg", "TEST", 23, 25], ["IVP of AAV2", "TEST", 42, 53], ["cell culture", "TEST", 80, 92], ["3 L bioreactor", "TREATMENT", 105, 119], ["maximum", "OBSERVATION_MODIFIER", 2, 9]]], ["The yields of two runs of AAV2 and one run of AAV6 obtained in the bioreactor experiments are summarized in Table 3 .DiscussionFigs.", [["AAV2", "ORGANISM", 26, 30], ["AAV6", "PROTEIN", 46, 50], ["AAV2", "PROBLEM", 26, 30], ["AAV6", "TEST", 46, 50], ["AAV2", "OBSERVATION", 26, 30], ["bioreactor experiments", "OBSERVATION", 67, 89]]], ["1 and 2 demonstrated that there was certain improvement in the overall %GFP positive cells for higher cell densities when the plasmid DNA was supplied on the basis of 1 g/million cells, but improvement was not worth the cost of addition of extra plasmid.", [["cells", "ANATOMY", 85, 90], ["cell", "ANATOMY", 102, 106], ["plasmid", "ANATOMY", 126, 133], ["cells", "ANATOMY", 179, 184], ["plasmid", "ANATOMY", 246, 253], ["GFP", "GENE_OR_GENE_PRODUCT", 72, 75], ["cells", "CELL", 85, 90], ["cell", "CELL", 102, 106], ["DNA", "CELLULAR_COMPONENT", 134, 137], ["cells", "CELL", 179, 184], ["GFP positive cells", "CELL_LINE", 72, 90], ["plasmid DNA", "DNA", 126, 137], ["the overall %GFP positive cells", "PROBLEM", 59, 90], ["higher cell densities", "PROBLEM", 95, 116], ["the plasmid DNA", "TEST", 122, 137], ["extra plasmid", "TREATMENT", 240, 253], ["improvement", "OBSERVATION_MODIFIER", 44, 55], ["positive cells", "OBSERVATION", 76, 90], ["higher cell densities", "OBSERVATION", 95, 116]]], ["The cell cultures with higher DNA concentrations showed significantly larger number of aggregates.", [["cell cultures", "ANATOMY", 4, 17], ["cell cultures", "CELL", 4, 17], ["DNA", "CELLULAR_COMPONENT", 30, 33], ["cell cultures", "CELL_LINE", 4, 17], ["The cell cultures", "TEST", 0, 17], ["higher DNA concentrations", "PROBLEM", 23, 48], ["cell cultures", "OBSERVATION", 4, 17], ["significantly", "OBSERVATION_MODIFIER", 56, 69], ["larger", "OBSERVATION_MODIFIER", 70, 76], ["number", "OBSERVATION_MODIFIER", 77, 83], ["aggregates", "OBSERVATION_MODIFIER", 87, 97]]], ["This result was probably due to excess plasmid DNA or a high concentration of PEI associated with DNA in polyplexes formed with a higher DNA load at the time of transfection.", [["plasmid", "ANATOMY", 39, 46], ["PEI", "CHEMICAL", 78, 81], ["PEI", "CHEMICAL", 78, 81], ["polyplexes", "CHEMICAL", 105, 115], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["PEI", "SIMPLE_CHEMICAL", 78, 81], ["DNA", "CELLULAR_COMPONENT", 98, 101], ["polyplexes", "SIMPLE_CHEMICAL", 105, 115], ["DNA", "CELLULAR_COMPONENT", 137, 140], ["plasmid DNA", "DNA", 39, 50], ["excess plasmid DNA", "PROBLEM", 32, 50], ["a high concentration of PEI", "PROBLEM", 54, 81], ["DNA in polyplexes", "PROBLEM", 98, 115], ["a higher DNA load", "PROBLEM", 128, 145], ["probably due to", "UNCERTAINTY", 16, 31], ["high concentration", "OBSERVATION_MODIFIER", 56, 74], ["transfection", "OBSERVATION", 161, 173]]], ["Polyplexes have a net positive charge.", [["Polyplexes", "SIMPLE_CHEMICAL", 0, 10], ["Polyplexes", "PROBLEM", 0, 10], ["a net positive charge", "PROBLEM", 16, 37], ["net", "OBSERVATION_MODIFIER", 18, 21], ["positive charge", "OBSERVATION", 22, 37]]], ["It is hypothesized that polyplexes, when present in excess, may act as bridges between the cells that are usually negatively charged and cause aggregation.", [["cells", "ANATOMY", 91, 96], ["polyplexes", "CHEMICAL", 24, 34], ["polyplexes", "SIMPLE_CHEMICAL", 24, 34], ["cells", "CELL", 91, 96], ["polyplexes", "PROBLEM", 24, 34], ["aggregation", "PROBLEM", 143, 154], ["polyplexes", "OBSERVATION", 24, 34], ["cells", "ANATOMY", 91, 96]]], ["Therefore, a PEI to DNA ratio of 2:1 was used in all the transfections done in this study based on earlier work in the author's laboratory.", [["PEI", "CHEMICAL", 13, 16], ["PEI", "CHEMICAL", 13, 16], ["PEI", "SIMPLE_CHEMICAL", 13, 16], ["DNA", "CELLULAR_COMPONENT", 20, 23], ["a PEI to DNA ratio", "TEST", 11, 29], ["this study", "TEST", 79, 89]]], ["These observations and recommendations were dependent on the formulation of the serum-free medium selected.", [["serum", "ANATOMY", 80, 85], ["serum", "ORGANISM_SUBSTANCE", 80, 85], ["the serum", "TEST", 76, 85]]], ["Because of the proprietary nature of the commercial serum-free medium used, it was difficult to speculate the effect of other macromolecules present in the cell culture medium.", [["serum", "ANATOMY", 52, 57], ["cell", "ANATOMY", 156, 160], ["serum", "ORGANISM_SUBSTANCE", 52, 57], ["cell", "CELL", 156, 160], ["the commercial serum", "TEST", 37, 57], ["other macromolecules", "PROBLEM", 120, 140], ["the cell culture", "TEST", 152, 168], ["cell culture medium", "OBSERVATION", 156, 175]]], ["It was also difficult to assess the interactions with polyplexes and the mechanism of transfection.", [["polyplexes", "CHEMICAL", 54, 64], ["polyplexes", "SIMPLE_CHEMICAL", 54, 64], ["polyplexes", "TREATMENT", 54, 64], ["transfection", "PROBLEM", 86, 98], ["transfection", "OBSERVATION", 86, 98]]], ["Park et al. (2006) showed that the quantity of DNA that was optimal for AAV production was dependent on the cell line, the mode of production (such as anchorage or suspension) and the type of the medium.", [["cell line", "ANATOMY", 108, 117], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["AAV", "ORGANISM", 72, 75], ["cell line", "CELL", 108, 117], ["cell line", "CELL_LINE", 108, 117], ["DNA", "PROBLEM", 47, 50], ["AAV production", "PROBLEM", 72, 86], ["the cell line", "TREATMENT", 104, 117], ["anchorage or suspension", "TREATMENT", 151, 174], ["cell line", "OBSERVATION", 108, 117]]], ["Optimal DNA concentrations for suspension cells were 6-12 g/mL for HEK293 and HEK293T (adapted for suspension) with yields of 24,000 and 115,000 Vg/cell, respectively.", [["suspension cells", "ANATOMY", 31, 47], ["HEK293", "ANATOMY", 67, 73], ["HEK293T", "ANATOMY", 78, 85], ["cell", "ANATOMY", 148, 152], ["DNA", "CELLULAR_COMPONENT", 8, 11], ["cells", "CELL", 42, 47], ["HEK293", "CELL", 67, 73], ["HEK293T", "CELL", 78, 85], ["cell", "CELL", 148, 152], ["suspension cells", "CELL_LINE", 31, 47], ["HEK293", "CELL_LINE", 67, 73], ["HEK293T", "CELL_LINE", 78, 85], ["Optimal DNA concentrations", "TEST", 0, 26], ["suspension cells", "TEST", 31, 47], ["HEK293", "TEST", 67, 73], ["HEK293T", "TEST", 78, 85], ["yields", "TEST", 116, 122]]], ["For the anchorage dependent cells, the optimal DNA concentration was 3 g/mL for HEK293T with a yield of 65,000 Vg/cell (Park et al., 2006) .", [["cells", "ANATOMY", 28, 33], ["HEK293T", "ANATOMY", 80, 87], ["cell", "ANATOMY", 114, 118], ["cells", "CELL", 28, 33], ["DNA", "CELLULAR_COMPONENT", 47, 50], ["HEK293T", "CELL", 80, 87], ["cell", "CELL", 114, 118], ["anchorage dependent cells", "CELL_TYPE", 8, 33], ["the anchorage dependent cells", "TREATMENT", 4, 33], ["the optimal DNA concentration", "TREATMENT", 35, 64], ["anchorage dependent", "OBSERVATION_MODIFIER", 8, 27]]], ["Among the different media tested, Hildinger et al. (2007) reported that optimal AAV yield was obtained with 1.25 g DNA/mL with a PEI:DNA ratio of 3:1 in a medium composed of 1:1 mixture of RPMI and Ex-Cell media.", [["PEI", "CHEMICAL", 129, 132], ["AAV", "ORGANISM", 80, 83], ["DNA", "CELLULAR_COMPONENT", 133, 136], ["Ex-Cell", "CELL", 198, 205], ["AAV", "SPECIES", 80, 83], ["DNA ratio", "TEST", 133, 142], ["RPMI", "TEST", 189, 193], ["Cell media", "OBSERVATION", 201, 211]]], ["It was also reported that cutting down the DNA to half reduced the yield by about 50% but by increasing the DNA did not have proportional gain in the yield.DiscussionThe cell-specific yield at low cell densities has been reported between 100 and 17,000 Vg/cell (Chadeuf et al., 2005; Collaco et al., 1999; Drittanti et al., 2001; Feng et al., 2007; Okada et al., 2001) for GFP or lacZ reporter gene production by HEK293 cells using plasmid transfection technology.", [["cell", "ANATOMY", 170, 174], ["cell", "ANATOMY", 197, 201], ["cell", "ANATOMY", 256, 260], ["HEK293 cells", "ANATOMY", 413, 425], ["plasmid", "ANATOMY", 432, 439], ["DNA", "CELLULAR_COMPONENT", 43, 46], ["DNA", "CELLULAR_COMPONENT", 108, 111], ["cell", "CELL", 170, 174], ["cell", "CELL", 197, 201], ["GFP", "GENE_OR_GENE_PRODUCT", 373, 376], ["lacZ", "GENE_OR_GENE_PRODUCT", 380, 384], ["HEK293 cells", "CELL", 413, 425], ["lacZ reporter gene", "DNA", 380, 398], ["HEK293 cells", "CELL_LINE", 413, 425], ["GFP", "PROBLEM", 373, 376], ["plasmid transfection technology", "TREATMENT", 432, 463]]], ["Volumetric production did not increase proportionally at cell densities higher than 1.0 \u00d7 10 6 cells/mL (Fig. 3) , which was also reflected by the cellspecific yield (Fig. 4) .", [["cell", "ANATOMY", 57, 61], ["cells", "ANATOMY", 95, 100], ["cell", "CELL", 57, 61], ["Volumetric production", "TEST", 0, 21], ["cell densities", "TEST", 57, 71], ["increase", "OBSERVATION_MODIFIER", 30, 38], ["proportionally", "OBSERVATION_MODIFIER", 39, 53], ["cell densities", "OBSERVATION", 57, 71], ["higher", "OBSERVATION_MODIFIER", 72, 78]]], ["Similar reduced transfection efficiency was observed by Hildinger et al. (2007) and they concluded that it could be because DNA-PEI polyplexes were added on a volumetric basis.", [["PEI", "CHEMICAL", 128, 131], ["polyplexes", "CHEMICAL", 132, 142], ["DNA", "CELLULAR_COMPONENT", 124, 127], ["-PEI polyplexes", "SIMPLE_CHEMICAL", 127, 142], ["Similar reduced transfection efficiency", "PROBLEM", 0, 39], ["DNA", "PROBLEM", 124, 127], ["PEI polyplexes", "TREATMENT", 128, 142], ["reduced", "OBSERVATION_MODIFIER", 8, 15], ["transfection efficiency", "OBSERVATION", 16, 39]]], ["The low yield in cell cultures at higher cell densities could be due to the exhaustion of some key components from the medium necessary for AAV production and cell maintenance.", [["cell cultures", "ANATOMY", 17, 30], ["cell", "ANATOMY", 41, 45], ["cell", "ANATOMY", 159, 163], ["cell cultures", "CELL", 17, 30], ["cell", "CELL", 41, 45], ["AAV", "ORGANISM", 140, 143], ["cell", "CELL", 159, 163], ["cell cultures", "CELL_LINE", 17, 30], ["The low yield in cell cultures", "PROBLEM", 0, 30], ["higher cell densities", "PROBLEM", 34, 55], ["some key components", "PROBLEM", 90, 109], ["AAV production", "TREATMENT", 140, 154], ["cell maintenance", "TREATMENT", 159, 175], ["low yield", "OBSERVATION_MODIFIER", 4, 13], ["higher cell densities", "OBSERVATION", 34, 55], ["could be due to", "UNCERTAINTY", 56, 71]]], ["These observations also indicated that there is a potential for improvement in the AAV production yield by optimizing the medium and designing some feeding strategies for high cell density cultures in a fed-batch mode.", [["cell", "ANATOMY", 176, 180], ["AAV", "ORGANISM", 83, 86], ["cell", "CELL", 176, 180], ["high cell density cultures", "CELL_LINE", 171, 197], ["the medium", "TREATMENT", 118, 128], ["some feeding strategies", "TREATMENT", 143, 166], ["high cell density cultures", "PROBLEM", 171, 197], ["a fed", "TREATMENT", 201, 206], ["cell density", "OBSERVATION", 176, 188]]], ["This problem remains largely unsolved and requires a more detailed analyses and a better understanding of the cell metabolism and kinetic mechanisms involved in the transfection and expression processes.", [["cell", "ANATOMY", 110, 114], ["cell", "CELL", 110, 114], ["largely", "OBSERVATION_MODIFIER", 21, 28], ["unsolved", "OBSERVATION", 29, 37]]], ["The \"cell density effect\" is a metabolic limitation that has been observed in the author's laboratory with other expression systems.", [["cell", "ANATOMY", 5, 9], ["cell", "CELL", 5, 9], ["The \"cell density effect", "PROBLEM", 0, 24], ["a metabolic limitation", "PROBLEM", 29, 51], ["cell density", "OBSERVATION", 5, 17], ["metabolic limitation", "OBSERVATION", 31, 51]]], ["Henry et al. (2004) addressed this phenomenon by proposing a perfusion system for adenovirus production to alleviate nutrient limitations caused by high cell density cultures.", [["cell", "ANATOMY", 153, 157], ["adenovirus", "ORGANISM", 82, 92], ["cell", "CELL", 153, 157], ["high cell density cultures", "CELL_LINE", 148, 174], ["adenovirus", "SPECIES", 82, 92], ["this phenomenon", "PROBLEM", 30, 45], ["a perfusion system", "TREATMENT", 59, 77], ["adenovirus production", "PROBLEM", 82, 103], ["nutrient limitations", "PROBLEM", 117, 137], ["high cell density cultures", "PROBLEM", 148, 174], ["high cell density", "OBSERVATION", 148, 165]]], ["For this study, it was decided to keep producing AAV by transfecting cells at the cell density of 1 \u00d7 10 6 cells/mL until other means of medium replacement or fed-batch techniques are developed or additives are found to improve the transfection efficiency and AAV yield.DiscussionSodium butyrate and butyric acid, for the regulation of gene expression by keeping histones in the acetylated state (inhibition of histone deacetylase) for easy accessibility of regulatory factors to DNA (Vidali et al., 1978) were exploited to improve the production yield of AAV.", [["cells", "ANATOMY", 69, 74], ["cell", "ANATOMY", 82, 86], ["cells", "ANATOMY", 107, 112], ["DiscussionSodium butyrate", "CHEMICAL", 270, 295], ["butyric acid", "CHEMICAL", 300, 312], ["DiscussionSodium butyrate", "CHEMICAL", 270, 295], ["butyric acid", "CHEMICAL", 300, 312], ["AAV", "ORGANISM", 49, 52], ["cells", "CELL", 69, 74], ["cell", "CELL", 82, 86], ["cells", "CELL", 107, 112], ["AAV", "ORGANISM", 260, 263], ["DiscussionSodium butyrate", "SIMPLE_CHEMICAL", 270, 295], ["butyric acid", "SIMPLE_CHEMICAL", 300, 312], ["histones", "GENE_OR_GENE_PRODUCT", 363, 371], ["histone deacetylase", "GENE_OR_GENE_PRODUCT", 411, 430], ["DNA", "CELLULAR_COMPONENT", 480, 483], ["AAV", "ORGANISM", 556, 559], ["transfecting cells", "CELL_LINE", 56, 74], ["histones", "PROTEIN", 363, 371], ["acetylated state", "PROTEIN", 379, 395], ["histone deacetylase", "PROTEIN", 411, 430], ["regulatory factors", "PROTEIN", 458, 476], ["this study", "TEST", 4, 14], ["the cell density", "TEST", 78, 94], ["medium replacement", "TREATMENT", 137, 155], ["batch techniques", "TREATMENT", 163, 179], ["the transfection efficiency", "PROBLEM", 228, 255], ["DiscussionSodium butyrate", "TREATMENT", 270, 295], ["butyric acid", "TREATMENT", 300, 312], ["histone deacetylase", "TREATMENT", 411, 430], ["AAV", "PROBLEM", 556, 559], ["cell density", "OBSERVATION_MODIFIER", 82, 94], ["transfection efficiency", "OBSERVATION", 232, 255], ["AAV", "OBSERVATION", 556, 559]]], ["In some cases, the use of sodium butyrate had increased (Backliwal et al., 2008; Hunt et al., 2002; Jiang and Sharfstein, 2008; Sena-Esteves et al., 2004 ) the yield of proteins and viruses, and in other cases, it had no effect (Sena-Esteves et al., 2004) .", [["sodium butyrate", "CHEMICAL", 26, 41], ["sodium butyrate", "CHEMICAL", 26, 41], ["sodium butyrate", "SIMPLE_CHEMICAL", 26, 41], ["sodium butyrate", "TREATMENT", 26, 41], ["proteins and viruses", "PROBLEM", 169, 189], ["viruses", "OBSERVATION", 182, 189]]], ["In the present study, although the expression levels of the transgene in the transfected cells were directly proportional to the concentrations of sodium butyrate or butyric acid, their use did not contribute to increase the yield of AAV production.", [["cells", "ANATOMY", 89, 94], ["sodium butyrate", "CHEMICAL", 147, 162], ["butyric acid", "CHEMICAL", 166, 178], ["sodium butyrate", "CHEMICAL", 147, 162], ["butyric acid", "CHEMICAL", 166, 178], ["cells", "CELL", 89, 94], ["sodium butyrate", "SIMPLE_CHEMICAL", 147, 162], ["butyric acid", "SIMPLE_CHEMICAL", 166, 178], ["AAV", "ORGANISM", 234, 237], ["transfected cells", "CELL_LINE", 77, 94], ["the present study", "TEST", 3, 20], ["sodium butyrate", "TREATMENT", 147, 162], ["butyric acid", "TREATMENT", 166, 178], ["AAV production", "PROBLEM", 234, 248]]], ["Based on the high expression of GFP protein, the addition of sodium butyrate or butyric acid would also have produced Rep proteins in excess.", [["sodium butyrate", "CHEMICAL", 61, 76], ["butyric acid", "CHEMICAL", 80, 92], ["sodium butyrate", "CHEMICAL", 61, 76], ["butyric acid", "CHEMICAL", 80, 92], ["GFP", "GENE_OR_GENE_PRODUCT", 32, 35], ["sodium butyrate", "SIMPLE_CHEMICAL", 61, 76], ["butyric acid", "SIMPLE_CHEMICAL", 80, 92], ["Rep", "GENE_OR_GENE_PRODUCT", 118, 121], ["GFP protein", "PROTEIN", 32, 43], ["Rep proteins", "PROTEIN", 118, 130], ["GFP protein", "PROBLEM", 32, 43], ["sodium butyrate", "TREATMENT", 61, 76], ["butyric acid", "PROBLEM", 80, 92], ["Rep proteins in excess", "PROBLEM", 118, 140]]], ["The Rep proteins have a toxic effect on HEK293 cells (Chang and Shenk, 1990; Chang et al., 1989; Clark et al., 1995; Li et al., 1997; Yang et al., 1994; Zhou and Trempe, 1999) ; therefore, the low AAV yield in the presence of sodium butyrate or butyric acid could be due to accumulation of other toxic proteins in the cell culture environment.", [["HEK293 cells", "ANATOMY", 40, 52], ["cell", "ANATOMY", 318, 322], ["sodium butyrate", "CHEMICAL", 226, 241], ["butyric acid", "CHEMICAL", 245, 257], ["sodium butyrate", "CHEMICAL", 226, 241], ["butyric acid", "CHEMICAL", 245, 257], ["Rep", "GENE_OR_GENE_PRODUCT", 4, 7], ["HEK293 cells", "CELL", 40, 52], ["AAV", "ORGANISM", 197, 200], ["sodium butyrate", "SIMPLE_CHEMICAL", 226, 241], ["butyric acid", "SIMPLE_CHEMICAL", 245, 257], ["cell", "CELL", 318, 322], ["Rep proteins", "PROTEIN", 4, 16], ["HEK293 cells", "CELL_LINE", 40, 52], ["toxic proteins", "PROTEIN", 296, 310], ["The Rep proteins", "TEST", 0, 16], ["Trempe", "TEST", 162, 168], ["the low AAV yield", "PROBLEM", 189, 206], ["sodium butyrate", "PROBLEM", 226, 241], ["butyric acid", "PROBLEM", 245, 257], ["other toxic proteins", "PROBLEM", 290, 310], ["toxic", "OBSERVATION_MODIFIER", 24, 29], ["toxic", "OBSERVATION_MODIFIER", 296, 301]]], ["Lentivirus production by HEK293 cells has been increased by the use of sodium butyrate (Ansorge et al., 2009; Karolewski et al., 2003) and caffeine (Ellis et al., 2011) .", [["HEK293 cells", "ANATOMY", 25, 37], ["sodium butyrate", "CHEMICAL", 71, 86], ["caffeine", "CHEMICAL", 139, 147], ["sodium butyrate", "CHEMICAL", 71, 86], ["caffeine", "CHEMICAL", 139, 147], ["Lentivirus", "ORGANISM", 0, 10], ["HEK293 cells", "CELL", 25, 37], ["sodium butyrate", "SIMPLE_CHEMICAL", 71, 86], ["caffeine", "SIMPLE_CHEMICAL", 139, 147], ["HEK293 cells", "CELL_LINE", 25, 37], ["Lentivirus", "SPECIES", 0, 10], ["Lentivirus production", "PROBLEM", 0, 21], ["HEK293 cells", "PROBLEM", 25, 37], ["sodium butyrate", "TREATMENT", 71, 86], ["caffeine", "TREATMENT", 139, 147], ["HEK293 cells", "OBSERVATION", 25, 37], ["increased", "OBSERVATION_MODIFIER", 47, 56]]], ["AAV2 production was not increased by sodium butyrate (present study) or caffeine (Ellis et al., 2011) using HEK293 cells.", [["HEK293 cells", "ANATOMY", 108, 120], ["sodium butyrate", "CHEMICAL", 37, 52], ["caffeine", "CHEMICAL", 72, 80], ["sodium butyrate", "CHEMICAL", 37, 52], ["caffeine", "CHEMICAL", 72, 80], ["AAV2", "ORGANISM", 0, 4], ["sodium butyrate", "SIMPLE_CHEMICAL", 37, 52], ["caffeine", "SIMPLE_CHEMICAL", 72, 80], ["HEK293 cells", "CELL", 108, 120], ["HEK293 cells", "CELL_LINE", 108, 120], ["AAV2", "SPECIES", 0, 4], ["sodium butyrate", "TEST", 37, 52], ["caffeine", "TREATMENT", 72, 80], ["increased", "OBSERVATION_MODIFIER", 24, 33]]], ["However, an increase in AAV production has been shown by the addition of 5 mM sodium butyrate when the insect cells/baculovirus system was used and baculovirus-mediated transduction of HEK 293 cells gave higher AAV yield by the addition of sodium butyrate .DiscussionKinetics of AAV production showed that the infectious titers lagged behind the genomic particle titers most likely because their maturation into infectious particles took place after the formation of capsids and encapsidation of the viral genome (Fig. 6 ).", [["cells", "ANATOMY", 110, 115], ["HEK 293 cells", "ANATOMY", 185, 198], ["sodium butyrate", "CHEMICAL", 78, 93], ["HEK 293", "CHEMICAL", 185, 192], ["sodium butyrate", "CHEMICAL", 240, 255], ["sodium butyrate", "CHEMICAL", 78, 93], ["sodium butyrate", "CHEMICAL", 240, 255], ["AAV", "ORGANISM", 24, 27], ["sodium butyrate", "SIMPLE_CHEMICAL", 78, 93], ["insect cells", "CELL", 103, 115], ["baculovirus", "ORGANISM", 116, 127], ["baculovirus", "ORGANISM", 148, 159], ["HEK 293 cells", "CELL", 185, 198], ["AAV", "ORGANISM", 211, 214], ["sodium butyrate", "SIMPLE_CHEMICAL", 240, 255], ["AAV", "ORGANISM", 279, 282], ["insect cells", "CELL_TYPE", 103, 115], ["HEK 293 cells", "CELL_LINE", 185, 198], ["viral genome", "DNA", 500, 512], ["baculovirus", "SPECIES", 116, 127], ["baculovirus", "SPECIES", 148, 159], ["an increase in AAV production", "PROBLEM", 9, 38], ["5 mM sodium butyrate", "TREATMENT", 73, 93], ["the insect cells/baculovirus system", "TREATMENT", 99, 134], ["baculovirus", "TREATMENT", 148, 159], ["sodium butyrate", "TREATMENT", 240, 255], ["AAV production", "TEST", 279, 293], ["the infectious titers", "PROBLEM", 306, 327], ["the genomic particle titers", "PROBLEM", 342, 369], ["their maturation into infectious particles", "PROBLEM", 390, 432], ["capsids", "TREATMENT", 467, 474], ["the viral genome", "TREATMENT", 496, 512], ["increase", "OBSERVATION_MODIFIER", 12, 20], ["AAV production", "OBSERVATION", 24, 38], ["infectious", "OBSERVATION", 310, 320], ["infectious", "OBSERVATION", 412, 422], ["viral genome", "OBSERVATION", 500, 512]]], ["Viral genomic (Vg) particles started to accumulate as early as 12 hpt however, IVP were not seen until 24 hpt.", [["Viral genomic (Vg) particles", "PROBLEM", 0, 28], ["IVP", "TREATMENT", 79, 82]]], ["This could be due to 12 h sampling interval and sensitivity of assay.", [["sampling interval", "TEST", 26, 43], ["assay", "TEST", 63, 68]]], ["The genomic viral particles are produced earlier and infective viral particles are matured later.", [["The genomic viral particles", "PROBLEM", 0, 27], ["infective viral particles", "PROBLEM", 53, 78], ["viral particles", "OBSERVATION", 12, 27], ["infective", "OBSERVATION_MODIFIER", 53, 62], ["viral particles", "OBSERVATION", 63, 78]]], ["Myers and Carter (1980) showed by radioactive pulse chase labeling method that AAV capsid proteins assemble into empty capsids very quickly.", [["AAV", "ORGANISM", 79, 82], ["AAV capsid proteins", "PROTEIN", 79, 98], ["AAV", "SPECIES", 79, 82], ["radioactive pulse chase", "TREATMENT", 34, 57], ["AAV capsid proteins", "TREATMENT", 79, 98]]], ["Their experiment suggested that these empty capsids are later transferred to DNA-containing full particles or defective-interfering particles.", [["DNA", "CELLULAR_COMPONENT", 77, 80], ["these empty capsids", "TREATMENT", 32, 51], ["defective-interfering particles", "PROBLEM", 110, 141]]], ["They further showed that the maturation to stable full particles took much longer in terms of several hours whereas, empty capsids appeared very rapidly.", [["stable", "OBSERVATION_MODIFIER", 43, 49]]], ["The GFP positive cells remained same after 24 hpt suggesting that there was no secondary infection seen for AAV2 (Figs.", [["GFP positive cells", "ANATOMY", 4, 22], ["infection", "DISEASE", 89, 98], ["GFP", "GENE_OR_GENE_PRODUCT", 4, 7], ["cells", "CELL", 17, 22], ["AAV2", "ORGANISM", 108, 112], ["GFP positive cells", "CELL_LINE", 4, 22], ["AAV2", "SPECIES", 108, 112], ["The GFP positive cells", "TEST", 0, 22], ["secondary infection", "PROBLEM", 79, 98], ["AAV2", "PROBLEM", 108, 112], ["positive cells", "OBSERVATION", 8, 22], ["no", "UNCERTAINTY", 76, 78], ["secondary", "OBSERVATION_MODIFIER", 79, 88], ["infection", "OBSERVATION", 89, 98]]], ["Xiao (2010) argued that AAV2, AAV6 and AAV8RQNR (a mutant that binds strongly to HSPG) would show less particles in free medium because of re-adsorption onto the cell membrane and re-entry into the live cells, resulting in a low AAV yield because of the un-coating and degradation of re-entered viruses.", [["cell membrane", "ANATOMY", 162, 175], ["cells", "ANATOMY", 203, 208], ["AAV2", "ORGANISM", 24, 28], ["AAV6", "GENE_OR_GENE_PRODUCT", 30, 34], ["AAV8RQNR", "GENE_OR_GENE_PRODUCT", 39, 47], ["HSPG", "GENE_OR_GENE_PRODUCT", 81, 85], ["cell membrane", "CELLULAR_COMPONENT", 162, 175], ["cells", "CELL", 203, 208], ["AAV", "ORGANISM", 229, 232], ["AAV6", "PROTEIN", 30, 34], ["AAV8RQNR", "PROTEIN", 39, 47], ["HSPG", "PROTEIN", 81, 85], ["live cells", "CELL_TYPE", 198, 208], ["AAV2", "SPECIES", 24, 28], ["AAV2", "TEST", 24, 28], ["AAV6", "PROBLEM", 30, 34], ["AAV8RQNR", "PROBLEM", 39, 47], ["the cell membrane", "TREATMENT", 158, 175], ["a low AAV yield", "PROBLEM", 223, 238], ["the un-coating and degradation of re-entered viruses", "PROBLEM", 250, 302], ["less particles", "OBSERVATION_MODIFIER", 98, 112], ["cell membrane", "OBSERVATION", 162, 175], ["low AAV", "OBSERVATION", 225, 232]]], ["This argument implies that there should be at least a small increase in the number of transduced cells at a later stage of AAV production because of an equal probability of adsorption by non-transfected cells.", [["cells", "ANATOMY", 97, 102], ["cells", "ANATOMY", 203, 208], ["cells", "CELL", 97, 102], ["AAV", "ORGANISM", 123, 126], ["cells", "CELL", 203, 208], ["transduced cells", "CELL_LINE", 86, 102], ["non-transfected cells", "CELL_LINE", 187, 208], ["a small increase", "PROBLEM", 52, 68], ["transduced cells", "PROBLEM", 86, 102], ["AAV production", "PROBLEM", 123, 137], ["non-transfected cells", "PROBLEM", 187, 208], ["small", "OBSERVATION_MODIFIER", 54, 59], ["increase", "OBSERVATION_MODIFIER", 60, 68], ["transduced cells", "OBSERVATION", 86, 102], ["equal", "OBSERVATION_MODIFIER", 152, 157], ["non-transfected cells", "OBSERVATION", 187, 208]]], ["An increase in GFP positive cells was not observed (Figs.", [["GFP positive cells", "ANATOMY", 15, 33], ["GFP", "GENE_OR_GENE_PRODUCT", 15, 18], ["cells", "CELL", 28, 33], ["GFP positive cells", "CELL_LINE", 15, 33], ["An increase in GFP positive cells", "PROBLEM", 0, 33], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["GFP positive cells", "OBSERVATION", 15, 33]]], ["The low Vg/IVP ratio of less than 20 at 48 hpt in cell culture indicated acceptable encapsidation of AAV2 vectors achieved by transfection technology using HEK293SF cells.DiscussionIn this study, it has been shown that different serotypes of AAV (1-9) can be produced using PEI with transfection technology in a serum-free medium with yields close to 10 13 Vg/L cell culture (Fig. 8 ) using 1 \u00d7 10 6 cells/mL and 1 g total DNA/mL cell culture, determined by first purifying by iodixanol protocol to remove plasmid and non-encapsulated viral DNA present in the samples.", [["cell culture", "ANATOMY", 50, 62], ["HEK293SF cells", "ANATOMY", 156, 170], ["serum", "ANATOMY", 312, 317], ["cell", "ANATOMY", 362, 366], ["cells", "ANATOMY", 400, 405], ["cell", "ANATOMY", 430, 434], ["plasmid", "ANATOMY", 506, 513], ["samples", "ANATOMY", 560, 567], ["AAV (1-9", "CHEMICAL", 242, 250], ["PEI", "CHEMICAL", 274, 277], ["iodixanol", "CHEMICAL", 477, 486], ["PEI", "CHEMICAL", 274, 277], ["Vg", "GENE_OR_GENE_PRODUCT", 8, 10], ["IVP", "GENE_OR_GENE_PRODUCT", 11, 14], ["cell", "CELL", 50, 54], ["AAV2", "ORGANISM", 101, 105], ["HEK293SF cells", "CELL", 156, 170], ["AAV", "ORGANISM", 242, 245], ["PEI", "SIMPLE_CHEMICAL", 274, 277], ["serum", "ORGANISM_SUBSTANCE", 312, 317], ["cell", "CELL", 362, 366], ["DNA", "CELLULAR_COMPONENT", 423, 426], ["cell", "CELL", 430, 434], ["iodixanol", "SIMPLE_CHEMICAL", 477, 486], ["DNA", "CELLULAR_COMPONENT", 541, 544], ["Vg", "PROTEIN", 8, 10], ["HEK293SF cells", "CELL_LINE", 156, 170], ["plasmid", "DNA", 506, 513], ["non-encapsulated viral DNA", "DNA", 518, 544], ["AAV2", "SPECIES", 101, 105], ["The low Vg/IVP ratio", "TEST", 0, 20], ["cell culture", "TEST", 50, 62], ["AAV2 vectors", "TREATMENT", 101, 113], ["this study", "TEST", 184, 194], ["different serotypes of AAV", "PROBLEM", 219, 245], ["PEI with transfection technology", "TREATMENT", 274, 306], ["a serum", "TEST", 310, 317], ["Vg/L cell culture", "TEST", 357, 374], ["cell culture", "TEST", 430, 442], ["iodixanol protocol", "TREATMENT", 477, 495], ["plasmid", "TREATMENT", 506, 513], ["non-encapsulated viral DNA", "PROBLEM", 518, 544], ["low Vg", "OBSERVATION_MODIFIER", 4, 10], ["encapsidation", "OBSERVATION", 84, 97], ["AAV2 vectors", "OBSERVATION", 101, 113], ["viral DNA", "OBSERVATION", 535, 544]]], ["The infectious viral particle assay used HEK293 cells, but the AAV serotypes had different specificities for this cell line.", [["HEK293 cells", "ANATOMY", 41, 53], ["cell line", "ANATOMY", 114, 123], ["HEK293 cells", "CELL", 41, 53], ["AAV", "ORGANISM", 63, 66], ["cell line", "CELL", 114, 123], ["HEK293 cells", "CELL_LINE", 41, 53], ["AAV", "SPECIES", 63, 66], ["The infectious viral particle assay", "TEST", 0, 35], ["HEK293 cells", "PROBLEM", 41, 53], ["the AAV serotypes", "PROBLEM", 59, 76], ["this cell line", "TREATMENT", 109, 123], ["infectious", "OBSERVATION_MODIFIER", 4, 14], ["cell line", "OBSERVATION", 114, 123]]], ["The infectious viral particle productions reflected by the infectivity assay are provided only to demonstrate that different AAV serotypes produced using this scalable process are functional in terms of infectivity.", [["AAV", "ORGANISM", 125, 128], ["AAV", "SPECIES", 125, 128], ["The infectious viral particle productions", "PROBLEM", 0, 41], ["the infectivity assay", "TEST", 55, 76], ["different AAV serotypes", "PROBLEM", 115, 138], ["this scalable process", "TREATMENT", 154, 175], ["infectivity", "PROBLEM", 203, 214], ["infectious", "OBSERVATION_MODIFIER", 4, 14], ["viral particle", "OBSERVATION", 15, 29], ["infectivity", "OBSERVATION", 203, 214]]], ["The results indicated that the HEK293 or HeLa cell lines used for the transduction (infectivity) assay had variable \"permissiveness\" to different AAV serotypes.", [["HEK293", "ANATOMY", 31, 37], ["HeLa cell lines", "ANATOMY", 41, 56], ["HEK293", "CELL", 31, 37], ["HeLa cell lines", "CELL", 41, 56], ["AAV", "ORGANISM", 146, 149], ["HEK293", "CELL_LINE", 31, 37], ["HeLa cell lines", "CELL_LINE", 41, 56], ["the HEK293", "TREATMENT", 27, 37], ["HeLa cell lines", "TREATMENT", 41, 56], ["the transduction (infectivity) assay", "TEST", 66, 102], ["variable \"permissiveness\"", "PROBLEM", 107, 132], ["different AAV serotypes", "PROBLEM", 136, 159], ["HeLa cell lines", "OBSERVATION", 41, 56], ["AAV serotypes", "OBSERVATION", 146, 159]]], ["A cellbased assay should be used only when the titers from the same serotypes are compared to determine functionality loss during the vector processing, and genomic particles by PCR based assay may be used when titers from the same or different serotypes are compared (Grieger et al., 2006) .", [["A cellbased assay", "TEST", 0, 17], ["the titers", "TEST", 43, 53], ["functionality loss", "PROBLEM", 104, 122], ["the vector processing", "TREATMENT", 130, 151], ["PCR based assay", "TEST", 178, 193], ["titers", "TEST", 211, 217], ["different serotypes", "PROBLEM", 235, 254]]], ["The quantitation of AAV has been reviewed by Aucoin et al. (2008) .", [["AAV", "ORGANISM", 20, 23], ["AAV", "OBSERVATION", 20, 23]]], ["It is strongly suggested that any comparison with the data published in the literature should be done with great care considering different expression systems and different quantitation methods used.DiscussionThe 3-L bioreactor experiments for the production of AAV2 (two runs), and AAV6 (one run) demonstrated the scalability of the process (Table 3) .", [["AAV2", "ORGANISM", 262, 266], ["the data", "TEST", 50, 58], ["different expression systems", "PROBLEM", 130, 158], ["different quantitation methods", "TREATMENT", 163, 193], ["The 3-L bioreactor experiments", "TREATMENT", 209, 239], ["AAV2", "PROBLEM", 262, 266], ["AAV6", "TEST", 283, 287]]], ["Although the total cells continued to increase, after 40 hpt, the cell viability started to decrease.", [["cells", "ANATOMY", 19, 24], ["cell", "ANATOMY", 66, 70], ["cells", "CELL", 19, 24], ["cell", "CELL", 66, 70], ["the total cells", "PROBLEM", 9, 24], ["the cell viability", "TEST", 62, 80], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["cell viability", "OBSERVATION", 66, 80], ["decrease", "OBSERVATION_MODIFIER", 92, 100]]], ["The bioreactor experiment provided similar yields as observed in the shake flask experiments for similar conditions demonstrating scalability of the process.", [["bioreactor experiment", "OBSERVATION", 4, 25]]], ["The time of harvest may be set preferentially between 48 and 64 hpt (Fig. 9) .", [["harvest", "TREATMENT", 12, 19]]], ["The volumetric production of infectious and genomic viral particles remained constant around 6.8 \u00d7 10 11 IVP/L and 1.0 \u00d7 10 13 Vg/L, respectively, between 48 and 72 hpt.", [["The volumetric production", "TEST", 0, 25], ["infectious", "PROBLEM", 29, 39], ["genomic viral particles", "TEST", 44, 67], ["IVP/L", "TEST", 105, 110], ["infectious", "OBSERVATION_MODIFIER", 29, 39], ["viral particles", "OBSERVATION", 52, 67]]], ["The cell specific yields of 6800 Vg/cell and 460 IVP/cell were obtained for AAV2.", [["cell", "ANATOMY", 4, 8], ["Vg/cell", "ANATOMY", 33, 40], ["IVP/cell", "ANATOMY", 49, 57], ["cell", "CELL", 4, 8], ["cell", "CELL", 36, 40], ["cell", "CELL", 53, 57], ["AAV2", "ORGANISM", 76, 80], ["AAV2", "SPECIES", 76, 80], ["The cell specific yields", "TEST", 0, 24], ["Vg/cell", "TEST", 33, 40], ["IVP/cell", "TEST", 49, 57], ["AAV2", "PROBLEM", 76, 80]]], ["Using different plasmid constructs and medium selection providing better conditions, an improvement from earlier yields (Durocher et al., 2007) has been reported with better encapsidation (Vg/IVP ratio \u223c15) at a higher cell density of 1 \u00d7 10 6 cells/mL and without any medium exchange.", [["cell", "ANATOMY", 219, 223], ["cells", "ANATOMY", 244, 249], ["cell", "CELL", 219, 223], ["plasmid constructs", "DNA", 16, 34], ["different plasmid constructs", "TREATMENT", 6, 34], ["medium selection", "TREATMENT", 39, 55], ["Vg/IVP ratio", "TEST", 189, 201], ["any medium exchange", "TREATMENT", 265, 284], ["improvement", "OBSERVATION_MODIFIER", 88, 99], ["medium exchange", "OBSERVATION", 269, 284]]], ["The HEK293T cells adapted to a \"loose\" suspension in a 2-L bioreactor at a cell density of 1 \u00d7 10 6 cells/mL with FBS gave a cell-specific yield of 345 \u00b1 154 IVP/cell; the genomic particles per cell were not reported (Park et al., 2006) .", [["HEK293T cells", "ANATOMY", 4, 17], ["cell", "ANATOMY", 75, 79], ["cells", "ANATOMY", 100, 105], ["FBS", "ANATOMY", 114, 117], ["cell", "ANATOMY", 125, 129], ["cell", "ANATOMY", 162, 166], ["cell", "ANATOMY", 194, 198], ["HEK293T cells", "CELL", 4, 17], ["cell", "CELL", 75, 79], ["cells", "CELL", 100, 105], ["FBS", "ORGANISM_SUBSTANCE", 114, 117], ["cell", "CELL", 125, 129], ["cell", "CELL", 162, 166], ["cell", "CELL", 194, 198], ["HEK293T cells", "CELL_LINE", 4, 17], ["The HEK293T cells", "TREATMENT", 0, 17], ["a \"loose\" suspension", "PROBLEM", 29, 49], ["a cell density", "TEST", 73, 87], ["FBS", "TEST", 114, 117], ["a cell", "TEST", 123, 129], ["IVP/cell", "TREATMENT", 158, 166], ["HEK293T cells", "OBSERVATION", 4, 17], ["loose", "OBSERVATION_MODIFIER", 32, 37], ["suspension", "OBSERVATION_MODIFIER", 39, 49], ["cell density", "OBSERVATION_MODIFIER", 75, 87]]], ["Generally, the HEK293T produced higher cell-specific infectious particles than HEK293 cells (261 IVP/HEK293T cells vs. 44 IVP/HEK293 cells) (Park et al., 2006) .", [["HEK293T", "ANATOMY", 15, 22], ["cell", "ANATOMY", 39, 43], ["HEK293 cells", "ANATOMY", 79, 91], ["HEK293T cells", "ANATOMY", 101, 114], ["IVP/HEK293 cells", "ANATOMY", 122, 138], ["HEK293T", "CELL", 15, 22], ["cell", "CELL", 39, 43], ["HEK293 cells", "CELL", 79, 91], ["HEK293T cells", "CELL", 101, 114], ["HEK293 cells", "CELL", 126, 138], ["HEK293T", "CELL_LINE", 15, 22], ["HEK293 cells", "CELL_LINE", 79, 91], ["HEK293T cells", "CELL_LINE", 101, 114], ["HEK293 cells", "CELL_LINE", 126, 138], ["the HEK293T", "TEST", 11, 22], ["HEK293 cells", "TEST", 79, 91], ["IVP", "TEST", 97, 100], ["HEK293T cells", "TEST", 101, 114], ["IVP/HEK293 cells", "TREATMENT", 122, 138]]], ["Yuan et al. (2011) produced single stranded (ssAAV) and self-complementing (scAAV) AAV vectors of serotypes AAV2, AAV8, and AAV9 by the AAV producer cell line and triple transfection.", [["cell line", "ANATOMY", 149, 158], ["AAV", "ORGANISM", 83, 86], ["AAV2", "ORGANISM", 108, 112], ["AAV8", "GENE_OR_GENE_PRODUCT", 114, 118], ["AAV9", "GENE_OR_GENE_PRODUCT", 124, 128], ["AAV", "ORGANISM", 136, 139], ["cell line", "CELL", 149, 158], ["self-complementing (scAAV) AAV vectors", "DNA", 56, 94], ["AAV8", "DNA", 114, 118], ["AAV9", "DNA", 124, 128], ["AAV2", "SPECIES", 108, 112], ["AAV9", "SPECIES", 124, 128], ["single stranded (ssAAV)", "PROBLEM", 28, 51], ["serotypes AAV2", "TREATMENT", 98, 112], ["AAV8", "TEST", 114, 118], ["AAV9", "TREATMENT", 124, 128], ["the AAV producer cell line", "TREATMENT", 132, 158], ["triple transfection", "TREATMENT", 163, 182], ["serotypes AAV2", "OBSERVATION", 98, 112], ["AAV8", "ANATOMY", 114, 118], ["AAV9", "ANATOMY", 124, 128], ["AAV", "ANATOMY", 136, 139], ["producer cell line", "OBSERVATION", 140, 158], ["triple transfection", "OBSERVATION", 163, 182]]], ["The group reported 5-8 \u00d7 10 13 vector genomic particles of AAV2 per Nunc Cell Factory and 1.3 \u00d7 10 5 genomic particles per cell.", [["Cell", "ANATOMY", 73, 77], ["cell", "ANATOMY", 123, 127], ["AAV2", "ORGANISM", 59, 63], ["cell", "CELL", 123, 127], ["AAV2", "TEST", 59, 63]]], ["Their cell line produced AAV2 vectors with Vg/transducing units (TU) ratio of 85 and Vg/TU ratio of 480 by triple transfection method.", [["cell line", "ANATOMY", 6, 15], ["cell line", "CELL", 6, 15], ["AAV2", "ORGANISM", 25, 29], ["Vg", "PROTEIN", 43, 45], ["AAV2", "SPECIES", 25, 29], ["AAV2 vectors", "TREATMENT", 25, 37], ["Vg/transducing units", "TREATMENT", 43, 63], ["TU) ratio", "TEST", 65, 74], ["Vg/TU ratio", "TEST", 85, 96], ["triple transfection method", "TEST", 107, 133], ["cell line", "OBSERVATION", 6, 15]]], ["Lock et al. (2010) produced AAV1, 6, 7, 8 and 9 by transient transfection at small scale using anchorage dependent cells with yields in the range of 0.5-3 \u00d7 10 5 genome copies/cell.", [["cells", "ANATOMY", 115, 120], ["cell", "ANATOMY", 176, 180], ["AAV1", "GENE_OR_GENE_PRODUCT", 28, 32], ["cells", "CELL", 115, 120], ["cell", "CELL", 176, 180], ["AAV1, 6, 7, 8 and 9", "PROTEIN", 28, 47], ["anchorage dependent cells", "CELL_TYPE", 95, 120], ["AAV1", "TEST", 28, 32], ["transient transfection at small scale using anchorage dependent cells", "PROBLEM", 51, 120], ["yields", "TEST", 126, 132]]], ["Their ten liter productions of AAV6, 8 and 9 gave yields in the range of 3 \u00d7 10 13 to 1 \u00d7 10 15 genome copies by anchorage dependent cells.", [["cells", "ANATOMY", 133, 138], ["AAV6, 8 and 9", "CHEMICAL", 31, 44], ["cells", "CELL", 133, 138], ["anchorage dependent cells", "CELL_TYPE", 113, 138], ["AAV6", "TEST", 31, 35], ["anchorage dependent cells", "PROBLEM", 113, 138], ["anchorage dependent", "OBSERVATION_MODIFIER", 113, 132], ["cells", "OBSERVATION", 133, 138]]], ["Although the cells during production were grown in serum free medium, but were kept in 10% fetal bovine serum prior to the transfection.", [["cells", "ANATOMY", 13, 18], ["serum", "ANATOMY", 51, 56], ["fetal bovine serum", "ANATOMY", 91, 109], ["cells", "CELL", 13, 18], ["serum", "ORGANISM_SUBSTANCE", 51, 56], ["bovine", "ORGANISM", 97, 103], ["serum", "ORGANISM_SUBSTANCE", 104, 109], ["bovine", "SPECIES", 97, 103], ["bovine", "SPECIES", 97, 103], ["the cells", "PROBLEM", 9, 18], ["serum free medium", "TEST", 51, 68], ["fetal bovine serum", "TEST", 91, 109], ["the transfection", "TREATMENT", 119, 135]]], ["Grieger and Samulski (2012) reported high AAV yields using a HEK293 cell line that was selected for high transfection efficiency and high AAV production.", [["HEK293 cell line", "ANATOMY", 61, 77], ["AAV", "ORGANISM", 42, 45], ["HEK293 cell line", "CELL", 61, 77], ["AAV", "ORGANISM", 138, 141], ["HEK293 cell line", "CELL_LINE", 61, 77], ["a HEK293 cell line", "TREATMENT", 59, 77], ["high transfection efficiency", "PROBLEM", 100, 128], ["high AAV production", "PROBLEM", 133, 152], ["HEK293 cell line", "OBSERVATION", 61, 77], ["transfection efficiency", "OBSERVATION", 105, 128], ["high AAV production", "OBSERVATION", 133, 152]]], ["This cell line was able to produce >10 5 Vg/cell in a serum-free suspension cell culture.", [["cell line", "ANATOMY", 5, 14], ["cell", "ANATOMY", 44, 48], ["serum", "ANATOMY", 54, 59], ["cell", "ANATOMY", 76, 80], ["cell line", "CELL", 5, 14], ["cell", "CELL", 44, 48], ["serum", "ORGANISM_SUBSTANCE", 54, 59], ["cell", "CELL", 76, 80], ["cell line", "CELL_LINE", 5, 14], ["serum-free suspension cell culture", "CELL_LINE", 54, 88], ["This cell line", "TREATMENT", 0, 14], ["a serum", "TEST", 52, 59], ["free suspension cell culture", "TEST", 60, 88], ["cell line", "OBSERVATION", 5, 14]]], ["This shows that there is a great potential yet to be explored to optimize the cell lines for better optimization of transfection efficiencies.DiscussionIn author's laboratory, the baculovirus/insect cell system is a well optimized process to support high cell density production of AAV vectors.", [["cell lines", "ANATOMY", 78, 88], ["cell", "ANATOMY", 199, 203], ["cell", "ANATOMY", 255, 259], ["cell lines", "CELL", 78, 88], ["baculovirus", "ORGANISM", 180, 191], ["insect cell", "CELL", 192, 203], ["high cell", "CELL", 250, 259], ["AAV", "ORGANISM", 282, 285], ["cell lines", "CELL_LINE", 78, 88], ["baculovirus", "SPECIES", 180, 191], ["the cell lines", "TREATMENT", 74, 88], ["transfection efficiencies", "PROBLEM", 116, 141], ["the baculovirus/insect cell system", "TREATMENT", 176, 210], ["high cell density production of AAV vectors", "TREATMENT", 250, 293], ["cell lines", "OBSERVATION", 78, 88], ["transfection efficiencies", "OBSERVATION", 116, 141], ["high cell density", "OBSERVATION", 250, 267]]], ["Combining low MOI and a fed-batch production strategy, it was shown that the insect cells/baculovirus system AAV yield can be increased seven-fold.", [["cells", "ANATOMY", 84, 89], ["insect cells", "CELL", 77, 89], ["baculovirus", "ORGANISM", 90, 101], ["AAV", "ORGANISM", 109, 112], ["insect cells", "CELL_TYPE", 77, 89], ["baculovirus", "SPECIES", 90, 101], ["Combining low MOI", "PROBLEM", 0, 17], ["a fed-batch production strategy", "TREATMENT", 22, 53], ["the insect cells/baculovirus system AAV yield", "TREATMENT", 73, 118], ["low MOI", "OBSERVATION_MODIFIER", 10, 17], ["increased", "OBSERVATION_MODIFIER", 126, 135]]], ["Approximately 2 \u00d7 10 14 Vg/L and 2 \u00d7 10 12 IVP/mL cell culture were obtained in the bioreactor experiment at a harvest cell density of 9.5 \u00d7 10 6 cells/mL (Mena et al., 2010) , which is proportionally similar to cell specific production by transfection at low cell density reported in this manuscript.", [["cell", "ANATOMY", 50, 54], ["cell", "ANATOMY", 119, 123], ["cells", "ANATOMY", 146, 151], ["cell", "ANATOMY", 212, 216], ["cell", "ANATOMY", 260, 264], ["cell", "CELL", 50, 54], ["cell", "CELL", 119, 123], ["cell", "CELL", 212, 216], ["cell", "CELL", 260, 264], ["IVP/mL cell culture", "TEST", 43, 62], ["a harvest cell density", "TEST", 109, 131], ["Mena et al.", "TEST", 156, 167], ["transfection at low cell density", "PROBLEM", 240, 272], ["harvest cell density", "OBSERVATION", 111, 131], ["low cell density", "OBSERVATION", 256, 272]]], ["From a process standpoint, it is remarkable that despite limited process improvements and operation at low cell density, the large scale transient transfection technology performs as well as the baculovirus/insect cell technology for production of AAV serotypes.", [["cell", "ANATOMY", 107, 111], ["cell", "ANATOMY", 214, 218], ["cell", "CELL", 107, 111], ["baculovirus", "ORGANISM", 195, 206], ["insect cell", "CELL", 207, 218], ["AAV", "ORGANISM", 248, 251], ["baculovirus", "SPECIES", 195, 206], ["AAV", "SPECIES", 248, 251], ["operation at low cell density", "PROBLEM", 90, 119], ["the large scale transient transfection technology", "TREATMENT", 121, 170], ["the baculovirus/insect cell technology", "TREATMENT", 191, 229], ["AAV serotypes", "PROBLEM", 248, 261], ["low cell", "OBSERVATION_MODIFIER", 103, 111], ["density", "OBSERVATION_MODIFIER", 112, 119], ["large", "OBSERVATION_MODIFIER", 125, 130], ["AAV serotypes", "OBSERVATION", 248, 261]]], ["Again, this underlines the yet non-exploited potential of the transient transfection in HEK293 cell suspension cultures for high yield and large scale industrial production of AAV 1-9 serotypes evaluated in this study, which is further supported by recent work by Grieger and Samulski (2012) .", [["HEK293 cell", "ANATOMY", 88, 99], ["AAV 1-9", "CHEMICAL", 176, 183], ["HEK293 cell suspension cultures", "CELL", 88, 119], ["AAV", "ORGANISM", 176, 179], ["HEK293 cell suspension cultures", "CELL_LINE", 88, 119], ["the transient transfection", "PROBLEM", 58, 84], ["HEK293 cell suspension cultures", "TEST", 88, 119], ["high yield", "PROBLEM", 124, 134], ["large scale industrial production of AAV 1", "PROBLEM", 139, 181], ["this study", "TEST", 207, 217], ["transient", "OBSERVATION_MODIFIER", 62, 71], ["transfection", "OBSERVATION", 72, 84], ["HEK293 cell", "OBSERVATION", 88, 99], ["large", "OBSERVATION_MODIFIER", 139, 144], ["scale", "OBSERVATION_MODIFIER", 145, 150], ["industrial production", "OBSERVATION", 151, 172], ["AAV", "ANATOMY", 176, 179]]], ["Also, based on the data from this study it can be said with confidence that other serotypes can be easily produced at larger scales in the cGMP HEK293SF cell line using the presented generic protocol.ConclusionsIt has been demonstrated that the human embryonic kidney (HEK) 293SF-3F6 cell line, a fully characterized GMP Master Cell Bank, is capable of producing different serotypes of AAV (AAV 1-9) in suspension cultures by transient transfection in a serum-free medium without medium exchange.", [["cGMP HEK293SF cell line", "ANATOMY", 139, 162], ["embryonic kidney (HEK) 293SF-3F6 cell line", "ANATOMY", 251, 293], ["Cell", "ANATOMY", 328, 332], ["cultures", "ANATOMY", 414, 422], ["serum", "ANATOMY", 454, 459], ["cGMP", "CHEMICAL", 139, 143], ["AAV 1-9", "CHEMICAL", 391, 398], ["cGMP", "CHEMICAL", 139, 143], ["cGMP HEK293SF cell line", "CELL", 139, 162], ["human", "ORGANISM", 245, 250], ["embryonic kidney", "CELL", 251, 267], ["HEK) 293SF-3F6 cell line", "CELL", 269, 293], ["GMP Master Cell", "CELL", 317, 332], ["AAV", "ORGANISM", 386, 389], ["AAV 1-9", "ORGANISM", 391, 398], ["serum", "ORGANISM_SUBSTANCE", 454, 459], ["cGMP HEK293SF cell line", "CELL_LINE", 139, 162], ["human embryonic kidney (HEK) 293SF-3F6 cell line", "CELL_LINE", 245, 293], ["suspension cultures", "CELL_LINE", 403, 422], ["human", "SPECIES", 245, 250], ["human", "SPECIES", 245, 250], ["AAV", "SPECIES", 386, 389], ["this study", "TEST", 29, 39], ["other serotypes", "PROBLEM", 76, 91], ["the cGMP HEK293SF cell line", "TREATMENT", 135, 162], ["the presented generic protocol", "TREATMENT", 169, 199], ["the human embryonic kidney", "TEST", 241, 267], ["AAV (AAV", "TREATMENT", 386, 394], ["suspension cultures", "TEST", 403, 422], ["transient transfection", "PROBLEM", 426, 448], ["a serum", "TEST", 452, 459], ["medium exchange", "TREATMENT", 480, 495], ["cell line", "OBSERVATION", 153, 162], ["kidney", "ANATOMY", 261, 267], ["cell line", "OBSERVATION", 284, 293], ["GMP Master Cell Bank", "OBSERVATION", 317, 337], ["AAV", "ANATOMY", 386, 389], ["transient", "OBSERVATION_MODIFIER", 426, 435], ["transfection", "OBSERVATION", 436, 448]]], ["Three bioreactor runs showed that the yields are comparable to shake-flask runs for the corresponding serotypes and therefore shows the potential to scale-up and industrialization of this generic process for manufacturing efficiently AAV serotypes.", [["AAV", "ORGANISM", 234, 237], ["Three bioreactor runs", "TEST", 0, 21], ["the corresponding serotypes", "PROBLEM", 84, 111], ["this generic process", "PROBLEM", 183, 203], ["manufacturing efficiently AAV serotypes", "PROBLEM", 208, 247], ["AAV serotypes", "OBSERVATION", 234, 247]]]], "PMC7270482": [["The burden of neurological diseaseApproximately 10% of Canadians are affected by neurological disorders based on Canada\u2019s National Population Health Study of Neurological Conditions, and this number is projected to increase in the coming decades.1 Those with chronic neurological conditions have higher stress levels and a higher prevalence of self-diagnosed mood or anxiety disorders.", [["neurological", "ANATOMY", 14, 26], ["neurological", "ANATOMY", 81, 93], ["neurological diseaseApproximately", "DISEASE", 14, 47], ["neurological disorders", "DISEASE", 81, 103], ["Neurological Conditions", "DISEASE", 158, 181], ["anxiety disorders", "DISEASE", 367, 384], ["Canadians", "ORGANISM", 55, 64], ["neurological diseaseApproximately", "PROBLEM", 14, 47], ["neurological disorders", "PROBLEM", 81, 103], ["chronic neurological conditions", "PROBLEM", 259, 290], ["higher stress levels", "PROBLEM", 296, 316], ["self-diagnosed mood", "PROBLEM", 344, 363], ["anxiety disorders", "PROBLEM", 367, 384], ["burden", "OBSERVATION_MODIFIER", 4, 10], ["neurological", "OBSERVATION_MODIFIER", 14, 26], ["increase", "OBSERVATION_MODIFIER", 215, 223], ["chronic", "OBSERVATION_MODIFIER", 259, 266]]], ["Many suffer functional impairments with regard to cognition, mobility, dexterity, bowel, and bladder control.", [["bowel", "ANATOMY", 82, 87], ["bladder", "ANATOMY", 93, 100], ["bowel", "ORGAN", 82, 87], ["bladder", "ORGAN", 93, 100], ["functional impairments", "PROBLEM", 12, 34], ["bowel, and bladder control", "PROBLEM", 82, 108], ["bowel", "ANATOMY", 82, 87], ["bladder", "ANATOMY", 93, 100]]], ["Neurological disease can also affect one\u2019s ability to work or work productively, which can lead to financial insecurity.1 It can also result in a significant loss of the number of years (14\u201341 years based on condition) of healthy living.", [["Neurological", "ANATOMY", 0, 12], ["Neurological disease", "DISEASE", 0, 20], ["Neurological disease", "PROBLEM", 0, 20], ["disease", "OBSERVATION", 13, 20], ["significant", "OBSERVATION_MODIFIER", 146, 157], ["loss", "OBSERVATION", 158, 162]]], ["Based on the results from the Living with the Impact of a Neurological Condition (LINC) project, those with chronic neurological conditions use more health care services across the continuum compared to other chronic health conditions.2 In a study from British Columbia, physician service utilization is 1.4\u20135.6 times higher in people with chronic neurological conditions, as are the total direct health costs and out-of-pocket expenses for people affected by chronic neurological conditions.1 There are also limitations in health care services for this population with the physical environment cited as one of the significant barriers to the provision of adequate services.", [["neurological", "ANATOMY", 348, 360], ["neurological", "ANATOMY", 468, 480], ["chronic neurological conditions", "DISEASE", 340, 371], ["people", "ORGANISM", 328, 334], ["people", "ORGANISM", 441, 447], ["people", "SPECIES", 328, 334], ["people", "SPECIES", 441, 447], ["chronic neurological conditions", "PROBLEM", 108, 139], ["chronic neurological conditions", "PROBLEM", 340, 371], ["chronic neurological conditions", "PROBLEM", 460, 491], ["chronic", "OBSERVATION_MODIFIER", 340, 347], ["chronic", "OBSERVATION_MODIFIER", 460, 467]]], ["Thus, the burden of neurological diseases is not only shared by the individuals and families affected by it but also by the health care system.The burden of neurological diseaseThere is an urgent need within our health care system to address the unmet needs of individuals suffering from neurological disease.", [["neurological", "ANATOMY", 20, 32], ["neurological", "ANATOMY", 157, 169], ["neurological", "ANATOMY", 288, 300], ["neurological diseases", "DISEASE", 20, 41], ["neurological disease", "DISEASE", 157, 177], ["neurological disease", "DISEASE", 288, 308], ["individuals", "ORGANISM", 261, 272], ["neurological diseases", "PROBLEM", 20, 41], ["neurological disease", "PROBLEM", 157, 177], ["neurological disease", "PROBLEM", 288, 308], ["burden", "OBSERVATION_MODIFIER", 10, 16], ["neurological diseases", "OBSERVATION", 20, 41], ["neurological disease", "OBSERVATION", 157, 177], ["neurological disease", "OBSERVATION", 288, 308]]], ["This constitutes (1) reducing the per-capita cost of health care (out-of-pocket expenses and health system cost), (2) improving patient experiences of care (including quality and satisfaction), and (3) improving the health of populations.3 Virtual health care solutions are one way we can offer transformative changes to the practice of neurological ambulatory care in Canada, in order to meet some of the unmet needs of this challenging patient population.1,4", [["1,4", "CHEMICAL", 457, 460], ["patient", "ORGANISM", 128, 135], ["patient", "ORGANISM", 438, 445], ["1,4", "SIMPLE_CHEMICAL", 457, 460], ["patient", "SPECIES", 128, 135], ["patient", "SPECIES", 438, 445], ["Virtual health care solutions", "TREATMENT", 240, 269], ["neurological ambulatory care", "TREATMENT", 337, 365], ["this challenging patient population", "TREATMENT", 421, 456]]]]}